 MDS INC. AND BOREALIS
INFRASTRUCTURE MANAGEMENT INC. ASSET PURCHASE AGREEMENT DATED OCTOBER 4,
2006      
 

 



 

 



 

 



 

 

 

**MDS  INC.**

 

 



 

 

**-  AND -**

 

 



 

 

**BOREALIS  INFRASTRUCTURE MANAGEMENT INC.**

 

 



 

 



 

        

 

**ASSET  PURCHASE AGREEMENT**

 

    
--- 
    

 

 



 

 

Dated  this 4th day of October, 2006

 

 



 

 

Prepared  by:

 

 

![](fasken.jpg)

 

 

**Fasken  Martineau DuMoulin LLP**

 

**Toronto,  Ontario**

 

 



 




 

 

 

 

 

 

 

   

 

 

 

 

 

 

 


 
 

**ARTICLE 1 ****INTERPRETATION**

 

1.1Definitions

 

1.2Interpretation

 

1.3Entire  Agreement

 

1.4Amendment

 

1.5Waiver  of  Rights

 

1.6Schedules

 

1.7Applicable  Law

 

1.8Currency

 

1.9Performance  on Holidays

 

1.10Calculation  of Time

 

1.11Severability

 

1.12No  Third  Party Beneficiaries

 

 

**ARTICLE 2** **PURCHASE  AND SALE OF PURCHASED ASSETS**

 

2.1Purchase  and Sale of Purchased Assets

 

2.2Excluded  Assets

 

2.3Non-Assignable  Contracts

 

2.4Place  of  Closing

 

2.5Closing  Time

 

 

**ARTICLE 3** **CONSIDERATION  FOR PURCHASED ASSETS**

 

3.1Purchase  Price; Holdback Amount

 

3.2Post-Closing  Audit

 

3.3Determination  of Value of Inventory, Accounts Receivable

 

3.4Working  Capital Adjustment

 

3.5General  Adjustments

 

3.6Long-Term  Liability and Other Adjustments

 

3.7Interest

 

3.8Allocation  of Purchase Price

 

3.9Payment  of Purchase Price

 

3.10Transfer  Taxes and Tax Elections

 

3.11Excluded  Liabilities

 

 

**ARTICLE 4** **REPRESENTATIONS  AND WARRANTIES**

 

4.1Representations  and Warranties of MDS

 

4.2Representations  and Warranties of Buyer

 

4.3Commission

 

4.4Qualification  of Representations and Warranties

 

4.5Survival  of Representations and Warranties of MDS

 

4.6Survival  of Representations and Warranties of Buyer

 

4.7Knowledge  of MDS

 

4.8No  Breach

 

 

**ARTICLE 5** **OTHER  COVENANTS OF THE PARTIES**

 

5.1Conduct  Prior to Closing

 

5.2Regulatory  Consents

 

5.3Bulk  Sales

 

5.4Buyer's  Covenants

 

5.5Benefit  Plans

 

5.6Limited  Trade Mark Licence

 

5.7Migration  Agreement

 

5.8Non-Competition  Agreement

 

5.9Support  Services Agreement

 

5.10Shared  Contracts

 

5.11Designated  Buyer Affiliates

 

5.12Confidentiality

 

5.13Transaction  Structure

 

5.14Replacement  Material Contracts

 

 

**ARTICLE 6** **CONDITIONS  PRECEDENT**

 

6.1Buyer's  Conditions

 

6.2Conditions  of MDS

 

6.3Waiver

 

6.4Failure  to Satisfy Conditions

 

 

**ARTICLE 7** **POST-CLOSING  PROVISIONS**

 

7.1Insurance  and Risk of Loss

 

7.2Litigation

 

7.3Post-Closing  Access

 

7.4Excluded  Asset Adjustment

 

7.5Tax  Matters

 

7.6Privacy  Notification

 

7.7Other  Confidentiality Agreements

 

7.8Post-Closing  Reimbursements

 

7.9No  MDS  Guarantees on Lease Renewals

 

7.10Post-Closing  Conveyance of Migrating Assets

 

7.11Survival  of Covenants

 

7.12U.S.  Non-Competition and Non-Solicitation Agreements

 

 

**ARTICLE 8** **INDEMNIFICATION**

 

8.1Definitions

 

8.2Indemnification  by MDS

 

8.3Indemnification  by Buyer

 

8.4Agency  for Representatives

 

8.5Notice  of  the Defence of Third Party Claims

 

8.6Assistance  for Third Party Claims

 

8.7Settlement  of Third Party Claims

 

8.8Direct  Claims

 

8.9Failure  to Give Timely Notice

 

8.10Limitation

 

8.11Reductions  and Subrogation

 

8.12Exclusive  Remedy

 

8.13Duty  to  Mitigate

 

8.14General  Limitations

 

8.15Adjustment  to the Purchase Price

 

 

**ARTICLE 9** **ARBITRATION**

 

9.1Arbitration

 

9.2Laws  of  Ontario

 

9.3Arbitration  Act

 

 

**ARTICLE 10** **GENERAL**

 

10.1Expenses

 

10.2Time

 

10.3Notices

 

10.4Assignment,  Successors

 

10.5Further  Assurances

 

10.6Public  Announcements

 

10.7Counterparts

 

10.8Facsimile  Execution

 

10.9No  Partnership

 

10.10Survival

 

 

**SCHEDULE  2.5 ****TRANSACTION  STRUCTURE AND CLOSING SEQUENCE**

 

 

 

**SCHEDULE  3.1 ****HOLDBACK  AMOUNT**

 

 

 

**SCHEDULE  3.8 ****PURCHASE  PRICE ALLOCATION**

 

 

 

**SCHEDULE  5.6 ****FORM  OF LIMITED TRADE MARK LICENCE**

 

 

 

**SCHEDULE  5.7 ****FORM  OF CBS LICENSE AGREEMENT**

 

 

 

**SCHEDULE  5.8 ****FORM  OF NON-COMPETITION AGREEMENT**

 

 

 

**SCHEDULE  5.9 ****SUPPORT  SERVICES AGREEMENT TERM SHEET**

 

 

 

**SCHEDULE  5.12 FORM OF  MDS CONFIDENTIALITY AGREEMENT**

 

 

 

**SCHEDULE  6.1.5(B) CLOSING CONDITIONS IN  FAVOUR OF BUYER**

 

 

 

**SCHEDULE  6.2.4(B) CLOSING CONDITIONS IN  FAVOUR OF MDS**

 

 

 

**SCHEDULE  9.3 ****RULES  OF PROCEDURE FOR ARBITRATION**

 

 




 

 

 

**ASSET  PURCHASE AGREEMENT**

 

 

This  agreement is made this 4th day of October, 2006

 

 

**B  E T W E E N:**

 

 

**MDS  INC.** ,

 

 

a  corporation incorporated under the laws of Canada

 

 

(" **MDS** ")

 

 

-  and  -

 

 

**BOREALIS  INFRASTRUCTURE MANAGEMENT INC.** ,

 

 

a  corporation incorporated under the laws of Canada

 

 

(" **Buyer** ")

 

 

**RECITALS:**

 

 

        

1.

    |  

MDS  has agreed to sell and to cause the Sellers to sell to Buyer the 
diagnostics services business in Canada carried out by MDS, the Operators 
and the BC Operators. The parties have agreed to enter into separate 
purchase agreements in respect of the Diagnostics Business and the  BC 
Diagnostics Business.

    
---|--- 
    

 

 

        

2.

    |  

Contemporaneously  with and conditional upon the execution of this Agreement
by the  Parties,  MDS, Mether Properties Limited Partnership and Buyer shall
execute  and  deliver a purchase agreement with respect to the BC
Diagnostics Business  (the " **BC  Purchase Agreement** ")  and MDS, Dr.
Donald B. Rix and Rix Clinical Laboratories Ltd. shall  execute and deliver a
purchase agreement with respect to certain  assets  owned by Rix and Rixco
(as such terms are defined below) in the BC  Diagnostics Business on the
terms and subject to the conditions set  forth  in such agreement.

    
---|--- 
    

 

 

        

3.

    |  

Pursuant  to this Agreement, MDS has agreed to sell and to cause the
Sellers  to sell  to Buyer the Purchased Assets owned by them and the
Replacement Contracts  and the Migrating Assets to be acquired by them as
provided herein  and in  the Migration Agreement and the Buyer has agreed to
purchase the  Purchased  Assets, the Replacement Contracts and the Migrating
Assets and assume  the  Assumed Liabilities on the terms and subject to the
conditions set  forth  in this Agreement.

    
---|--- 
    

 

 

        

4.

    |  

The  boards of directors of MDS and Buyer have each approved the execution 
and  delivery of this Agreement, the performance of their respective 
obligations hereunder and the transactions contemplated by this  Agreement.

    
---|--- 
    

 

 

        

5.

    |  

Certain  of the Purchased Assets, the Replacement Contracts and Migrating 
Assets  may be acquired by Designated Buyer Affiliates pursuant to the
terms  of  this Agreement.

    
---|--- 
    

 

 

**IN  CONSIDERATION** of  the  premises and the respective agreements in
this Agreement, and of other  consideration (the receipt and sufficiency of
which are acknowledged by each  Party), the Parties agree as follows:

 

 

**ARTICLE 1**

 

**INTERPRETATION**

 

 

**1.1** **Definitions**

 

 

In  this  Agreement including the Recitals,

 

 

" **Accounts  Receivable** " means,  with respect to any Person at a given
time, all accounts receivable of the  Person as at that time;

 

 

" **Accrual  Adjustment Date** " has  the  meaning set forth in Subsection
3.6(b); 

 

 

" **Affiliate** " means,  with respect to any Person,

 

 

         |  

(i)

    |  

any  other Person who directly or indirectly controls, is controlled by,  or
is  under direct or indirect common control with, such Person;  or

    
---|---|--- 
    

 

 

         |  

(ii)

    |  

any  other Person that directly or indirectly owns all of the participating 
equity of such Person or for which all of the participating equity  is 
directly or indirectly owned by such Person;  and

    
---|---|--- 
    

 

 

a  Person  shall be deemed to "control" a Person if such Person possesses
directly or  indirectly the power to direct or cause the direction of the
management and  policies of such Person, whether through the ownership of
voting securities,  by  contract or otherwise, and "controlled" shall have a
similar  meaning;

 

 

" **Agreement** " means  this asset purchase agreement and all attached
schedules, in each case as  supplemented, amended, restated or replaced from
time to time;

 

 

" **Applicable  Law** " means  any domestic or foreign statute, law
(including the common law), ordinance,  rule, regulation, or Order, or the
terms of any consent, exemption, approval  or  Licence of any Governmental
Authority, that applies in whole or in part to  MDS,  Buyer, a Designated
Buyer Affiliate, an Operator, the Diagnostics Business  or  the way the
Diagnostics Business is carried on or to any of the Purchased  Assets;

 

 

" **Assignment  and Assumption Agreement** " has  the  meaning set forth
in Subsection 6.1.8(d);

 

 

" **Assumed  Liabilities** " means,  subject to Section 2.2,  the  Quebec
Liabilities, the Ontario Liabilities and any Liabilities associated  with 
the Migrating Assets;

 

 

" **Assumed  Long-Term Liabilities** " means  the Liabilities of the
Diagnostics Business reflected on the Closing Balance  Sheet other than those
included in Working Capital;

 

 

" **AutoLabs  Assets** " means  all assets owned, leased or otherwise held
by MDS and its Affiliates exclusively  in respect of the operation of the
AutoLabs Business;

 

 

" **AutoLabs  Business** " means  the business carried on by MDS and its
Affiliates relating to the hardware  system and related software known as APX
(AutoLab Process eXpert) that provides  specimen management, storage, results
and instrument interfacing capabilities  at  testing locations, consisting
of the licensing, maintenance and support of  such  system;

 

 

" **AutoLabs  Contracts** " has  the  meaning set forth in Schedule 5.9;

 

 

" **AutoLabs  Liabilities** " means  all Liabilities of MDS and its
Affiliates relating exclusively to the AutoLabs  Business;

 

 

" **BC  Closing** " has  the  meaning attributed thereto in the BC
Purchase Agreement;

 

 

" **BC  Diagnostics Business** " means  the specimen collection and
diagnostic services businesses carried on directly  by MDS, in British
Columbia, and the BC Operators consisting of the provision  of  clinical
laboratory testing for physicians, hospitals, non-hospital health  care 
institutions, employers or insurance companies, management of hospital 
laboratories and other support services for clinical diagnostics but
excluding,  for avoidance of doubt, the businesses carried on by any Person
in which MDS  does not directly or indirectly have a greater than 50%
interest;

 

 

" **BC  Documents** " means  the BC Purchase Agreement, the Regional
Purchase Agreements (as defined in  and  entered into pursuant to the BC
Purchase Agreement), and any document delivered  contemporaneously with the
execution of the BC Purchase Agreement by the Parties  or prior to or at the
BC Closing as contemplated by or pursuant to the BC  Purchase Agreement;

 

 

" **BC  Operators** " means  Metro LP, Metro-McNair Clinical Laboratories
Ltd., Mether LP, Mether Management  Ltd., Mether Properties Ltd.,
Metropolitan Laboratories of Victoria Ltd., Prince  George Medical Laboratory
Partnership, Dawson Creek Medical Laboratory and  Stirrat Laboratories Ltd.;

 

 

" **BC  Purchase Agreement** " has  the  meaning set forth in the recitals
to this Agreement;

 

 

" **BC  Purchased Assets** " means  the " **Purchased  Assets** " as 
that  term is defined in the BC Purchase Agreement;

 

 

" **Benefit  Plans** " means  all bonus, deferred compensation, incentive
compensation, share purchase, share  appreciation, phantom share, restricted
stock unit, deferred stock unit, share  option, severance or termination pay,
hospitalization or other medical benefits,  life or other insurance, dental,
disability, salary continuation, vacation,  supplemental unemployment
benefits, profit-sharing, mortgage assistance, legal  benefits, change of
control, retention, employee loan, employee assistance,  pension, retirement
or supplemental retirement plan or agreement (including  any  defined
benefit or defined contribution Pension Plan and any group registered 
retirement savings plan), and each other employee benefit plan or agreement 
sponsored, maintained or contributed to or required to be contributed to by 
MDS  or one or more Operators for the benefit of any Employees or former
employees,  officers or directors of the Diagnostics Business or their
dependants or  beneficiaries, whether written or unwritten, formal or
informal, funded or  unfunded, insured or uninsured, registered or
unregistered and whether or not  subject to any Applicable Law except that
the term "Benefit Plans" shall not  include any statutory plans with which
MDS or an Operator is required to comply,  including the Canada/Quebec
Pension Plan and plans administered pursuant to  applicable provincial health
Tax, workers' compensation and workers' safety and  employment insurance
legislation;

 

 

" **Books  and Records** " means  all books, records, books of account,
sales and purchase records, lists of  suppliers and customers, credit and
pricing information, formulae, business,  engineering and consulting reports,
research and development information, plans  and projections, personnel
records, operating guides, test data, health records,  manuals, records,
reports and information or documents of the Diagnostics  Business maintained
by or on behalf of MDS or an Operator pursuant to, or to  demonstrate
compliance with, Applicable Law and all other documents, files,  records,
correspondence, and all other data and information, financial or  otherwise,
of the Diagnostics Business held by or on behalf of MDS or an  Operator
including all service level reports, metrics and performance data  (including
raw data) relating to the provision of all services to the  Diagnostics
Business (whether by MDS or third parties) and all data and  information
stored electronically or on computer-related media (or in any other  form or
format);

 

 

" **Building** " means  a  plant, warehouse, building, structure, erection,
improvement, appurtenance  or  fixture (including fixed machinery and fixed
equipment) situate on or forming  part of the Land and includes without
limitation all heating, ventilating,  air  conditioning, plumbing,
sprinkler, life safety, electrical, mechanical,  drainage, elevating and
security systems and infrastructure incorporated in  or  situate on the
Building, together with all floor coverings and window coverings 
incorporated within such Building;

 

 

" **Business  Day** " means  a  day other than a Saturday or Sunday, on
which Canadian chartered banks are  open  for the transaction of domestic
business in the City of Toronto;

 

 

" **Buyer 's  Benefit Plans**" has  the  meaning set forth in Subsection
5.5(b);

 

 

" **Buyer 's  Pension Plans**" has  the  meaning set forth in Subsection
5.5(a);

 

 

" **Buyer  Purchase Structure** " has  the  meaning set forth in Section
5.13(a);

 

 

" **CBS  IP** " means  the technology, information, materials, data,
components and elements  proprietary to MDS that form a part of or are
included in the Oracle based  common back office system solution known
internally by MDS as " **CBS** ";

 

 

" **CBS  License Agreement** " has  the  meaning set forth in Section 5.7;

 

 

" **Closing** " means  the completion of the sale to, and the purchase by,
Buyer of the Purchased  Assets, the Replacement Contracts and the Migrating
Assets, the assumption  of  the Assumed Liabilities by Buyer and the
completion of all other transactions  contemplated by this Agreement that are
to occur contemporaneously with or  prior  to the purchase and sale of the
Purchased Assets, the Replacement Contracts  and  the Migrating Assets and
the assumption of the Assumed Liabilities;

 

 

" **Closing  Balance Sheet** " means  an audited combined balance sheet of
the MDS Diagnostics Division as at the  Closing Time as prepared in
accordance with Section 3.2;

 

 

" **Closing  Cash Amount** " means  the portion of the Purchase Price paid
to Sellers by wire transfer at the  Closing as described in Subsection
3.1(a);

 

 

" **Closing  Date** " means  (i) the later of: (A) November 29, 2006, and
(B) if any of the conditions set  forth in Section 6.1 or 6.2 is not
satisfied or waived on any date, the second  Business Day following the date
the last of such conditions is satisfied or  waived; or (ii) such later date
as the Parties may agree in writing as the  date  the Closing shall take
place;

 

 

" **Closing  Documents** " means  the Regional Purchase Agreement,
Migration Agreement, Limited Trade Mark  Licence, Non-Competition Agreement,
CBS License Agreement, Support Services  Agreement, MDS Confidentiality
Agreement and, if required, the International  Boulevard Licenses and the
Post-Closing Services Agreement, and any document  delivered
contemporaneously with the execution of this Agreement by the Parties  or
prior to or at the Closing Time as contemplated by or pursuant to this 
Agreement but excluding, for greater certainty, the BC Documents;

 

 

" **Closing  Regional Balance Sheet** " means  an unaudited supplementary
schedule to the Closing Balance Sheet consisting  of a  balance sheet of the
MDS Diagnostics Division in Ontario and Quebec and the  head  office of the
MDS Diagnostics Division as at the Closing Date;

 

 

" **Closing  Time** " means  2:00 p.m. (Toronto time) on the Closing Date,
or such other time on that date  as  the Parties agree in writing that the
Closing shall take place;

 

 

" **Commissioner** " means  the Commissioner of Competition under the
Competition Act or any person duly  authorized to exercise the powers of the
Commissioner of  Competition;

 

 

" **Competition  Act** " means  the _Competition  Act_   (Canada);

 

 

" **Competition  Act Clearance** " means  either of the following:

 

 

         |  

(a)

    |  

the  issuance of an advance ruling certificate by the Commissioner under 
section 102(1) of the Competition Act, which advance ruling certificate 
remains in force at the Closing; or

    
---|---|--- 
    

 

 

         |  

(b)

    |  

the  applicable waiting period, if any, under section 123 of the
Competition  Act __ shall  have expired or been earlier terminated or waived
and the Commissioner  shall have issued a No-Action Letter, in form and
substance satisfactory  to the Buyer, acting reasonably, to the effect that
the Commissioner  is  satisfied that the Commissioner would not have
sufficient grounds  upon  which to apply to the Competition Tribunal for an
order under section  92  of the Competition Act with respect to the
transactions contemplated  herein, which letter remains in force at the
Closing; 

    
---|---|--- 
    

 

 

" **Competition  Tribunal** " means  the Competition Tribunal established
under the _Competition  Tribunal Act_   (Canada);

 

 

" **Confidentiality  Agreement** " has  the  meaning set forth in Section
1.3;

 

 

" **Consent  Exclusion** " has  the  meaning set forth in Subsection
2.2(b);

 

 

" **Contracts** " means  the contracts, agreements, licence agreements and
other legally binding  instruments entered into by a Person or to which a
Person is bound or entitled  including restrictive agreements and negative
covenant agreements, the full  benefit of all unfilled supplier purchase
orders, quotations, tenders for  contracts which remain open for acceptance,
and entitlements and engagements,  to  which such Person is entitled
including any deposits made in connection  therewith, and forward commitments
of any Person for supplies or materials,  in  all cases, whether written or
oral;

 

 

" **Corporate  Operator** " has  the  meaning set forth in Subsection
4.1.1(a);

 

 

" **Designated  Buyer Affiliate** " has  the  meaning set forth in Section
5.11;

 

 

" **Diagnostics  Business** " means  the specimen collection and diagnostic
services businesses carried on in Ontario  and Quebec directly by MDS and the
Operators consisting of the provision of  clinical laboratory testing for
physicians, hospitals, non-hospital health  care  institutions, employers or
insurance companies, management of hospital  laboratories and other support
services for clinical diagnostics and the  AutoLabs Business as well as the
US Support Service Assets but excluding, for  avoidance of doubt, the
businesses carried on by any Person in which MDS does  not directly or
indirectly have a greater than 50% interest;

 

 

" **Disclosed  Matter** " has  the  meaning set forth in Section 8.2(d);

 

 

" **Disclosed  Personal Information** " has  the  meaning set forth in
Section 5.1.4;

 

 

" **Disclosure  Letter** " means  the letter of MDS to Buyer dated the date
hereof which sets forth, or refers  to  documents which set forth, certain
information, including information to qualify  the representations and
warranties of MDS contained in Section 4.1;

 

 

" **Employees** " means,  collectively, the Quebec Employees and the Ontario
Employees;

 

 

" **Encumbrance** " means  any encumbrance, security interest, mortgage,
lien, hypothec, pledge,  hypothecation, title retention agreement,
reservation of title, easement,  servitude, right of occupation, executions,
judgments, assignment, charge,  trust  or deemed trust affecting an asset;

 

 

" **Environmental  Laws** " means  all Applicable Laws relating to
environmental matters or occupational health  and  safety including but not
limited to pollution, contamination or protection  of  the environment, the
prevention or reduction to acceptable levels of pollution  and further
including those relating to Releases of Hazardous Material into  the 
environment (including ambient air, soil, surface water, ground water and 
subsurface strata) or otherwise relating to the manufacture, processing, 
distribution, use, treatment, storage, disposal, transport or handling of 
Hazardous Material;

 

 

" **Environmental  Permit** " means  any Licence required by or pursuant to
any applicable Environmental Law in  connection with the Diagnostics Business
or connected to the Diagnostics  Business;

 

 

" **Equipment** " means,  in respect of a Person, all equipment, machines,
machinery, motor vehicles,  trucks and other mobile equipment, fixtures,
gauges, furniture, furnishings,  material handling, data processing
equipment, laboratory equipment, collection  centre equipment, typewriters,
computers, servers, telecom equipment, data  bases, photocopiers, office
equipment, implements, tools and spare parts,  wherever located and similar
tangible personal property;

 

 

" **Equipment  Leases** " means,  in respect of a Person, the leases,
subleases and conditional sales contracts  of  Equipment to which such
Person is a party;

 

 

" **Estimated  Long-Term Liabilities** " means  an estimate of the Assumed
Long-Term Liabilities as at the Closing  Time;

 

 

" **Excluded  Asset Event** " has  the  meaning set forth in Subsection
2.2(b);

 

 

" **Excluded  Assets** " means,  subject to Section 2.2,  the  following:

 

 

         |  

(a)

    |  

all  cash, bank balances, moneys in possession of banks and other
depositories,  term deposits and similar cash property and bank accounts and
trust  accounts of, owned or held by or for the account of any Seller in 
the  Diagnostics Business, at the Closing Time but excluding for greater 
certainty any Petty Cash;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

any  interest of MDS, directly or indirectly, in MDS Quebec or the Ontario 
GP  and any interest of the Ontario GP in MDS ONT  LP;

    
---|---|--- 
    

 

 

         |  

(c)

    |  

any  interest of MDS Quebec, directly or indirectly, in MDS (Canada)  Inc.;

    
---|---|--- 
    

 

 

         |  

(d)

    |  

all  non-transferable Licences of a Seller listed in Section 1.1 of the 
Disclosure Letter;

    
---|---|--- 
    

 

 

         |  

(e)

    |  

all  property, rights, assets and undertaking of a Seller which are not 
used  Primarily in the Diagnostics Business (including, for avoidance of 
doubt,  all furniture, fixtures and equipment located at 75 International 
Boulevard, Toronto, Ontario other than that listed at Section 1.1  of  the
Disclosure Letter under the heading "Ontario Assets" and the  furniture,
fixtures, artwork and equipment located at 100 International  Boulevard,
Toronto, Ontario listed at Section 1.1 of the Disclosure  Letter) and those
assets, contracts, trade marks and computer software  listed in Section 1.1
of the Disclosure Letter; 

    
---|---|--- 
    

 

 

         |  

(f)

    |  

all  information and that part of any Books and Records of a Seller
relating  thereto which must not be disclosed by the Seller to Buyer
pursuant  to the  provisions of Applicable Law or which would be libellous
if  disclosed;

    
---|---|--- 
    

 

 

         |  

(g)

    |  

any  confidential documents, data, information or records prepared by  or
on  behalf of a Seller or an Operator and undisclosed to Buyer specifically 
in  connection with the proposed sale of the Diagnostics Business and  the 
Purchased Assets;

    
---|---|--- 
    

 

 

         |  

(h)

    |  

the  corporate and Tax records of  Sellers;

    
---|---|--- 
    

 

 

         |  

(i)

    |  

any  information or records related to an Employee who does not accept 
Buyer's  offer of employment or to other businesses of Sellers or to MDS
and  its  Affiliates as a whole, and not reasonably required in connection 
with the  Purchased Assets or the Diagnostics Business or its  operations;

    
---|---|--- 
    

 

 

         |  

(j)

    |  

Intentionally  deleted;

    
---|---|--- 
    

 

 

         |  

(k)

    |  

all  insurance policies of Sellers and benefits for claims thereunder 
relating  to occurrences in the Diagnostics Business prior to the Closing 
Time;

    
---|---|--- 
    

 

 

         |  

(l)

    |  

all  amounts due from one Seller to another Seller or an Affiliate  thereof;

    
---|---|--- 
    

 

 

         |  

(m)

    |  

all  Tax and GST credits, losses, rebates and refunds of Sellers including 
any  rebate, refund or credit relating to a real estate assessment in 
respect  of the Real Property included in the Purchased Assets earned or
otherwise  arising from or relating to the operation of the Diagnostics
Business  prior to the Closing Time or relating to a period of time prior
to  the  Closing Time which become payable after the Closing Time and are 
not  reflected on the balance sheet included in the Quarterly  Statements;

    
---|---|--- 
    

 

 

         |  

(n)

    |  

all  right, title and interest of Sellers in, to or under, and the full 
benefit  of, the Shared Contracts and the U.S. Support Services Contracts 
other  than the AutoLabs Contracts; and

    
---|---|--- 
    

 

 

         |  

(o)

    |  

any  Ontario Asset or Quebec Asset for which a replacement asset or
contract  will be created or entered into (or sourced from a third party)
in  accordance with the provisions of (x) the Migration Agreement, which 
replacement asset or contract will be conveyed or assigned to the  Buyer as 
a Migrating Asset; or (y) Sections 5.10  and 5.14,  which Replacement
Contracts will be assigned to the Buyer pursuant  to this  Agreement;

    
---|---|--- 
    

 

 

" **Excluded  Liabilities** " has  the  meaning set forth in Section 3.11;

 

 

" **Excluded  Refund** " has  the  meaning set forth in Section 7.4;

 

 

" **Field** " means  the collection, testing, monitoring and/or reporting of
test results of bodily,  cytological and other specimens from a patient at
the request of any other  Person, including a patient, health care
professional, employer or insurance  company;

 

 

" **Financial  Statements** " means  the audited combined financial
statements for the MDS Diagnostics Division  as at  October 31, 2005,
including the notes thereto, copies of which financial  statements are
annexed to the Disclosure Letter as Schedule A;

 

 

" **General  Conveyance** " has  the  meaning set forth in Subsection
6.1.8(c);

 

 

" **Generally  Accepted Accounting Principles** " or  " **GAAP** " means 
generally accepted accounting principles of Canada, applicable as at the
date  on  which any calculation or determination is required to be made in
accordance  with  generally accepted accounting principles, and where the
Canadian Institute  of  Chartered Accountants includes a recommendation in
its Handbook concerning  the  treatment of any accounting matter, such
recommendation shall be regarded as  the  only generally accepted accounting
principle applicable to the circumstances  that it covers;

 

 

" **Governmental  Authority** " means  any domestic or foreign government
whether federal, provincial, state or  municipal and any governmental agency,
governmental authority, governmental  tribunal or governmental commission of
any kind whatsoever;

 

 

" **GST** " means  all goods and service Taxes, sales Taxes levied by the
federal government of  Canada, value added Taxes or multi-stage Taxes and all
provincial sales Taxes  integrated with such federal Taxes;

 

 

" **Hazardous  Material** " means  any substance, pollutant, contaminant,
material or waste that could reasonably  be expected to impair the quality of
the environment or that causes or could  reasonably be expected to cause an
adverse effect on the environment for any  use  which can be made of it and
which is regulated under any Environmental Law,  including any such material
regulated as hazardous, toxic, deleterious, caustic,  dangerous, a
contaminant, hazardous waste, a source of contaminant and including  but not
limited to any pathogen, bacteria, microbe, virus, parasite, nuclear 
substance as defined in the _Nuclear  Safety and Control Act_   or any 
related regulations, asbestos, petroleum products, urea formaldehyde,
chemical  and biochemical waste;

 

 

" **Holdback  Amount** " means  the amount determined as set forth in
Schedule 3.1, which shall not exceed  $78,750,000;

 

 

" **Inscyte  Assets** " means  a  33 1/3% interest in Inscyte (Information
System for Cytology, etc.) Corporation  held by MDS;

 

 

" **Intellectual  Property Rights** " means  all trade or brand names,
business names, trade-marks (including logos), trade  mark registrations and
applications, service marks, service mark registrations  and applications,
copyrights (registered or otherwise), moral rights, copyright  registrations
and applications, issued patents and pending applications and  other patent
rights (including divisions, reissues, renewals, re-examinations, 
continuations, continuations in part and extensions) applied for or
registered  in any and all jurisdictions and all rights of priority, rights
to file  applications for inventions and derivative applications and patents
in any  and  all jurisdictions, industrial design registrations, pending
applications for  industrial design rights and other industrial design
rights, integrated circuit  topographies, internet domain names (including
Internet protocol addresses)  and  rights in and to e-mail addresses and
Software;

 

 

" **Interim  Period** " means  the period between the date of this
Agreement and the Closing Time;

 

 

" **International  Boulevard Licenses** " has  the  meaning set forth in
Section 5.1.7;

 

 

" **International  Survey** " means  the survey of that portion of the Real
Property municipally known as 100  International Boulevard, Toronto dated
August 2, 2006 prepared by K.S. Thom  of  Lloyd and Purcell Ltd., Ontario Land
Surveyors;

 

 

" **Inventory** " means,  in respect of a Person, all inventories of
replacements, laboratory supplies,  spare and component parts, supplies,
packaging and advertising and publicity  materials, wherever located, and
whether on consignment or not;

 

 

" **Investment  Canada Act** " means  the _Investment  Canada Act_  
(Canada);

 

 

" **ITA** " means  the _Income  Tax Act_   (Canada);

 

 

" **Land** " means  the lands and Buildings owned by MDS at 100
International Boulevard, Toronto,  Ontario and the lands and Buildings owned
by an Operator, or, to the extent  owned and used exclusively in the
Diagnostics Business, MDS, as described in  Section 4.1.20 of the Disclosure
Letter and all rights of way, easements,  licences, benefits, covenants and
privileges and other rights relating  thereto;

 

 

" **Leased  Premises** " means  the premises or portions thereof which are
subject to the Leases;

 

 

" **Leases** " means,  in respect of a Person, the leases, licenses,
occupancy agreements or agreements  or arrangements in the nature of a lease,
license or occupancy agreement of  real  property to which such Person is a
party, whether as lessor or  lessee;

 

 

" **Liabilities** " means  all debts, obligations and liabilities, of any
nature or kind whatsoever,  whether accrued or fixed, absolute or contingent,
matured or unmatured, secured  or unsecured, liquidated or unliquidated and
whether or not reflected or  required to be reflected in a balance sheet in
accordance with  GAAP;

 

 

" **Licence** " means  any licence, permit, approval, right, privilege,
concession or franchise issued,  granted, conferred or otherwise created by a
Governmental  Authority;

 

 

" **Licensed  IP** " has  the  meaning set forth in Subsection 4.1.18(b);

 

 

" **Limited  Trade Mark Licence** " has  the  meaning set forth in Section
5.6;

 

 

" **LPBP  Consent** " means  the consent of the limited partner of MDS ONT
LP to the sale by MDS ONT LP  of  its Ontario Assets in accordance with the
terms of the limited partnership  agreement governing MDS ONT LP;

 

 

" **Material  Adverse Effect** " means  any circumstance, state of facts or
matter, either alone or in combination,  which is materially adverse to, or
could reasonably be expected to have a  material adverse effect on, the
financial condition, results of operations,  prospects or value of the
Diagnostics Business or the Purchased Assets, the  Replacement Contracts and
the Migrating Assets taken as a whole, provided,  however, that any adverse
circumstance, state of facts or matter directly or  indirectly:

 

 

         |  

(a)

    |  

arising  out of or resulting in the ordinary course of business or from
actions  taken by MDS, Rix, Buyer, a Designated Buyer Affiliate or an
Operator  pursuant to, or as contemplated by, this Agreement, the BC
Purchase  Agreement or the Rix Agreement;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

resulting  from the announcement or performance of this Agreement, the BC
Purchase  Agreement or the Rix Agreement or the transactions contemplated
hereby  or  thereby;

    
---|---|--- 
    

 

 

         |  

(c)

    |  

resulting  from economic factors affecting the Canadian economy as a  whole;

    
---|---|--- 
    

 

 

         |  

(d)

    |  

resulting  from factors generally affecting the specific markets in which
the  Diagnostics Business operates, including any adjustment to the insured 
laboratory services fee rates or the provincial insured laboratory  services
payment cap imposed by a Governmental Authority; 

    
---|---|--- 
    

 

 

         |  

(e)

    |  

resulting  from any change in Applicable Laws or  GAAP;

    
---|---|--- 
    

 

 

         |  

(f)

    |  

arising  from a material worsening of current conditions caused by acts of 
God,  terrorism or war (whether or not declared);  or

    
---|---|--- 
    

 

 

         |  

(g)

    |  

resulting  from any failure of the Diagnostics Business to meet projections 
and  estimates;

    
---|---|--- 
    

 

 

shall  not  be deemed in themselves, either alone or in combination, to
constitute a  Material Adverse Effect;

 

 

" **MDS  Confidentiality Agreement** " means  the confidentiality agreement
to be entered into on the Closing Date  substantially in the form attached
hereto as Schedule 5.12;

 

 

" **MDS  Contracting Party** " has  the  meaning set forth in Schedule
5.9;

 

 

" **MDS  Diagnostics Division** " means  the combined operations, assets
and Liabilities of the Diagnostics Business  and  the BC Diagnostics
Business and including MDS' proportionate consolidated  interest in Toronto
Labs and MDS' equity interest in Windsor Labs;

 

 

" **MDS  ESOP** " means  the employee share ownership plan of MDS as
amended and restated as of September  8, 2004;

 

 

" **MDS  ONT LP** " means  MDS Laboratory Services Limited Partnership, a
limited partnership governed  by  the laws of Ontario;

 

 

" **MDS  Option Plan** " means  the MDS Inc. Stock Option Plan as amended
and restated on December 5,  2005;

 

 

" **MDS  Quebec** " means  Laboratoires MDS Quebec Ltee., a wholly-owned
subsidiary of MDS incorporated  under the laws of Quebec;

 

 

" **Mether  LP** " means  Mether Properties Limited Partnership, a limited
partnership governed by the  laws of British Columbia;

 

 

" **Metro  LP** " means  Metro-McNair Clinical Laboratories Limited
Partnership, a limited partnership  governed by the laws of British Columbia;

 

 

" **Migrating  Assets** " has  the  meaning attributed thereto in the
Migration Agreement;

 

 

" **Migration  Agreement** " has  the  meaning set forth in Section 5.7;

 

 

" **Minimum  Required Consents** " has  the  meaning set forth in Schedule
3.1;

 

 

" **No-Action  Letter** " means  a  letter wherein the Commissioner
advises the Parties, and whether or not subject  to any conditions or
qualifications, that the Commissioner is of the view that  there are not
sufficient grounds at that time to initiate proceedings before  the 
Competition Tribunal under the merger provisions of the Competition Act in 
respect of the transactions contemplated herein and in the BC Purchase 
Agreement;

 

 

" **Non-Assignable  Contract** " means  any of the Contracts, Leases,
Equipment Leases, Shared Contracts, Warranty  Rights or Transferable Licences
included in the Purchased Assets:

 

 

         |  

(i)

    |  

an  assignment or attempted assignment of which would constitute a breach 
thereof without the consent of a third party if such consent has  not been 
obtained; or

    
---|---|--- 
    

 

 

         |  

(ii)

    |  

an  assignment of which would contravene any Applicable  Law,

    
---|---|--- 
    

 

 

including  those set forth in Section 1.1 of the Disclosure Letter;

 

 

" **Non-Assigned  Leases** " has  the  meaning set forth in Section
2.3(c);

 

 

" **Non-Competition  Agreement** " has  the  meaning set forth in Section
5.8;

 

 

" **Non-Controlled  Corporate Operator** " has  the  meaning set forth in
Subsection 4.1.1(a);

 

 

" **Non-Controlled  Operators** " means,  collectively, the Non-Controlled
Corporate Operator and the Non-Controlled  Partnership Operator;

 

 

" **Non-Controlled  Partnership Operator** " has  the  meaning set forth
in Subsection 4.1.1(a);

 

 

" **Ontario  Assets** " means  the AutoLabs Assets and all of the assets,
property and undertaking of every  kind and nature and wherever located,
owned, leased, used or otherwise held  by  MDS ONT LP, Ontario GP or MDS
Primarily in respect of the operation of the  Diagnostics Business carried on
in Ontario, excluding the Excluded Assets,  but  including the following:

 

 

         |  

(a)

    |  

the  Ontario Premises and the Building, Equipment and Inventory located  in,
on  or about the Ontario Premises, in each case to the extent they relate 
Primarily to the Diagnostics Business carried on in Ontario including,  for 
greater certainty, the furniture, fixtures and equipment at 100 
International Boulevard, Toronto, Ontario, except as set forth in  Section 
1.1  of  the Disclosure Letter under the heading "Excluded Assets", and
the  furniture, fixtures and equipment at 75 International Boulevard, 
Toronto,  Ontario set forth in Section 1.1  of  the Disclosure Letter;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

all  right, title and interest of MDS ONT LP, Ontario GP or MDS in, to 
and  under the Leases and the Leased Premises as described under the
subheading  Ontario in Schedule C annexed to the Disclosure Letter, all
leasehold  improvements pertaining to the Leases and Leased Premises, all
Equipment  and Inventory located in, on or about the Leased Premises and
all  appurtenances thereto, in each case to the extent they relate
Primarily  to  the Diagnostics Business carried on in  Ontario;

    
---|---|--- 
    

 

 

         |  

(c)

    |  

all  right, title and interest of MDS ONT LP, Ontario GP or MDS in, to 
and  under, and the full benefit of, the Contracts and the Equipment Leases 
relating Primarily to the Diagnostics Business carried on in Ontario 
including those listed in Schedule D annexed to the Disclosure  Letter;

    
---|---|--- 
    

 

 

         |  

(d)

    |  

all  Intellectual Property Rights of MDS ONT LP, Ontario GP and MDS
relating  Primarily to the Diagnostics Business carried on in Ontario,
including  the  Intellectual Property Rights set forth in Schedule E annexed
to the  Disclosure Letter;

    
---|---|--- 
    

 

 

         |  

(e)

    |  

the  Accounts Receivable (save and except for any Accounts Receivable  of
MDS  ONT LP or Ontario GP owing by MDS or any of its Affiliates), Books 
and  Records, Petty Cash, Prepaid Expenses, Technical Information, Warranty 
Rights and Transferable Licences of MDS ONT LP, Ontario GP or MDS,  in each 
case relating Primarily to the Diagnostics Business carried on in  Ontario;

    
---|---|--- 
    

 

 

         |  

(f)

    |  

all  claims of MDS, Ontario GP or MDS ONT LP relating to the Diagnostics 
Business carried on in Ontario (except to the extent such claims  relate to 
any Excluded Assets) or the Purchased Assets or the Replacement Contracts  in
Ontario, whether choate or inchoate, known or unknown, contingent  or 
otherwise;

    
---|---|--- 
    

 

 

         |  

(g)

    |  

the  goodwill of the Diagnostics Business carried on in Ontario, including 
the  exclusive right to the Buyer to represent itself as carrying on the 
Diagnostics Business in Ontario in continuation of and in succession  to 
MDS, Ontario GP and MDS ONT LP, subject to the provisions of the  Limited 
Trade Mark Licence; and

    
---|---|--- 
    

 

 

         |  

(h)

    |  

the  Toronto Assets, the Windsor Assets and the Inscyte  Assets;

    
---|---|--- 
    

 

 

" **Ontario  Employees** " means  all of the employees of MDS working
exclusively in the Diagnostics Business  carried on in Ontario as at the
Closing Time, which are, as at August 28, 2006,  those Employees identified
in Schedule F annexed to the Disclosure Letter under  the subheading Ontario
Employees and all of the employees of the Ontario GP  as  at the Closing
Time, which are, as at August 28, 2006, those Employees  identified in
Schedule F annexed to the Disclosure Letter under the subheading  Ontario GP
Employees;

 

 

" **Ontario  GP** " means  MDS Laboratory Services Inc., a wholly-owned
subsidiary of MDS incorporated  under the laws of Ontario;

 

 

" **Ontario  Liabilities** " means,  without duplication,

 

 

         |  

(a)

    |  

all  Liabilities of MDS ONT LP, Ontario GP or MDS relating to the
Diagnostics  Business carried on in Ontario or the Ontario Assets in each
case  included  in or provided for in, or required to be included in or
provided  for in,  the Closing Balance Sheet in accordance with GAAP
(including those  Liabilities included in or provided for in the Financial
Statements  that  remain outstanding at the Closing Time) but excluding
payables owed  by MDS  ONT LP or Ontario GP to MDS or any of its 
Affiliates;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

all  AutoLab Liabilities arising after the Closing  Time;

    
---|---|--- 
    

 

 

         |  

(c)

    |  

all  Liabilities of MDS ONT LP, Ontario GP or MDS under the Contracts, 
Leases  and Equipment Leases included in the Purchased Assets and the
Replacement  Contracts, in each case arising after the Closing Time and not
related  to  any default of MDS ONT LP, Ontario GP or MDS existing prior to
(and  remaining unremedied at the Closing Time) or as a consequence of 
Closing;

    
---|---|--- 
    

 

 

         |  

(d)

    |  

all  Liabilities of MDS ONT LP, Ontario GP or MDS relating to the Ontario 
Employees who accept the Buyer's or Designated Buyer Affiliate's offer of 
employment as contemplated by Subsection 5.4.1(a)  and which arise or become
payable on or after the Closing Time, including  wages and any other form of
compensation, remuneration or benefits  under  any Benefit Plan including
bonuses, termination and severance pay,  pensions and all other post-
retirement benefits and employee health  and  welfare obligations and
including any claims by any such Employee  arising  on or after the Closing
Time other than any Liabilities arising under  or  with respect to the MDS
Option Plan or MDS ESOP or the lack of such  plans  or any retention, change
of control or deal bonus pertaining to the  sale  of the Diagnostics
Business;

    
---|---|--- 
    

 

 

         |  

(e)

    |  

all  Liabilities of MDS and its Affiliates arising in respect of the 
Replacement Contracts to the extent same relate directly to the  Diagnostics
Business carried on in Ontario or the Ontario Assets  and arise  after the
Closing Time and are not related to any default of MDS  or its  Affiliates
existing prior to (and remaining unremedied at the Closing  Time) or as a
consequence of  Closing;

    
---|---|--- 
    

 

 

         |  

(f)

    |  

all  other Liabilities of MDS, Ontario GP and MDS ONT LP not otherwise 
provided  for herein relating directly to the Diagnostics Business carried 
on in  Ontario arising, accruing or relating to periods on or after the 
Closing  Time;

    
---|---|--- 
    

 

 

         |  

(g)

    |  

all  Liabilities of MDS, Ontario GP and MDS ONT LP relating to the claims 
referred to in clause (f) of the definition of Ontario Assets arising  after
the Closing Time; and

    
---|---|--- 
    

 

 

         |  

(h)

    |  

the  Toronto Liabilities and Windsor  Liabilities.

    
---|---|--- 
    

 

 

" **Ontario  Licensing Act** " means  the _Laboratory  and Specimen
Collection Centre Licensing Act_ (Ontario)  and the related _Specimen 
Collection Centres_   Regulation, and _Laboratories_   Regulation;

 

 

" **Ontario  Premises** " means  the Lands described in Section 4.1.20  of
the  Disclosure Letter;

 

 

" **Operators** " means,  collectively, MDS ONT LP, Ontario GP and MDS
Quebec, and "Operator" means any  one of them;

 

 

" **Order** " means  any order, judgment, injunction, decree, award or writ
of any court, arbitrator  or Governmental Authority;

 

 

" **ordinary  course** " or  " **normal  course** ",  when  used in
relation to the conduct by a Person, means any transaction or conduct  which
constitutes an ordinary day-to-day business activity of the Person  conducted
in a commercially reasonable and businesslike manner consistent with  such
Person's past customs and practices;

 

 

" **Other  Confidentiality Agreements** " means  all of the confidentiality
agreements between MDS and each party (other than  the  Buyer and Rix) that
was in discussions with MDS to purchase the Purchased Assets  and/or the BC
Purchased Assets;

 

 

" **Parties** " means  MDS and Buyer, and upon a Designated Buyer Affiliate
signing a contract of  adhesion as required by Section 5.11,  such 
Designated Buyer Affiliate, collectively, and "Party" means either (or, as 
applicable, any) one of them;

 

 

" **Partnership  Interest** " in  respect of a partner in a partnership,
means all the units and/or other interest  held by such partner in such
partnership, if any, and all right, title and  interest of such partner under
the partnership agreement governing such  partnership and Applicable Law
including all rights, benefits and entitlement  to  profits and losses,
insurance proceeds, current account, capital account, return  of capital,
repayment of indebtedness and any other benefit in connection with  the
business, sale or dissolution of such partnership whether as a general  or 
limited partner and whether of a general or limited partnership;

 

 

" **Partnership  Operator** " has  the  meaning set forth in Subsection
4.1.1(a);

 

 

" **Pension  Plan** " means  each of the Benefit Plans that is a
"Registered Pension Plan" as that term is  defined in subsection 248(1) of
the ITA;

 

 

" **Permitted  Encumbrances** "  means:

 

 

         |  

(a)

    |  

inchoate  or statutory liens for Taxes and assessments, both general and
special,  and other governmental charges not yet due and payable as of the 
Closing  Time;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

statutory  liens incurred or deposits made by an Operator or MDS in
connection  with  workers' compensation, unemployment insurance and similar
legislation; 

    
---|---|--- 
    

 

 

         |  

(c)

    |  

any  reservations or exceptions contained in the original grants from  the
Crown  as amended by statute;

    
---|---|--- 
    

 

 

         |  

(d)

    |  

all  encroachments, overlaps, overhangs, unrecorded servitudes and
easements,  variations in area or measurement, rights of parties in
possession  or any  other matters not of record which would be disclosed by
an accurate  survey  or physical inspection of the Real Property, provided
that same are  not of  such nature as to, individually or in aggregate, have
a material  adverse  effect on the use or value of the Real Property
subject  thereto;

    
---|---|--- 
    

 

 

         |  

(e)

    |  

all  encroachments, overlaps, overhangs, servitudes and easements,
variations  in area or measurement, rights of parties in possession,
discrepancies  in  the legal description of that portion of the Real
Property municipally  known as 100 International Boulevard, Toronto or any
other matters  disclosed by the International Survey; 

    
---|---|--- 
    

 

 

         |  

(f)

    |  

minor  discrepancies in the legal description of the Land or any adjoining 
real  property which would be disclosed in an up to date  survey;

    
---|---|--- 
    

 

 

         |  

(g)

    |  

all  servitudes and easements (including conservation easements and public 
trust easements, rights-of-way, road use agreements, covenants,  conditions,
restrictions, reservations, licences, agreements and  other  matters of
record) and zoning by-laws, ordinances and other restrictions  as to the use
of real property, provided that same are not of such  nature  as to,
individually or in aggregate, have a material adverse effect  on the  use or
value of the Real Property subject thereto and provided the  same  have been
complied with by MDS or the Operators, as the case may  be, in  all material
respects to the Closing  Date;

    
---|---|--- 
    

 

 

         |  

(h)

    |  

all  registered and unregistered municipal agreements and agreements with 
public and private utilities, provided the same have been complied  with by 
MDS or the Operators, as the case may be, in all material respects  to the 
Closing Date;

    
---|---|--- 
    

 

 

         |  

(i)

    |  

the  rights of third parties under the Contracts, Equipment Leases, Leases, 
Shared Contracts, the Replacement Contracts and the Migrating Assets 
including the partnership agreements and shareholders' agreements included 
in the Purchased Assets including the consent rights and rights of  first 
refusal of third parties triggered upon the transfer of Partnership 
Interests or shares included in the Purchased Assets but excluding  rights 
against Sellers arising in respect of indebtedness; and 

    
---|---|--- 
    

 

 

         |  

(j)

    |  

in  respect of MDS or any Operator, the Encumbrances set forth in Section 
1.1  of the Disclosure Letter;

    
---|---|--- 
    

 

 

" **Permitted  Proposal** " has  the  meaning set forth in Subsection
5.1.1(e);

 

 

" **Person** " shall  be broadly interpreted and includes an individual,
body corporate, partnership,  joint venture, trust, association,
unincorporated organization, the Crown,  any  Governmental Authority or any
other entity recognized by law;

 

 

" **Personal  Information** " means  personal information in each case as
defined by the applicable Privacy Laws  and  collected, used, disclosed or
retained by MDS or an Operator in connection  with  the Diagnostics
Business;

 

 

" **Petty  Cash** " means  the petty cash of the MDS Diagnostics Division
in Ontario and Quebec for use  in  the business at the premises at which the
business is carried on;

 

 

" **Post-Closing  Services Agreement** " has  the  meaning set forth in
the Migration Agreement;

 

 

" **Prepaid  Expenses** " means,  in respect of a Person, all deposits and
prepaid expenses of such Person  including those with any public utility or
any municipal, governmental or other  public authority, to the extent the
same are transferable;

 

 

" **Primarily** " **** means  in  respect of any asset of a Person, each
asset that has been used by such Person  during the previous 12 **** months 
not less than 70% of the time, in the aggregate in the ordinary course of
the  Diagnostics Business;

 

 

" **Prime  Rate** " for  any  day means the rate of interest expressed as
a rate per annum that Canadian  Imperial Bank of Commerce establishes at its
head office in Toronto as the  reference rate of interest that it will charge
on that day for Canadian dollar  demand loans to its customers in Canada and
which at present it refers to as  its  prime rate;

 

 

" **Privacy  Laws** " means  all applicable federal and provincial laws
governing the collection, use,  disclosure and retention of Personal
Information, including, the _Personal  Information Protection and Electronic
Documents Act_   (Canada), the _Personal  Health Information Protection Act_
  (Ontario) and _An  Act Respecting the Protection of Personal Information
in the Private  Sector_   (Quebec);

 

 

" **Proprietary  IP** " has  the  meaning set forth in Subsection
4.1.18(a);

 

 

" **Purchase  Price** " has  the  meaning set forth in Subsection 3.1(a);

 

 

" **Purchased  Assets** " means,  subject to Section 2.2,  the  Quebec
Assets and the Ontario Assets;

 

 

" **Quarterly  Statements** " means  the unaudited combined financial
statements prepared by MDS for the MDS  Diagnostics Division for the three
(3), six (6) and nine (9) month periods  ended  January 31, 2006, April 30,
2006 and July 31, 2006, respectively, a copy of  which financial statements
are annexed to the Disclosure Letter as Schedule  B;

 

 

" **Quebec  Assets** " means  all of the assets, property and undertaking
of every kind and nature and  wherever located, owned, leased, used or
otherwise held by MDS Quebec or MDS  Primarily in respect of the operation of
the Diagnostics Business carried on  in  Quebec, excluding the Excluded
Assets, but including the following:

 

 

         |  

(a)

    |  

all  right, title and interest of MDS Quebec or MDS in, to and under the 
Leases  and the Leased Premises as described under the subheading Quebec 
in  Schedule C annexed to the Disclosure Letter, all leasehold improvements 
pertaining to the Leases and Leased Premises, all Equipment and Inventory 
located in, on or about the Leased Premises and all appurtenances  thereto, 
in each case to the extent they relate Primarily to the Diagnostics  Business
carried on in Quebec;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

all  right, title and interest of MDS Quebec or MDS in, to and under,  and
the  full benefit of, the Contracts and the Equipment Leases relating 
Primarily  to the Diagnostics Business carried on in Quebec including those 
listed in  Schedule D annexed to the Disclosure  Letter;

    
---|---|--- 
    

 

 

         |  

(c)

    |  

all  Intellectual Property Rights of MDS Quebec or MDS relating Primarily 
to  the Diagnostics Business in Quebec, including the Intellectual Property 
Rights set forth in Schedule E annexed to the Disclosure  Letter;

    
---|---|--- 
    

 

 

         |  

(d)

    |  

the  Accounts Receivable (save and except for any Accounts Receivable  of
MDS  Quebec owing by MDS or any of its Affiliates), Books and Records, 
Petty  Cash, Prepaid Expenses, Technical Information, Warranty Rights and 
Transferable Licences of MDS Quebec or MDS, in each case relating  Primarily
to the Diagnostics Business carried on in  Quebec;

    
---|---|--- 
    

 

 

         |  

(e)

    |  

all  claims of MDS or MDS Quebec relating to the Diagnostics Business 
carried  on in Quebec (except to the extent such claims relate to any
Excluded  Assets) or the Purchased Assets or the Replacement Contracts in
Quebec,  whether choate or inchoate, known or unknown, contingent or
otherwise;  and

    
---|---|--- 
    

 

 

         |  

(f)

    |  

the  goodwill of the Diagnostics Business carried on in Quebec, including 
the  exclusive right to the Buyer to represent itself as carrying on the 
Diagnostics Business in Quebec in continuation of and in succession  to MDS 
and MDS Quebec, subject to the provisions of the Limited Trade Mark  Licence;

    
---|---|--- 
    

 

 

" **Quebec  Employees** " means  all of the employees of MDS Quebec or MDS
working exclusively in the Diagnostics  Business carried on in Quebec as at
the Closing Time, which are, as at August  28, 2006, those Employees
identified in Schedule F annexed to the Disclosure  Letter under the
subheading Quebec Employees;

 

 

" **Quebec  Liabilities** " means,  without duplication,

 

 

         |  

(a)

    |  

all  Liabilities of MDS Quebec or MDS relating to the Diagnostics Business 
carried on in Quebec or the Quebec Assets in each case included in  or 
provided for in, or required to be included in or provided for in,  the 
Closing Balance Sheet in accordance with GAAP (including those Liabilities 
included in or provided for in the Financial Statements that remain 
outstanding at the Closing Time) but excluding payables owed by MDS  Quebec 
to MDS or any of its Affiliates;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

all  Liabilities of MDS Quebec or MDS under the Contracts, Leases and 
Equipment  Leases included in the Purchased Assets and the Replacement
Contracts,  in  each case arising after the Closing Time and not related to
any default  of  MDS Quebec or MDS existing prior to (and remaining
unremedied at  the  Closing Time) or as a consequence of  Closing;

    
---|---|--- 
    

 

 

         |  

(c)

    |  

all  Liabilities of MDS Quebec or MDS relating to the Quebec Employees 
who  accept the Buyer's or Designated Buyer Affiliate's offer of employment
as  contemplated by Subsection 5.4.1(a)  and which arise or become payable
on or after the Closing Time, including  wages and any other form of
compensation, remuneration or benefits  under  any Benefit Plan including
bonuses, termination and severance pay,  pensions and all other post-
retirement benefits and employee health  and  welfare obligations and
including any claims by any such Employee  arising  on or after the Closing
Time other than any Liabilities arising under  or  with respect to the MDS
Option Plan or MDS ESOP or the lack of such  plans  or any retention, change
of control or deal bonus pertaining to the  sale  of the Diagnostics
Business;

    
---|---|--- 
    

 

 

         |  

(d)

    |  

all  Liabilities of MDS and its Affiliates arising in respect of the 
Replacement Contracts to the extent same relate directly to the  Diagnostics
Business carried on in Quebec or the Quebec Assets and  arise  after the
Closing Time and are not related to any default of MDS  or its  Affiliates
existing prior to (and remaining unremedied at the Closing  Time) or as a
consequence of Closing; 

    
---|---|--- 
    

 

 

         |  

(e)

    |  

all  other Liabilities of MDS Quebec not otherwise provided for herein 
relating  directly to the Diagnostics Business carried on in Quebec
arising,  accruing or relating to periods on or after the Closing Time;  and

    
---|---|--- 
    

 

 

         |  

(f)

    |  

all  Liabilities of MDS and MDS Quebec relating to the claims referred  to
in  clause (e) of the definition of the Quebec Assets arising after the 
Closing Time;

    
---|---|--- 
    

 

 

" **Quebec  Licensing Act** " means  _an  act respecting medical
laboratories, organ, tissue, gamete and embryo  conservation and the disposal
of human bodies_   (Quebec)  and its regulation entitled _Regulation 
respecting the application of the public health protection act_ ;

 

 

" **Quebec  Personal Information** " means  "personal information" as
defined in Section 2 of _An  Act Respecting the Protection of Personal
Information in the Private  Sector_   (Quebec)  that has been collected and
used by MDS Quebec in Quebec;

 

 

" **Real  Property** " means  the Land and the Buildings thereon;

 

 

" **Regional  Assets** " has  the  meaning set forth in Section 2.1(b);

 

 

" **Regional  Financial Statements** " means  the unaudited supplementary
schedule to the Quarterly Statements for the period  ended July 31, 2006 for
the MDS Diagnostics Division in Ontario and Quebec  and  the head office of
the MDS Diagnostic Division consisting of a balance sheet  as  at July 31,
2006 and an income statement for the nine-month period ending July  31, 2006;

 

 

" **Regional  Purchase Agreement** " has  the  meaning set forth in
Subsection 2.1(b);

 

 

" **Regulatory  Consents** " means  the Competition Act Clearance and all
approvals and consents of Governmental  Authorities required by reason of the
transactions contemplated herein in  relation to the specimen collection and
laboratory testing Licences required  under the Ontario Licensing Act and
Quebec Licensing Act for the diagnostic  testing facilities of MDS and the
Operators in Ontario and Quebec, respectively,  relating exclusively to the
Diagnostics Business and the specimen collection  Licences for the patient
service centers of MDS and the Operators in Ontario  and  Quebec,
respectively, relating exclusively to the Diagnostics Business including 
those set forth in Section 1.1 of the Disclosure Letter;

 

 

" **Release** " means  releasing, spilling, seeping, leaking, pumping,
pouring, emitting, emptying,  discharging, depositing, injecting, escaping,
leaching, disposing or dumping  into the environment of any Hazardous
Materials or any consequent release,  spill, leak, emission, discharge,
deposit, seepage, and/or exhaust of any  Hazardous Material;

 

 

" **Replacement  Contracts** " means,  collectively, each of the Contracts
relating to the Diagnostics Business entered  into pursuant to (i) Section
5.10  in  respect of Shared Contracts, or (ii) Section 5.14  in  respect
of a Subject Contract, which are transferred and assigned to Buyer  or a 
Designated Buyer Affiliate as contemplated herein;

 

 

" **Representative** " means,  in respect of a Person, each director,
officer, employee, agent, solicitor,  accountant, professional advisor and
other representative of the  Person;

 

 

" **Rix** " means  Donald B. Rix, a resident of Vancouver, British Columbia;

 

 

" **Rix  Agreement** " means  the agreement dated the date hereof between
MDS, Rixco and Rix pursuant to  which, among other things, Rixco agrees to
sell to MDS the Rix Partnership  Interests (as defined in the Rix Agreement)
and MDS agrees to purchase the  Rix  Partnership Interests and assume the
Rix Liabilities (as defined in the Rix  Agreement) on the terms and subject
to the conditions set forth in such  agreement, as such agreement may be
supplemented, amended, restated or replaced  from time to time;

 

 

" **Rixco** " means  Rix Clinical Laboratories Ltd., a corporation
incorporated under the laws of  British Columbia controlled by Rix;

 

 

" **ROFR  Exclusion** " has  the  meaning set forth in Subsection 2.2(b);

 

 

" **Rules** " has  the  meaning set forth in Section 9.3;

 

 

" **Sellers** " means,  collectively, MDS, Ontario GP, MDS ONT LP and MDS
Quebec, and " **Seller** " means  any one of them;

 

 

" **Shared  Contract** " means  each Contract listed on Schedule H annexed
to the Disclosure Letter pursuant  to  which MDS and one or more Operators
is a party and whereby such parties share  the rights, interests, benefits
and Liabilities thereunder in accordance with  the terms of each such
Contract;

 

 

" **Software** " means  all computer software (in all forms and formats,
including source code and  object code) owned by the Operators or, to the
extent owned for use Primarily  in  the Diagnostics Business, MDS, including
the computer programs known by the  names as set forth in Schedule E to the
Disclosure Letter, including all  versions thereof, and all related
documentation (of any kind or nature),  development tools, diagnostic tools,
manuals, program files, data files (to  the  extent required to execute and
operate the Software), specifications, data  model  structures, program and
system logic, technical interfaces, program modules,  routines, sub-routines,
algorithms, program architecture, design concepts,  system designs, program
structure, sequence and organization, graphical user  interfaces (including
screen displays and so called "look and feel" but  excluding all logos and
trade marks other than to the extent set forth in  Section 4.1.18  of the 
Disclosure Letter) and report layouts;

 

 

" **Subject  Contract** " has  the  meaning set forth in Section 5.14;

 

 

" **Support  Services Agreement** " has  the  meaning set forth in Section
5.9;

 

 

" **Support  Services Agreement Term Sheet** " has  the  meaning set forth
in Section 5.9;

 

 

" **Target  Working Capital** " means  the targeted amount of Working
Capital of the MDS Diagnostics Division in  Ontario and Quebec and the head
office of the MDS Diagnostics Division being  $8,000,000;

 

 

" **Tax  Returns** " means  any return, declaration, report, schedule,
information statement or return  with  respect to Taxes required to be filed
with a Governmental  Authority;

 

 

" **Taxes** " means,  in respect of a Person, any and all taxes and related
governmental charges  (including assessments, charges, duties, rates, fees,
imposts, levies or other  governmental charges and interest, penalties or
additions associated therewith)  including Canadian federal, provincial,
municipal and local, foreign or other  income, franchise, capital, real
property, personal property, tangible,  withholding, payroll, employer
health, social security, transfer, sales, use,  consumption, GST, excise,
anti-dumping, stamp, countervail and value added  taxes, all other taxes of
any kind for which the Person may have any Liability  whether disputed or not
and all Canada Pension Plan contributions and employment  insurance premiums;

 

 

" **Technical  Information** " means,  in respect of a Person, all right,
title and interest in and to all trade  secrets, confidential information and
proprietary know-how, in each case used  Primarily in the Diagnostics
Business and to the extent not subject to an  Intellectual Property Right,
whether developed or acquired by or on behalf  of  such Person including:

 

 

         |  

(a)

    |  

all  confidential information of a scientific, technical or business nature 
whether in written, graphic, machine readable, electronic or physical  form;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

all  patterns, plans, designs, research data, research plans, processes, 
formulae, drawings, unpatented blue prints, flow sheets, equipment  and 
parts lists, instructions, manuals, records and procedures;  and

    
---|---|--- 
    

 

 

         |  

(c)

    |  

all  inventions other than as embodied in any issued patents and pending 
patent  applications;

    
---|---|--- 
    

 

 

" **Threshold  Adjustment** " has  the  meaning set forth in Section 3.5;

 

 

" **Toronto  Assets** " means  the following:

 

 

         |  

(a)

    |  

1,000  common shares of Toronto GP held by  MDS;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

49.995%  Partnership Interest in Toronto Labs held by MDS, as a limited
partner  or,  at the option of MDS, all of the issued and outstanding shares
of  a newly  incorporated corporation holding such 49.995% Partnership
Interest  of  Toronto Labs, as a limited partner and no other assets; 

    
---|---|--- 
    

 

 

         |  

(c)

    |  

all  right, title and interest of MDS in, to and under the shareholders' 
agreement governing Toronto GP; and

    
---|---|--- 
    

 

 

         |  

(d)

    |  

all  right, title and interest of MDS in, to and under the [REDACTED] 
agreement  dated November 29, 1996 between The Toronto Hospital, MDS,
Toronto  Labs  and Toronto GP;

    
---|---|--- 
    

 

 

" **Toronto  GP** " means  Toronto Medical Laboratories Limited, a
corporation incorporated under the  laws  of Ontario;

 

 

" **Toronto  Labs** " means  Toronto Medical Laboratories Limited
Partnership, a limited partnership governed  by the laws of Ontario;

 

 

" **Toronto  Liabilities** " means  all Liabilities of MDS and its
Affiliates:

 

 

         |  

(a)

    |  

under  the shareholders' agreement governing Toronto GP arising after the
Closing  Time and not related to any default of MDS existing prior to (and 
remaining unremedied at the Closing Time) or as a consequence of  Closing;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

in  respect of the Partnership Interest of Toronto Labs held by MDS or  an 
Affiliate, as a limited partner;  and

    
---|---|--- 
    

 

 

         |  

(c)

    |  

under  the [REDACTED] agreement dated November 29, 1996 between The Toronto 
Hospital, MDS, Toronto Labs and Toronto GP arising after the Closing  Time 
and not related to any default of MDS existing prior to (and remaining 
unremedied at the Closing Time) or as a consequence of  Closing;

    
---|---|--- 
    

 

 

" **Transferable  Licences** " means,  in respect of a Person, all rights
and interest in and to all Licences issued  to  such Person which are
transferable, with or without the consent of a  Governmental Authority;

 

 

" **Unaccounted  Excluded Refund** " has  the  meaning set forth in
Section 7.4;

 

 

" **U.S.  Non-Competition Agreements** " has  the  meaning set forth in
Section 7.12;

 

 

" **U.S.  Support Services Contracts** " means  the support, transition and
related services agreements between MDS and/or  certain of MDS' U.S.
Affiliates and purchasers of certain diagnostics businesses  formerly
operated by any Seller or its Affiliates as listed in Section 1.1  of  the
Disclosure Letter:

 

 

" **U.S.  Transition Services Contracts** " has  the  meaning set forth in
Schedule 5.9;

 

 

" **Warranty  Rights** " means,  in respect of a Person, the full benefit
of all warranties, warranty rights,  guarantees, indemnities, undertakings
and similar covenants (implied, express  or  otherwise) against
manufacturers or sellers held by such Person or to which  such  Person is
entitled;

 

 

" **Windsor  Assets** " means  the following:

 

 

         |  

(a)

    |  

40  common shares of Windsor Labs held by MDS;  and

    
---|---|--- 
    

 

 

         |  

(b)

    |  

all  right, title and interest of MDS in, to and under the Windsor 
Shareholders' Agreement;

    
---|---|--- 
    

 

 

" **Windsor  Labs** " means  Medical Laboratories of Windsor Limited, a
corporation incorporated under the  laws of Ontario;

 

 

" **Windsor  Liabilities** " means  all Liabilities of MDS under the
Windsor Shareholders' Agreement arising after  the Closing Time and not
related to any default of MDS existing prior to (and  remaining unremedied at
the Closing Time) or as a consequence of  Closing;

 

 

" **Windsor  Shareholders ' Agreement**" means  the shareholders' agreement
governing Windsor Labs dated as of November 1,  2002;

 

 

" **Working  Capital** " means,  as at any time, the sum of Petty Cash,
Accounts Receivable, Inventory, Prepaid  Expenses and instalments, refunds or
other recoverables in respect of Taxes  (other than income Taxes) of the MDS
Diagnostics Division in Ontario and Quebec  and the head office of the MDS
Diagnostics Division at that time, determined  in  accordance with Sections
3.2  and 3.3,  less  the amount of accounts payable or accrued current
Liabilities of the MDS  Diagnostics Division in Ontario and Quebec and the
head office of the MDS  Diagnostics Division that would be included in or
provided in a balance sheet  under GAAP at that time but excluding any
provision for income Taxes under  GAAP  and the current portion of long term
debt; and

 

 

" **Working  Capital Adjustment Date** " has  the  meaning set forth in
Subsection 3.2(d).

 

 

**1.2** **Interpretation**

 

 

         |  

(a)

    |  

Unless  specified otherwise, reference in this Agreement to a statute
refers  to  that statute as it may be amended, or to any restated or
successor  legislation of comparable effect.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

All  accounting and financial terms used herein, unless specifically
provided  to the contrary, shall be interpreted and applied in accordance
with  GAAP.

    
---|---|--- 
    

 

 

         |  

(c)

    |  

The  division of this Agreement into articles, sections, subsections and 
schedules and the insertion of headings are for convenience of reference 
only and shall not affect the construction or interpretation of this 
Agreement. The article, section, subsection and schedule headings  in this 
Agreement are not intended to be full or precise descriptions of  the text 
to which they refer and are not to be considered part of this Agreement.  All
uses of the words " **hereto** ",  " **herein** ",  " **hereof** ",  "
**hereby** "  and " **hereunder** "  and similar expressions refer to this
Agreement and not to any particular  section or portion of it. References to
an Article, Section, Subsection  or  Schedule refer to the applicable
article, section, subsection or  schedule  of this Agreement.

    
---|---|--- 
    

 

 

         |  

(d)

    |  

In  this Agreement, words in the singular include the plural and vice-versa 
and words in one gender include all  genders.

    
---|---|--- 
    

 

 

         |  

(e)

    |  

This  Agreement is the joint product of MDS and Buyer, has been subject 
to  mutual consultation, negotiation and agreement of the Parties and 
shall  not be construed for or against any  Party.

    
---|---|--- 
    

 

 

         |  

(f)

    |  

Reference  in this Agreement to the term " **including** "  shall mean "
**including** **without  limitation** "  and shall not be construed to limit
any general statement which it  follows  to the specific or similar items or
matters immediately following  it.

    
---|---|--- 
    

 

 

         |  

(g)

    |  

MDS  shall cause MDS Quebec and, subject to the LPBP Consent, Ontario  GP,
as  general partner of, MDS ONT LP, to perform their respective obligations 
as  Sellers under this Agreement subject to and in accordance with this 
Agreement. References in this Agreement to Seller agreeing or otherwise 
covenanting to take some action or to MDS causing the other Sellers  to 
take some action shall, in the case of MDS ONT LP mean that Ontario  GP, as 
general partner, will cause MDS ONT LP to perform such action, subject  to 
LPBP Consent.

    
---|---|--- 
    

 

 

         |  

(h)

    |  

If  there is any conflict or inconsistency between the provisions of  this 
Agreement and the provisions of any Regional Purchase Agreement,  the 
provisions of this Agreement shall govern. 

    
---|---|--- 
    

 

 

         |  

(i)

    |  

Reference  in Section 5.2.1  to  the Buyer using " **best  efforts** " 
to obtain one or more Regulatory Consents, in the time stipulated  in this 
Agreement, shall mean that the Buyer shall, if necessary or advantageous  to
securing such Regulatory Consents within such time period and  without 
limiting its general obligations to use best efforts, (i) agree to  such 
undertakings as may be required by the applicable Governmental Authority  as
a condition of granting its consent, approval or non-disapproval;  and  (ii)
propose to the applicable Governmental Authority, and negotiate,  offer to
take, and, if such offer is accepted, effect by consent  order,  undertaking
and/or otherwise to:

    
---|---|--- 
    

 

 

         |  

(i)

    |  

restructure  the transaction as now contemplated in this Agreement prior to
or  at  Closing to the satisfaction of the Governmental Authority (such as 
the  sale of some of the assets, shares and/or other ownership interests 
that  are the subject of this Agreement to a third party), but only with 
the  consent of MDS, acting reasonably;

    
---|---|--- 
    

 

 

         |  

(ii)

    |  

divest  post-Closing certain assets, shares and/or other ownership
interests;  and/or

    
---|---|--- 
    

 

 

         |  

(iii)

    |  

agree  to abide by post-Closing conduct requirements as specified by the 
Governmental Authority.

    
---|---|--- 
    

 

 

         |  

(j)

    |  

For  greater certainty, each reference in this Agreement to the term  "
**Primarily** ",  notwithstanding any reference to the "Diagnostics Business"
as it is being  carried on in Ontario or Quebec immediately following, is
intended  by the  Parties to relate to the Diagnostics Business alone or
together with  any  part or portion of the BC Diagnostics Business, with the
intention  that  any applicable Purchased Asset that meets the test set
forth in the  definition of "Primarily", either excluding its use in the BC
Diagnostics  Business or as a result of the inclusion of its use in the BC
Diagnostics  Business where its use as at the Closing Date is predominantly
in  the  Diagnostics Business in Ontario or Quebec, as the case may be,
such  Purchased Asset shall be conveyed to the Buyer pursuant to this 
Agreement.

    
---|---|--- 
    

 

 

**1.3** **Entire  Agreement**

 

 

This  Agreement, the confidentiality agreement between MDS and Buyer, dated
December  6, 2005, as amended by agreement of even date herewith (the "
**Confidentiality  Agreement** "),  a  letter of even date from Buyer or an
Affiliate thereof to MDS, the Closing  Documents and the BC Documents
constitute the entire agreement between the  Parties pertaining to the
subject matter hereof and thereof, respectively,  and  supersede all prior
agreements, negotiations, discussions and understandings,  written or oral,
between the Parties. There are no representations, warranties,  conditions,
other agreements or acknowledgements, whether direct or collateral,  express
or implied, that form part of or affect this Agreement, or which induced  any
Party to enter into this Agreement or on which reliance is placed by any 
Party, except as specifically set forth in this Agreement, the
Confidentiality  Agreement and the Closing Documents.

 

 

**1.4** **Amendment**

 

 

Subject  to Section 2.2,  this  Agreement may be amended, modified or
supplemented only by a written agreement  signed by MDS and Buyer.

 

 

**1.5** **Waiver  of Rights**

 

 

Any  waiver of, or consent to depart from, the requirements of any provision
of  this  Agreement shall be effective only if it is in writing and signed
by the Party  giving it, and only in the specific instance and for the
specific purpose for  which it has been given. No failure on the part of any
Party to exercise, and  no  delay in exercising, any right under this
Agreement shall operate as a waiver  of  such right. No single or partial
exercise of any such right shall preclude  any  other or further exercise of
such right or the exercise of any other  right.

 

 

**1.6** **Schedules**

 

 

The  following Schedules are incorporated by reference into and form part of
this  Agreement:

 



 

        

**Schedule**

    |  

**Description  of Schedule**

    
---|--- 
     

Schedule  .5

    |  

Transaction  Structure and Closing Sequence

    
     

Schedule  3.1

    |  

Holdback  Amount

    
     

Schedule  3.8

    |  

Purchase  Price Allocation

    
     

Schedule  5.6

    |  

Form  of Limited Trade Mark Licence

    
     

Schedule  5.7(a)

    |  

Form  of Migration Agreement

    
     

Schedule  5.7(b)

    |  

Form  of CBS License Agreement

    
     

Schedule  5.8

    |  

Form  of Non-Competition Agreement

    
     

Schedule  5.9

    |  

Support  Services Agreement Term Sheet

    
     

Schedule  5.12

    |  

Form  of MDS Confidentiality Agreement

    
     

Schedule  6.1.5(b)

    |  

Closing  Conditions in favour of Buyer

    
     

Schedule  6.2.4(b)

    |  

Closing  Conditions in favour of MDS

    
     

Schedule  9.3

    |  

Rules  of Procedure for Arbitration

    
    

 

 

**1.7** **Applicable  La** w

 

 

This  Agreement shall be governed by, and interpreted and enforced in
accordance  with,  the laws in force in the Province of Ontario (excluding
any rule or principle  of  the conflict of laws which might refer such
interpretation to the laws of  another jurisdiction). Subject to Article 9, 
each  Party irrevocably submits to the non-exclusive jurisdiction of the
courts of  Ontario with respect to any matter arising hereunder or related
hereto. The  Parties expressly exclude the application of the United Nations
Convention  on  Contracts for the International Sale of Goods.

 

 

**1.8** **Currency**

 

 

Unless  specified otherwise, all statements of or references to dollar
amounts in this  Agreement are to Canadian currency.

 

 

**1.9** **Performance  on Holidays**

 

 

If  any  action is required to be taken pursuant to this Agreement on or by
a specified  date which is not a Business Day, then such action shall be
valid if taken  on or  by the next succeeding Business Day.

 

 

**1.10** **Calculation  of Time**

 

 

In  this  Agreement, a period of days shall be deemed to begin on the first
day after  the  event which began the period and to end at 6:00 p.m.
(Toronto time) on the  last  day of the period. If, however, the last day of
the period does not fall on  a  Business Day, the period shall terminate at
6:00 p.m. (Toronto time) on the  next  Business Day.

 

 

**1.11** **Severability**

 

 

If  any  provision of this Agreement is determined by a court of competent
jurisdiction  to be invalid, illegal or unenforceable in any respect, such
determination  shall  not impair or affect the validity, legality or
enforceability of the remaining  provisions hereof, and each provision is
hereby declared to be separate,  severable and distinct.

 

 

**1.12** **No  Third Party Beneficiaries**

 

 

Nothing  in this Agreement is intended expressly or by implication to, or
shall, confer  upon any Person other than Sellers, Buyer, Designated Buyer
Affiliates, as  applicable, and, solely in respect of Article 8  and 
Section 5.13,  their  respective Representatives, respectively, and, solely
in respect of Section  7.12,  the MDS  Contracting Parties (other than
MDS), any rights or remedies of any kind. MDS  accepts each covenant in
favour of the other Sellers, the Representatives of  Sellers and the MDS
Contracting Parties as agent and trustee of that Seller,  the 
Representative and MDS Contracting Party, as applicable, and MDS shall be 
responsible for and liable for such covenants and may enforce such covenant 
on  behalf of such Seller, the Representatives of Sellers and the MDS
Contracting  Parties.

 

 

**ARTICLE 2**

 

 

**PURCHASE  AND SALE OF PURCHASED ASSETS**

 

 

**2.1** **Purchase  and Sale of Purchased Assets**

 

 

         |  

(a)

    |  

Subject  to Section 2.2, MDS agrees to sell and transfer and to cause the 
other  Sellers to sell and transfer the Purchased Assets owned by them and 
the  Replacement Contracts and the Migrating Assets to be acquired by 
them  under this Agreement and the Migration Agreement, respectively, to 
Buyer  (and, as applicable, one or more Designated Buyer Affiliates), and 
Buyer  agrees to acquire and pay for (and/or, as applicable, to cause one 
or more  Designated Buyer Affiliates to acquire and pay for) the Purchased 
Assets,  the Replacement Contracts and the Migrating Assets and assume the 
Assumed  Liabilities, on the terms and subject to the conditions contained 
in this  Agreement.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

Buyer  acknowledges that any one or both of (i) the entering into of this 
Agreement by MDS, and (ii) the transfer of the [REDACTED] (each a  "
**Regional  Asset** "  and collectively, the " **Regional  Assets** ") 
and the associated Assumed Liabilities to Buyer and/or any Designated  Buyer
Affiliate may require certain consents or approvals (including,  in  certain
cases, consent or approval to enter into this Agreement,  and, in  certain
cases, such consents or approvals may be unreasonably or  arbitrarily
withheld) and/or trigger rights of certain third parties.  To  facilitate
the Closing, seek to obtain the required consents or approvals  of such third
parties and where applicable, trigger the third party  rights  with respect
to such Regional Assets (and the associated Assumed  Liabilities), the
Parties shall take commercially reasonable efforts  to  comply with the
agreements and constating documents governing each  Regional Asset,
including, as required to trigger the third party  rights,  execution and
delivery on October 27, 2006 (or such earlier date  as  mutually agreed
between the Parties, acting reasonably) of a purchase  and  sale agreement
with respect to one or more of the Regional Assets  on terms  mutually
agreed to between Buyer and MDS, acting reasonably (each  a  " **Regional 
Purchase Agreement** ").

    
---|---|--- 
    

 

 

         |  

(c)

    |  

Buyer  agrees that the transfer of the Purchased Assets, the Replacement 
Contracts and the Migrating Assets shall be on an "as is, where is basis" 
and none of Sellers makes or will make any representation or warranty  and 
there are no conditions, including as to title, merchantability,  fitness 
for purpose, value or condition, except as expressly set forth herein  and 
in the Regional Purchase  Agreements.

    
---|---|--- 
    

 

 

**2.2** **Excluded  Assets**

 

 

         |  

(a)

    |  

Neither  Buyer nor any Designated Buyer Affiliate will purchase or acquire 
any of  the Excluded Assets.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

Notwithstanding  anything else herein contained, but subject to Subsection
2.2(c),  (A) should Sellers be unable to obtain any required third party 
consent or approval (or waiver thereto) to the transfer of a Regional  Asset
to Buyer (or, as applicable, any Designated Buyer Affiliate)  on or  before
the Closing Time (a " **Consent  Exclusion** "),  (B) should any third party
exercise its right to acquire and acquires  a  Regional Asset, or **** (C) 
should the period in which the right of any third party to exercise  a 
right to acquire a Regional Asset not have expired on or before the  Closing
Time and such right has not prior to that time been waived  by all 
applicable Persons (a " **ROFR  Exclusion** ")  (any event referred to in
(A), (B) or (C) being an " **Excluded  Asset Event** "),  the following
shall and shall be deemed to occur automatically and  without  any further
act or formality and this Agreement shall be deemed to  be  amended
accordingly in respect of an Excluded Asset Event: (i) the  Regional Assets,
the Books and Records and the Assumed Liabilities  relating thereto shall not
be transferred to or assumed by Buyer  or any  Designated Buyer Affiliate,
as applicable, on the Closing Date and  shall  be excluded from the
definition of Diagnostics Business, MDS Diagnostics  Division, Purchased
Assets and Assumed Liabilities, and shall be  deemed  removed from the
Disclosure Letter and applicable Schedules thereto  and  elsewhere in the
Agreement where the context so requires, (ii) such  Regional Assets shall be
an Excluded Asset, (iii) the amount of each  of  the Purchase Price and the
Closing Cash Amount shall be reduced by,  in the  event of an Excluded Asset
Event under (B) or (C) above, the last  price  offered within the range, or,
in the event of a Consent Exclusion,  the  highest value in the range for
the amount of the Purchase Price allocated  to each such Excluded Asset under
Section 3.8, and, in each case,  the  definition of Purchase Price and
Closing Cash Amount shall be amended  accordingly, (iv) the Closing Balance
Sheet and Working Capital as  at the  Closing Time shall be calculated
without regard to such Excluded  Assets  and Assumed Liabilities related
thereto; and (v) neither Buyer (nor  any  Designated Buyer Affiliate) nor
any of the Sellers shall have any  further  obligation or Liability under
this Agreement or the applicable Regional  Purchase Agreement with respect to
such Regional Asset and Assumed  Liabilities relating thereto. The
representations and warranties  of MDS  provided in this Agreement shall be
deemed to have been given as  of the  date of this Agreement and as required
in respect of the Closing  Date only  with respect to the Diagnostics
Business, MDS Diagnostics Division,  the  Purchased Assets and the Assumed
Liabilities as such terms may be  amended  in accordance with this
Subsection.

    
---|---|--- 
    

 

 

         |  

(c)

    |  

Notwithstanding  Subsection 2.2(b),  if following the Closing Time, in
respect of a Consent Exclusion,  the  required third party consent or
approval (or waiver thereto) to the  transfer of the applicable Regional
Asset to Buyer is obtained or  waived  or, in respect of a ROFR Exclusion,
the rights of all applicable  third  parties to acquire the applicable
Regional Asset are waived, no longer  apply or expire without having been
exercised, Subsection 2.2(b)  shall no longer apply in respect of such
Regional Asset, such Regional  Asset shall no longer be an Excluded Asset and
Buyer shall, as soon  as  practicable, purchase such Regional Asset on the
terms and conditions  hereof applicable to such Regional  Asset.

    
---|---|--- 
    

 

 

**2.3** **Non-Assignable  Contracts**

 

 

         |  

(a)

    |  

Neither  this Agreement nor any Closing Document shall constitute an
assignment  or  an attempted assignment of any Non-Assignable Contract. MDS
agrees  to  assign and to cause each other Seller to assign any Non-
Assignable  Contracts to Buyer or the applicable Designated Buyer Affiliate
when  such  assignment is permitted and as Buyer or the applicable
Designated  Buyer  Affiliate may from time to time direct. MDS shall, and
shall cause  each  other Seller to, use commercially reasonable efforts to
obtain all  consents required for the assignment to Buyer or the applicable
Designated  Buyer Affiliate of the Contracts, the Equipment Leases, the
Warranty  Rights and Transferable Licences included in the Purchased Assets 
of such  Seller. No Seller shall, however, be obliged to commence
arbitration  or  any other legal proceeding or make any payments to third
parties  other  than any administrative, processing or similar fee or any
other amounts  contemplated by the particular Contract, Equipment Lease,
Warranty  Rights  or Transferable Licence to be payable in connection with
the assignment  thereof to the Buyer pursuant hereto. Buyer and each
Designated Buyer  Affiliate shall co-operate with and assist each Seller in
such Seller's  efforts to obtain such consents.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

In  respect of Non-Assignable Contracts other than Leases, to the extent 
permitted by Applicable Law and the provisions of such Non-Assignable 
Contract: (i) if any of the Non-Assignable Contracts are not assignable  by 
the terms thereof or consents to the assignment thereof have not  been 
obtained prior to the Closing Time, such Non-Assignable Contracts  shall be 
held by the applicable Seller (without any additional expense to  the 
Seller whatsoever) in trust for Buyer or the applicable Designated  Buyer 
Affiliate and the covenants and obligations thereunder shall be performed  by
Buyer or the applicable Designated Buyer Affiliate in the name  of the 
applicable Seller and all benefits and obligations existing thereunder  shall
be for the account of Buyer or the applicable Designated Buyer  Affiliate
(without any additional expense to Sellers whatsoever);  and (ii)  MDS shall
take, and shall cause the applicable Seller (if other than  MDS)  to take or
cause to be taken such reasonable action in the Seller's name  or otherwise
as Buyer or the applicable Designated Buyer Affiliate  may  reasonably
require so as to provide Buyer or the applicable Designated  Buyer Affiliate
with the benefits thereof and each Seller shall promptly  pay over or deliver
to Buyer or the applicable Designated Buyer Affiliate  all money or other
consideration, if any, received by such Seller  in  respect of all such Non-
Assignable Contracts. Upon the Closing, MDS  shall  and shall cause each
other Seller to authorize Buyer or the applicable  Designated Buyer
Affiliate, to the extent permitted by Applicable  Law and  the terms of such
Non-Assignable Contracts, at the expense of Buyer  or the  applicable
Designated Buyer Affiliate, to perform all of such Seller's  obligations
arising under such applicable Non-Assignable Contracts  after  the Closing
Time. MDS shall continue to use and cause the Sellers  to  continue to use
commercially reasonable efforts to obtain and deliver  all  remaining
consents required for the assignment to Buyer or the applicable  Designated
Buyer Affiliate of the remaining Non-Assignable Contracts  after  the
Closing Time. If a Non-Assignable Contract is not validly assigned  to 
Buyer or the applicable Designated Buyer Affiliate within twelve  (12) 
months after the Closing Date, such Non-Assignable Contract shall  be 
deemed to be an Excluded Asset and all obligations of Sellers to  Buyer or 
the applicable Designated Buyer Affiliate and all obligations hereunder  of 
Buyer and the applicable Designated Buyer Affiliate to Sellers with  respect
to such Non-Assignable Contract shall  terminate.

    
---|---|--- 
    

 

 

         |  

(c)

    |  

In  respect of those Non-Assignable Contracts which are Leases included  in
the  Purchased Assets (the " **Non-Assigned  Leases** "),  the following
provisions shall  apply:

    
---|---|--- 
    

 

 

         |  

(i)

    |  

if  the landlord's consent to the assignment of the Non-Assigned Lease has
not  been obtained prior to the Closing Time, the applicable Lease shall 
remain  in the name of MDS or the applicable Seller, and such party shall 
continue  to pay the rents and otherwise observe and perform the covenants 
and  obligations of the tenant under the provisions of the applicable  Non-
Assigned Lease (including without limitation, maintenance and  repair 
obligations and insurance  requirements);

    
---|---|--- 
    

 

 

         |  

(ii)

    |  

on  the Closing, to the extent permitted by Applicable Law and the
provisions  of such Non-Assigned Lease, the applicable Seller and the Buyer
or  the  applicable Designated Buyer Affiliate shall enter into a
sublease,  licence  or other occupancy agreement relating to such premises
on terms and  conditions mutually acceptable to the Parties, acting
reasonably,  pending  the delivery of the landlord's consent to the
assignment of the applicable  Non-Assigned Lease, and the applicable Seller
shall take or cause  to be  taken such reasonable action in its name or
otherwise as Buyer or  the  applicable Designated Buyer Affiliate shall
reasonably require so  as to  provide Buyer or the applicable Designated
Buyer Affiliate with,  and/or  not deprive, Buyer or the applicable
Designated Buyer Affiliate of,  the  benefit of quiet and uninterrupted use
and possession of the applicable  premises for its conduct of the
Diagnostics  Business;

    
---|---|--- 
    

 

 

         |  

(iii)

    |  

on  the Closing, to the extent permitted by Applicable Law and the
provisions  of such Non-Assigned Lease, the Buyer or the applicable
Designated  Buyer  Affiliate shall access and occupy the applicable premises
under such  sublease, licence or other form of occupancy agreement, shall
comply  with  the obligations of the occupant of the applicable premises
under  the  provisions of the applicable Non-Assigned Lease (including
without  limitation, repair of any damage to the premises caused by the
Buyer  or  the applicable Designated Buyer Affiliate, and insurance for
its  own  operations) and shall, provided access and occupancy is obtained 
and  during the period that the Buyer or the applicable Designated Buyer 
Affiliate enjoys and/or is not deprived of the benefit of quiet and 
uninterrupted use and possession of the applicable Leased Premises  (other 
than as a result of force majeure or a default by the Buyer or Designated 
Buyer Affiliate under the applicable sublease, licence or other form  of 
occupancy agreement or the applicable landlord under the Non-Assigned  Lease)
for the conduct of the Diagnostics Business from such premise,  promptly
reimburse the applicable Seller for or, at the written direction  of such
Seller pay directly to the landlord, the rents (including  any  applicable
Taxes) and all other amounts payable by the tenant under  the  Non-Assigned
Lease, including utility costs, realty Taxes and common  area  charges, in
respect of the applicable premises accruing from and  after the  Closing
Time, but for greater certainty shall not be responsible  for the  payment
of any amount due by the tenant prior to the Closing Time,  or in  respect
of obtaining the consent, or the consequences of the failure  to  obtain the
consent of the landlord to the assignment of the Non-Assigned  Lease;

    
---|---|--- 
    

 

 

         |  

(iv)

    |  

MDS  shall, or shall cause the applicable Seller (if other than MDS),  as
may be  the case, to and Buyer shall, continue to use commercially
reasonable  efforts to obtain and deliver the applicable landlord's consent
to the  assignment to the Buyer or the applicable Designated Buyer
Affiliate  of  the applicable Non-Assigned Lease, and in the event that such
consent  is  not obtained and delivered within eighteen (18) months after
the  Closing  Date, then, at the option of the Buyer or the applicable
Designated  Buyer  Affiliate, the foregoing interim occupancy arrangement
shall come  to an  end on the last day of the eighteenth (18th)  month
following the Closing Date, the Buyer or the applicable Designated  Buyer
Affiliate shall remove all of the Purchased Assets from the  applicable
premises, the applicable Non-Assigned Lease shall be deemed  to  be an
Excluded Asset, and all obligations of the Buyer or the applicable 
Designated Buyer Affiliate with respect to such Non-Assigned Lease  shall 
terminate; and

    
---|---|--- 
    

 

 

         |  

(v)

    |  

Buyer  shall have reasonable access to all MDS personnel, information and 
data as  may be reasonably required or requested by Buyer in connection
with  the  obligations of MDS to obtain and deliver the applicable
landlord's consent  to the assignment of the applicable Non-Assigned Lease to
the Buyer  or the  applicable Designated Buyer Affiliate. From and after
this date,  MDS shall  keep Buyer apprised of its activities concerning its
obtaining and  delivering such applicable landlord consents including,
without limitation  providing the Buyer with monthly reports identifying
which additional  consents have been obtained, whether there were any changes
in the  status  of discussions with the landlords, and identifying the
parties contacted  and the statements made in connection with all outstanding
consents.  MDS  shall consult with and provide Buyer with all reasonable
opportunities  to  assist MDS in such activities and agrees to consider, in
good faith,  all  Buyer input and requests provided in the course of the
aforementioned  activities of MDS in respect of such applicable landlord
consents  and not  to unreasonably refuse to take into account and/or
implement any  reasonable Buyer requests or input  received.

    
---|---|--- 
    

 

 

**2.4** **Place  of Closing**

 

 

The  Closing shall take place at the Closing Time at the offices of Fasken
Martineau  DuMoulin LLP, Toronto, Ontario, or at such other place as may be
agreed upon  by  the Parties.

 

 

**2.5** **Closing  Time**

 

 

Notwithstanding  any provision herein to the contrary, the transactions
comprising the Closing  shall be effective in the sequence contemplated in
Schedule 2.5.

 

 

**ARTICLE 3**

 

 

**CONSIDERATION  FOR PURCHASED ASSETS**

 

 

**3.1** **Purchase  Price** **;  Holdback Amount**

 

 

         |  

(a)

    |  

Subject  to Section 2.2  and to the adjustments set forth in Sections
3.1(a)(iv),  3.4,  3.5  and 3.6  and Schedule 3.1,  the purchase price
(the " **Purchase  Price** ")  payable to MDS or as MDS directs for all of
the Purchased Assets,  the  Replacement Contracts and the Migrating Assets
is $801,000,000. The  cash  amount payable on Closing (the " **Closing 
Cash Amount** ")  is equal to the Purchase Price less (i) the amount of the
Estimated  Long-Term Liabilities; (ii) a contribution of capital of
$7,000,000  being  the amount of cash, which together with the Target
Working Capital  will  permit Buyer immediately after the Closing Time to
carry on the  Diagnostics Business in the ordinary course of business; (iii)
the  Holdback Amount; and (iv) the aggregate amount of the net proceeds 
received by MDS or any Operators from the sale of any assets Primarily 
related to the Diagnostics Business since April 30, 2006 to the extent  that,
in respect of any sale completed, such net proceeds are not  less  than
$100,000 and have been distributed to MDS or the partners of  MDS ONT  LP,
as applicable. Buyer acknowledges that the Purchase Price does  not  include
any amount payable by Buyer as contemplated under Subsection  3.10(c).  MDS
shall provide a statement of the Estimated Long-Term Liabilities  to  the
Buyer three Business Days prior to the Closing Date. MDS acknowledges  that
the Purchase Price is inclusive of the purchase price consideration  payable
by Buyer or the applicable Designated Buyer Affiliate to  MDS under  a
Regional Purchase Agreement. Consequently, appropriate adjustments  shall 
be made to the Closing Cash Amount to reflect the actual purchase  price 
paid under all Regional Purchase  Agreements.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

The  Parties covenant and agree that the Holdback Amount shall be
calculated  under, governed by the principles set forth in, and released
and  paid to  MDS subject to the terms and conditions prescribed by,
Schedule  3.1.

    
---|---|--- 
    

 

 

**3.2** **Post-Closing  Audit**

 

 

         |  

(a)

    |  

Forthwith  following the Closing Time, MDS shall cause its auditor, Ernst and
Young  LLP, to conduct an audit of the MDS Diagnostics Division in order 
to  prepare the Closing Balance Sheet. Based on the Closing Balance Sheet, 
MDS  shall prepare the unaudited Closing Regional Balance Sheet and the 
calculation of the Working Capital of the MDS Diagnostics Division  in 
Ontario and Quebec and the head office of the MDS Diagnostics Division  as 
at the Closing Time. The Closing Balance Sheet, the Closing Regional  Balance
Sheet and such calculation of Working Capital shall be prepared  on  a
combined basis in accordance with GAAP, applied on a basis consistent  with
the Financial Statements. Buyer shall co-operate with MDS and  Ernst  and
Young LLP and shall provide to such Persons copies of all financial  and
other records and access to all necessary personnel required  to  conduct
the audit and prepare the Closing Balance Sheet, the Closing  Regional
Balance Sheet and calculation of Working Capital. At the  request  of MDS,
Buyer shall provide assistance in the preparation of the  Closing  Balance
Sheet, the Closing Regional Balance Sheet and the calculation  of  Working
Capital.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

MDS  shall co-operate with Buyer in conducting such audit and will provide 
to  Buyer and its auditor copies of all working papers prepared by MDS 
for  review. Representatives of Buyer or Buyer's auditor are permitted to
be  present at, and to participate in, any inventory counts and any other 
procedures used in preparing the Closing Balance Sheet, Closing Regional 
Balance Sheet and calculation of Working Capital. A copy of the Closing 
Balance Sheet, Closing Regional Balance Sheet and Working Capital 
calculation shall be delivered to each Party within seventy-five  (75) days 
of the Closing Date.

    
---|---|--- 
    

 

 

         |  

(c)

    |  

If  Buyer objects to any of the Closing Balance Sheet, the Closing Regional 
Balance Sheet and the calculation of Working Capital, then Buyer  shall 
prepare and deliver to MDS a statement (an " **Objection  Notice** ") 
setting forth the matters that are the subject of Buyer's objection and 
Buyer's position including reasonable details of calculations on or before 
the thirtieth (30th) day after the delivery of such statements and 
calculation. The Parties shall then use reasonable efforts to resolve  such 
objection for a period of twenty (20) days following the delivery  of the 
Objection Notice. If the matter is not resolved by the end of such  twenty 
(20) day period, then the matters remaining in dispute will be referred  to 
the CEO of each Party to attempt to resolve within ten (10) days  after the 
date of referral. If the matter is not resolved within such ten (10)  day 
period, then the items remaining in dispute shall be submitted by  the 
Parties to arbitration in accordance with Article 9.  If Buyer fails to
deliver an Objection Notice within the thirty (30)  day  period, it shall be
deemed to have agreed to the Closing Balance  Sheet,  the Closing Regional
Balance Sheet and Working Capital calculation  which  shall then be final
and binding upon the  Parties.

    
---|---|--- 
    

 

 

         |  

(d)

    |  

The  " **Working  Capital Adjustment Date** "  shall be the date that is
three (3) Business Days after (i) the date  Buyer  agrees in writing or is
deemed under clause (c) above to agree to  the  Closing Balance Sheet, the
Closing Regional Balance Sheet and Working  Capital calculation, whichever is
earlier or (ii) if Buyer issues  an  Objection Notice in accordance with the
foregoing, the date the Parties  agree to the Closing Balance Sheet, the
Closing Regional Balance  Sheet and  the calculation of Working Capital or
the date the Closing Balance  Sheet,  the Closing Regional Balance Sheet and
Working Capital calculation  are  finally determined by arbitration as
contemplated by this Section,  whichever is earlier.

    
---|---|--- 
    

 

 

**3.3** **Determination  of Value of Inventory, Accounts Receivable**

 

 

For  the  purposes of Section 3.4,  (a)  Inventory shall be valued at the
lower of actual cost or market value determined  in accordance with GAAP,
applied on a basis consistent with the Financial  Statements; and (b) the
value of the Accounts Receivable at the Closing Time  shall be the amount
included in the Closing Balance Sheet (and the Closing  Regional Balance
Sheet) less an amount equal to the balance of Accounts  Receivable owed by
Persons other than a Governmental Authority or hospital  that  are older
than 90 days and for which no provision has been made in the Closing  Balance
Sheet (and the Closing Regional Balance Sheet) and less the amount  of  any
Accounts Receivable excluded as an asset in the definition of Ontario Assets 
and Quebec Assets. For greater certainty, in determining Working Capital,
any  liability for Taxes arising from or in connection with the
implementation of  the  Buyer Purchase Structure shall be valued at zero.

 

 

**3.4** **Working  Capital Adjustment**

 

 

On  the  Working Capital Adjustment Date, the Purchase Price shall be
adjusted in  accordance with Section 3.5  and as  follows:

 

 

         |  

(a)

    |  

the  amount of any decrease in Working Capital of the MDS Diagnostics 
Division  in Ontario and Quebec and the head office of the MDS Diagnostics 
Division  as at the Closing Time from the Target Working Capital shall be
deducted  from the Purchase Price and the amount of any increase in Working 
Capital  of the MDS Diagnostics Division in Ontario and Quebec and the head 
office  of the MDS Diagnostics Division as at the Closing Time from the
Target  Working Capital shall be added to the Purchase Price, each on a
dollar  for  dollar basis; and

    
---|---|--- 
    

 

 

         |  

(b)

    |  

the  Purchase Price shall be increased, on a dollar for dollar basis,  by
the  amount that the cash, marketable securities and other cash equivalents 
as  set forth on the Closing Balance Sheet (and the Closing Regional 
Balance  Sheet) exceeds the Petty Cash included in the Working Capital of 
the MDS  Diagnostics Division in Ontario and Quebec and the head office of 
the MDS  Diagnostics Division,

    
---|---|--- 
    

 

 

and  the  aggregate or net payment required under this Section 3.4  shall
be  made by the appropriate Party to the other Party on the Working Capital 
Adjustment Date.

 

 

**3.5** **General  Adjustments**

 

 

The  Parties shall make, without duplication, and provided that such
adjustments  are  not already provided for on the Closing Balance Sheet and
the Closing Regional  Balance Sheet, the usual adjustments relating to the
sale of the Purchased  Assets as of the Closing Time and such adjustments
shall be readjusted, if  necessary, on the Working Capital Adjustment Date.
Adjustments shall  include:

 

 

         |  

(a)

    |  

**Realty  Taxes, etc.** All  amounts paid or payable with respect to realty
Taxes, local improvements  and other amounts usually adjusted with respect to
the Real Property  included in the Purchased Assets; ****

    
---|---|--- 
    

 

 

         |  

(b)

    |  

**Charges  Under Leases.** All  amounts paid or payable to or by MDS or an
Operator under the Leases  included in the Purchased Assets including,
without limitation, rental  (including percentage rental, prepaid rent and
security deposits),  Taxes  (including contributions by lessees to real
estate Taxes), common  area  maintenance charges or contributions towards
operating expenses,  utilities  charges, business Taxes, merchant's
association and advertising fees and  occupancy costs;

    
---|---|--- 
    

 

 

         |  

(c)

    |  

**Adjustments  Under Contracts and Equipment Leases**.  All amounts paid or
payable by, or in the case of amounts such as  rebates  or royalties,
payable to, any Seller under the Contracts and Equipment  Leases (including
any deposits) included in the Purchased  Assets;

    
---|---|--- 
    

 

 

         |  

(d)

    |  

**Employee  Remuneration and Benefits**.  Wages, bonuses, commissions, sick
pay, vacation pay, contributions  to  Benefit Plans and other remuneration
and health, welfare or other  benefits  accrued, paid or payable by any
Seller to or in respect of the Ontario  Employees and Quebec Employees who
accept the offer of employment  of Buyer  or a Designated Buyer Affiliate; 
and

    
---|---|--- 
    

 

 

         |  

(e)

    |  

**Fuel,  Utilities, etc.**   All fuel, water, telephone and other utility
charges paid or payable  by  any Seller in respect of the Real Property
included in the Purchased  Assets.

    
---|---|--- 
    

 

 

Notwithstanding  the foregoing, no adjustment shall be made in respect of any
one of the  aforementioned class of items specified in Subsections 3.5(a) 
through (c)  and (e)  unless  the particular adjustment amount (the "
**Threshold  Adjustment** ")  in  respect of an item in such class is at
least $25,000. Any readjustments and  payment therefor shall be made by the
appropriate Party on the Working Capital  Adjustment Date. Without limiting
the foregoing in respect of Leases, the  Parties acknowledge that certain
adjustments and payments therefor under each  Lease included in the Purchased
Assets such as common area charges, realty  Taxes  and contributions towards
operating expenses, shall be made when the lessor  under that Lease provides
to Buyer or the applicable Designated Buyer Affiliate  a final adjustment
amount in respect of such Lease for the lease years for  which  no such
adjustment has been given to Sellers at the Working Capital Adjustment  Date.
Once the Threshold Adjustment is obtained in respect of any one of the 
aforementioned items, Buyer or the applicable Designated Buyer Affiliate
shall  provide to MDS a copy of the adjustment(s) received from the
applicable third  party within ten (10) days of receipt of same and the
payment of any  readjustment between the Parties based upon the information
contained in such  third party's adjustments shall be made by the appropriate
Party promptly  thereafter.

 

 

**3.6** **Long-Term  Liability and Other Adjustments**

 

 

         |  

(a)

    |  

On  the Working Capital Adjustment Date, the Closing Cash Amount and 
Assumed  Liabilities shall be adjusted as follows: (i) the Assumed
Liabilities  shall be decreased and the Closing Cash Amount shall be
increased  by the  amount that the Assumed Long-Term Liabilities of the MDS
Diagnostics  Division in Ontario and Quebec and the head office of the MDS
Diagnostics  Division as at the Closing Time is less than the Estimated Long-
Term  Liabilities and (ii) the Assumed Liabilities shall be increased and 
the  Closing Cash Amount shall be decreased by the amount that the Assumed 
Long-Term Liabilities of the MDS Diagnostics Division in Ontario  and 
Quebec and the head office of the MDS Diagnostics Division as at  the 
Closing Time exceeds the Estimated Long-Term Liabilities, each on  a dollar 
for dollar basis and the aggregate or net payment required under  this 
Section 3.6  shall be made by the appropriate Party to the other Party on
the  Working  Capital Adjustment Date.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

Notwithstanding  the provisions of Sections 3.2 and 3.4, **** if,  prior to
the date that is eighteen (18) months **** after  the Closing Time (the "
**Accrual  Adjustment Date** "),  it is determined that a Liability provided
for on the Closing Balance  Sheet which is based on an estimate made in
accordance with GAAP  (including in respect of claims reported but not
incurred under applicable  health and dental Benefit Plans of the Employees)
is less than or  more  than the actual amount paid by MDS or an Affiliate
thereof in respect  of  such Liability, provided the difference between the
accrual and the  actual  Liability is at least $25,000, the Purchase Price
shall be reduced  or  increased, respectively, each on a dollar for dollar
basis and Buyer  or  MDS shall pay the other party, as appropriate, the
amount of such  difference within ten (10) Business Days of the Accrual
Adjustment  Date.

    
---|---|--- 
    

 

 

**3.7** **Interest**

 

 

Any  adjustments to the Purchase Price payable in accordance with
Sections 3.4  and 3.5  and any  amount payable pursuant to Section 3.6 
shall  bear interest at the Prime Rate calculated from the earlier of the
date the  adjustment is due or 120 days after the Closing Date to the date of
payment  of  the adjustment.

 

 

**3.8** **Allocation  of Purchase Price**

 

 

The  Parties shall allocate $1,000 to the Non-Competition Agreement and the
balance  of the Purchase Price among the Purchased Assets, the Replacement
Contracts  and  the Migrating Assets as mutually agreed and as set forth in
Schedule 3.8 -  Purchase Price Allocation.

 

 

The  Parties agree that the amount of the Purchase Price allocated to each
Purchased  Asset, Replacement Contract, Migrating Asset and the Non-
Competition Agreement  is the fair market value thereof and agree to file all
returns and forms, and  provide all information, under the ITA and any
applicable taxing statute or  regulation, on the basis of the agreed
allocation.

 

 

If  the  Purchase Price is adjusted pursuant to the terms of this Agreement,
appropriate  adjustments shall be made by the Parties jointly to the
allocations set forth  in  this Section 3.8.  The  Parties shall file
their respective Tax Returns in a manner that reflects and  is  consistent
with the foregoing. The Parties agree to amend any Tax filings or  elections
as may be required or as may be reasonable to reflect any revisions  to  the
allocations under this Section 3.8.

 

 

**3.9** **Payment  of Purchase Price**

 

 

At  the  Closing Time, Buyer or the applicable Designated Buyer Affiliate
shall pay  and  satisfy the Purchase Price as follows:

 

 

         |  

(a)

    |  

Buyer  or the applicable Designated Buyer Affiliate shall assume, pay,
perform  and discharge the Assumed Liabilities in accordance with their 
terms;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

Buyer  or the applicable Designated Buyer Affiliate shall pay the Closing 
Cash  Amount to or to the order or at the direction of the Sellers in
accordance  with Schedule 3.8 - Purchase Price Allocation by wire transfer
of  immediately available funds to one or more bank accounts as directed 
by  the Sellers prior to the Closing Time;  and

    
---|---|--- 
    

 

 

         |  

(c)

    |  

as  to the Holdback Amount, by release and payment of all or such portions 
thereof in accordance with Schedule 3.1  to  or to the order or at the
direction of the applicable Seller in accordance  with Schedule 3.1,

    
---|---|--- 
    

 

 

in  full  satisfaction thereof, subject to the adjustments to be made
pursuant to Sections  2.2,  3.1(a)(iv),  3.4,  3.5  and 3.6  and 
Schedule 3.1.

 

 

**3.10** **Transfer  Taxes and Tax Elections**

 

 

         |  

(a)

    |  

Where  permitted by Applicable Law, Buyer or the applicable Designated
Buyer  Affiliate and the applicable Seller of the Ontario Assets and Quebec 
Assets shall each execute on Closing and file a joint election under  section
22 of the ITA and the corresponding provisions of any other  applicable
taxing statute or regulation, within the prescribed time  periods, in respect
of the Accounts Receivable of the applicable  Seller  included in the
Purchased Assets and shall designate in such election  an  amount equal to
the portion of the Purchase Price allocated to such  Accounts Receivable as
the consideration paid by Buyer  therefor.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

To  the extent that a Seller has received an amount in respect of services 
not  rendered or goods not delivered and has an Assumed Liability arising 
therefrom and Purchased Assets having a fair market value equal to  such 
amounts are transferred to Buyer or the applicable Designated Buyer 
Affiliate as payment for such Assumed Liabilities, the applicable  Seller 
and Buyer or the applicable Designated Buyer Affiliate shall execute  on 
Closing and file an election pursuant to the provisions of subsection  20(24)
of the ITA and the corresponding provisions of any applicable  taxing statute
or regulation within the prescribed time  periods.

    
---|---|--- 
    

 

 

         |  

(c)

    |  

Buyer  or the applicable Designated Buyer Affiliate shall remit direct to 
the  appropriate Governmental Authority, all sales and transfer Taxes, 
registration charges and transfer fees payable by it in respect of  the 
purchase and sale of the Purchased Assets, the Replacement Contracts  and 
the Migrating Assets under this Agreement, and upon the request of  MDS or 
a Seller, the payor shall furnish proof of such payment except that  all 
Taxes properly collectable by a Seller on the sale of the Purchased  Assets,
the Replacement Contracts and the Migrating Assets (including  any  GST)
shall be paid by Buyer or the applicable Designated Buyer Affiliate  to the
Seller on Closing in addition to the Purchase  Price.

    
---|---|--- 
    

 

 

         |  

(d)

    |  

Where  permitted by Applicable Law, the applicable Seller and Buyer or the 
applicable Designated Buyer Affiliate shall, at the Closing, elect  jointly 
pursuant to the provisions of subsection 167(1) of the _Excise  Tax Act_
(Canada)  and under any similar provision of any applicable provincial
legislation  in the form prescribed for the purposes of that provision, in
respect  of  the sale and transfer of the Purchased Assets and Migrating
Assets  of the  applicable Seller hereunder, that for purposes of such
legislation  no GST  (and any comparable provincial Taxes) is payable on the
purchase  of such  Purchased Assets and Migrating Assets, provided, however,
that Buyer  or  the applicable Designated Buyer Affiliate shall be
responsible and  indemnify and hold harmless Sellers for any GST (and any
comparable  provincial Taxes) to the extent payable notwithstanding this
election  plus  any interest and/or penalties payable as a consequence 
thereof.

    
---|---|--- 
    

 

 

**3.11** **Excluded  Liabilities**

 

 

Neither  Buyer nor any Designated Buyer Affiliate shall assume or have any
obligation  to  discharge, perform or fulfill any Liabilities of Sellers of
any kind whatsoever  other than the Assumed Liabilities (collectively, the "
**Excluded  Liabilities** "),  all  of which shall remain obligations of
Sellers. For greater certainty, Excluded  Liabilities shall include any
Liabilities of Sellers or Operators arising,  directly or indirectly, from
the claims or causes of action of any third party  with an interest in any of
the Operators or their Affiliates, Toronto Labs  and  Windsor Labs and any
Liabilities of the Sellers or Operators arising from their  failure to obtain
prior to Closing the consent of [REDACTED] to the Buyer or  a  Designated
Buyer Affiliate.

 

 

**ARTICLE 4**

 

 

**REPRESENTATIONS  AND WARRANTIES**

 

 

**4.1** **Representations  and Warranties of MDS**

 

 

MDS  represents and warrants to Buyer and Designated Buyer Affiliates as set
forth  in  the following Subsections of this Section 4.1.  Buyer 
acknowledges that all representations and warranties made by MDS in this 
Agreement are qualified in their entirety by the information and exceptions 
disclosed in the Disclosure Letter and the schedules thereto. Without
limiting  the foregoing, all representations and warranties of MDS with
respect to the  assets, the Liabilities, employees, Benefit Plans and other
labour matters,  Taxes and business and operations of the Operators are
qualified to the extent  of any action taken or omitted to be taken or
Liability incurred in connection  with or in any way related to the
implementation of the Buyer Purchase  Structure.

 

 

**4.1.1** **Corporate  Matters**

 

 

         |  

(a)

    |  

Each  of the Ontario GP and MDS Quebec (each a " **Corporate  Operator**
")  and MDS is a corporation duly incorporated and validly existing under 
the  laws of its jurisdiction of incorporation. MDS ONT LP (the "
**Partnership  Operator** ")  is a limited partnership duly formed and
validly existing under the  laws  of its jurisdiction of formation. No
proceedings have been taken  or  authorized by MDS or an Operator or, to the
best of MDS' knowledge, by any  other Person, with respect to the bankruptcy,
insolvency, liquidation,  dissolution or winding up of MDS or an Operator. To
the knowledge  of MDS,  Toronto GP (the " **Non-Controlled  Corporate
Operator** ")  is a corporation duly incorporated and validly existing under
the  laws of  its jurisdiction. To the knowledge of MDS, Toronto Labs (a "
**Non-Controlled  Partnership Operator** ")  is a limited partnership duly
formed and validly existing under the  laws  of its jurisdiction of
formation. To the knowledge of MDS, no proceedings  have been taken or
authorized by MDS or a Non-Controlled Operator  or by  any other Person with
respect to the bankruptcy, insolvency, liquidation,  dissolution or winding
up of a Non-Controlled  Operator.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

MDS  has all necessary corporate power and capacity to execute and deliver, 
and  to observe and perform its covenants and obligations under, this 
Agreement  and the Closing Documents to which it is a party. MDS has taken
all  corporate action necessary to authorize its execution and delivery  of,
and  the observance and performance of its covenants and obligations under, 
this Agreement and the Closing Documents to which it is a party. 

    
---|---|--- 
    

 

 

         |  

(c)

    |  

(i)  MDS Quebec has all necessary corporate power and capacity and, subject 
to  the LPBP Consent, MDS ONT LP has all necessary power and capacity 
under  the partnership agreement governing it to execute and deliver and 
perform  its covenants and obligations under the Closing Documents to which 
it will  be a party; and (ii) MDS Quebec has taken all corporate action
necessary  and, subject to the LPBP Consent, MDS ONT LP has taken all
action  necessary under the partnership agreement governing it to authorize 
the  execution and delivery of, and the observance and performance of  its 
covenants and obligations under the Closing Documents to which it  will be 
a party.

    
---|---|--- 
    

 

 

         |  

(d)

    |  

MDS,  each Corporate Operator and, to the knowledge of MDS, the Non-
Controlled  Corporate Operator has all necessary corporate power and
capacity,  and the  Partnership Operator and, to the knowledge of MDS, the
Non-Controlled  Partnership Operator has all necessary power and capacity
under the  partnership agreement governing it, to own or lease the
Purchased  Assets  owned or leased by it and to carry on the Diagnostics
Business as  presently carried on by it. Neither the nature of the
Diagnostics  Business  nor the location or character of any of the Purchased
Assets requires  MDS  or any Operator to be registered, licensed or
otherwise qualified  as an  extra-provincial or foreign corporation or
partnership or to be in  good  standing in any jurisdiction other than (i)
jurisdictions where it  is duly  registered, licensed or otherwise qualified
and in good standing  for such  purpose or (ii) to the extent that any
failure to be so qualified  either  individually or in the aggregate, would
not have a Material Adverse  Effect.

    
---|---|--- 
    

 

 

         |  

(e)

    |  

This  Agreement has been duly executed and delivered by MDS and, subject  to
the  LPBP Consent, the Closing Documents to be entered into by a Seller 
will be  duly executed and delivered by such Seller. This Agreement
constitutes  a  valid and binding obligation of MDS enforceable against MDS
in accordance  with its terms and, subject to the LPBP Consent, each such
Closing  Document will constitute a valid and binding obligation of the
applicable  Seller enforceable against such Seller in accordance with its 
terms.

    
---|---|--- 
    

 

 

**4.1.2** **Absence  of Conflicting Agreements**

 

 

None  of  the execution and delivery of, or the observance and performance
by any Seller  of, any covenant or obligation under this Agreement or any
Closing Document  to  which such Seller is or will be a party:

 

 

         |  

(a)

    |  

contravenes  or results in, or will contravene or result in, a violation of
or  a  default under (with or without the giving of notice or lapse of
time,  or  both) or in the acceleration of any obligation  under:

    
---|---|--- 
    

 

 

         |  

(i)

    |  

subject  to the consents to the within transactions and the rights of the 
third  parties contemplated in Subsection 2.1(b)  and the LPBP Consent, the
articles or by-laws of MDS or each Corporate  Operator or the partnership
agreement governing the Partnership  Operator;

    
---|---|--- 
    

 

 

         |  

(ii)

    |  

except  for the Leases, the Equipment Leases and the Contracts included in 
the  Purchased Assets and the Shared Contracts, the consent to the
assignment  or transfer of which or a change of control of the party
thereto  which may  be required from landlords or other third parties
thereunder in connection  with the Closing, the consents to the within
transactions and the  rights  of the third parties contemplated in
Subsection 2.1(b)  and the LPBP Consent as set forth in, and in addition to
the others  set  forth in, Section 4.1.2  of  the Disclosure Letter, the
provisions of any material agreement,  lease,  mortgage or security document
to which MDS or any Operator is a party;  except, in each case any
contravention, violation, default under  or  acceleration of any obligations
under any such agreement, lease,  mortgage  or security document that would
not have a Material Adverse Effect  individually or in the aggregate;

    
---|---|--- 
    

 

 

         |  

(iii)

    |  

subject  to Subsection 5.1.4(d),  Applicable Law; or

    
---|---|--- 
    

 

 

         |  

(b)

    |  

will  result in the creation or imposition of any material Encumbrance  on
an  Operator or any of the Purchased Assets except as set forth in Section 
4.1.2  of  the Disclosure Letter.

    
---|---|--- 
    

 

 

**4.1.3** **Regulatory  Approvals**

 

 

Except  as  set forth in Section 4.1.3  of the  Disclosure Letter, no
consent, approval, or authorization of, or registration  or  filing with,
any Governmental Authority is required by MDS, any Operator or,  to  the
knowledge of MDS, any Non-Controlled Operator in connection with the 
execution and delivery by MDS of this Agreement or by any Seller of any
Closing  Document to which it will be a party or the observance and
performance by a  Seller of its obligations under this Agreement or such
Closing Documents to  which it will be a party other than the Regulatory
Consents and other than  those  consents, approvals, authorizations,
registrations, declarations or filings  with  any Governmental Authority
which are routine post-closing notifications or  filings or those the absence
of which will not have a Material Adverse  Effect.

 

 

**4.1.4** **Title  to Assets**

 

 

         |  

(a)

    |  

The  Persons set forth in Section 4.1.4  of  the Disclosure Letter are the
registered and beneficial owners of  the Real  Property, with good and
marketable title thereto and the Sellers  collectively are the legal and
beneficial owners of the remaining  Purchased Assets, and on completion of
the applicable Migration Project  (as defined in the Migration Agreement)
under the Migration Agreement  pertaining to a Migrating Asset and, upon a
Seller and the applicable  third party entering into a Replacement Contract,
MDS or the applicable  Seller will be the legal and beneficial owner or
authorized licensor  of  such Migrating Assets and Replacement Contracts, in
each case with  good  and valid title thereto, in each case free and clear
of any Encumbrances,  except for Permitted Encumbrances.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

Notwithstanding  subsection (a), the Sellers collectively, in respect of each
of the  Purchased Assets comprising Technical Information, are the legal 
and  beneficial owners of the Technical Information with good and valid 
title  thereto, free and clear of any Encumbrances, except for Permitted 
Encumbrances, and the applicable Seller has a valid and legally  enforceable
right in Canada and the United States to use (inclusive  of the  right to
commercially exploit and further license and convey) the  Technical
Information free from third party  interference.

    
---|---|--- 
    

 

 

         |  

(c)

    |  

Notwithstanding  subsection (a), the Sellers collectively, in respect of each
of the  Purchased Assets comprising Proprietary IP, are the sole and
exclusive  owner in Canada and the United States of all Proprietary IP
included  in  the Purchased Assets, free and clear of all Encumbrances,
except  for  Permitted Encumbrances.

    
---|---|--- 
    

 

 

**4.1.5** **No  Options**

 

 

Except  as  set forth in Section 4.1.5  of the  Disclosure Letter, no
Person other than Buyer has any written agreement, option,  warrant,
privilege or right, or any right capable of becoming any of the  foregoing
for the purchase from a Seller of any of the Purchased Assets or  the 
Replacement Contracts.

 

 

**4.1.6** **Litigation**

 

 

Except  as  set forth in Section 4.1.6 of the Disclosure Letter, there is no
claim, demand,  suit, action, cause of action, dispute, proceeding,
investigation, inquiry,  litigation, grievance, arbitration, governmental
proceeding or other proceeding  including appeals and applications for
review, in progress against, by or  relating to or affecting the Purchased
Assets, the Replacement Contracts or  the  Diagnostics Business, nor, to the
knowledge of MDS are any of the same  threatened, which if decided adversely
to MDS or an Operator would have a  Material Adverse Effect. There is no
Order outstanding against MDS or any  Operator that affects the Diagnostics
Business or any of the Purchased Assets  except those that would not have a
Material Adverse Effect.

 

 

**4.1.7** **The  Financial Statements**

 

 

         |  

(a)

    |  

The  Financial Statements and Quarterly  Statements:

    
---|---|--- 
    

 

 

         |  

(i)

    |  

have  been prepared in accordance with Generally Accepted Accounting
Principles,  applied on a basis consistent with that of the preceding
periods;  and

    
---|---|--- 
    

 

 

         |  

(ii)

    |  

present  fairly, in all material respects, the assets, Liabilities (whether 
accrued, absolute or contingent) and the financial position of the  MDS 
Diagnostics Division and the results of the operations of the MDS 
Diagnostics Division as at the dates thereof and for the periods  covered 
thereby in accordance with GAAP.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

The  Regional Financial Statements:

    
---|---|--- 
    

 

 

         |  

(i)

    |  

have  been prepared in accordance with Generally Accepted Accounting
Principles,  applied on a basis consistent with that of the Financial
Statements;  and

    
---|---|--- 
    

 

 

         |  

(ii)

    |  

present  fairly, in all material respects, the assets, Liabilities and the 
financial position of the MDS Diagnostics Division in Ontario and  Quebec 
and the head office of the MDS Diagnostics Division and the results  of the 
operations of the MDS Diagnostics Division in Ontario and Quebec  and the 
head office of the MDS Diagnostics Division as at the dates thereof  and 
for the period covered thereby in accordance with  GAAP.

    
---|---|--- 
    

 

 

**4.1.8** **Absence  of Changes**

 

 

Except  as  set forth in Section 4.1.8  of the  Disclosure Letter or as
contemplated by this Agreement, since the date of the  Financial Statements:

 

 

         |  

(a)

    |  

each  Operator and, to the knowledge of MDS, each Non-Controlled Operator 
has  conducted the Diagnostics Business carried on by it in the ordinary 
course;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

there  has not been any material change in the condition of the Diagnostics 
Business, the Purchased Assets, the Replacement Contracts or the  financial 
position or results of operations of MDS Diagnostics Division in  Ontario 
and Quebec other than changes reflected in the Quarterly Statements  and 
changes in the ordinary course of business, and such changes have  not, 
either individually or in the aggregate, had a Material Adverse Effect; 

    
---|---|--- 
    

 

 

         |  

(c)

    |  

there  has not been any damage, destruction, loss, technology failure,
labour  dispute, organizing drive, application for certification or other 
event,  development or condition of any character (whether or not covered 
by  insurance) which has had or would reasonably be expected to  have ****
a  Material Adverse Effect.

    
---|---|--- 
    

 

 

**4.1.9** **Absence  of Unusual Transactions**

 

 

Except  as  set forth in Section 4.1.9 of the Disclosure Letter or as
contemplated by this  Agreement, since the date of the Financial Statements:

 

 

         |  

(a)

    |  

neither  MDS nor any Operator has increased (or offered to increase) the 
compensation paid or payable to the Employees or increased (or offered  to 
increase) the benefits to which the Employees are entitled under  any 
benefit or pension plan of such Person or created (or offered to  create) 
any new benefit or pension plan for the Employees or entered into  any 
Contract with an Employee, in each case other than in the ordinary  course 
of business;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

no  Seller has created any Encumbrance on any of the Purchased Assets  or
the  Replacement Contracts or suffered or permitted any such Encumbrance 
that  has arisen on the Purchased Assets or the Replacement Contracts since 
that  date to remain, other than Permitted  Encumbrances;

    
---|---|--- 
    

 

 

         |  

(c)

    |  

no  Operator has:

    
---|---|--- 
    

 

 

         |  

(i)

    |  

changed  its accounting practices or policies in any material respect; 

    
---|---|--- 
    

 

 

         |  

(ii)

    |  

modified,  amended or terminated any Contract to which it is or was a
party,  or  waived or released any right which it has or had, other than in
the  ordinary course of its business or that has not individually or in 
the  aggregate had or would reasonably be expected to have **** a  Material
Adverse Effect;

    
---|---|--- 
    

 

 

         |  

(iii)

    |  

incurred  any material debt, liability or obligation for borrowed money, or 
incurred  any other material debt, liability or obligation, except in the
ordinary  course of its business;

    
---|---|--- 
    

 

 

         |  

(iv)

    |  

nor  MDS relating to the Diagnostics Business, suffered an operating loss 
or  any unusual or extraordinary loss, or entered into any commitment  or 
transaction not in the ordinary course where such loss, commitment  or 
transaction is or would be material in relation to the Purchased  Assets or 
the Diagnostics Business;

    
---|---|--- 
    

 

 

         |  

(v)

    |  

except  as set forth in Section 4.1.9 of the Disclosure Letter, nor MDS
relating  to the Diagnostics Business, hired or dismissed any senior 
Employees;

    
---|---|--- 
    

 

 

         |  

(vi)

    |  

except  as set forth in Section 4.1.9 of the Disclosure Letter, nor MDS
relating  to the Diagnostics Business, directly or indirectly, engaged in
any  transaction, made any loan or entered into any arrangement with any 
officer, director, partner, shareholder, Employee (whether current  or 
former or retired), consultant, independent contractor or agent of  MDS or 
an Operator, except in the ordinary course and consistent with past 
practice; and

    
---|---|--- 
    

 

 

         |  

(vii)

    |  

except  as set forth in Section 4.1.9 of the Disclosure Letter, nor MDS
relating  to the Diagnostics Business, deferred any capital expenditures or 
commitments therefor which were budgeted for in the capital expenditure 
budgets of the Diagnostics Business for the current fiscal year or  would 
have been made in the ordinary  course;

    
---|---|--- 
    

 

 

         |  

(d)

    |  

no  Corporate Operator nor, to the knowledge of MDS, any Non-Controlled 
Corporate Operator, has issued or sold any shares, bonds or other  securities
of any type whatsoever;

    
---|---|--- 
    

 

 

         |  

(e)

    |  

no  Partnership Operator nor, to the knowledge of MDS, any Non-Controlled 
Partnership Operator, has issued or sold any units, partnership interests  or
other securities of any type whatsoever; 

    
---|---|--- 
    

 

 

         |  

(f)

    |  

neither  MDS nor the Operators have authorized, agreed or otherwise become 
committed to do any of the matters set forth in paragraphs (c), (d)  and 
(e) above; and

    
---|---|--- 
    

 

 

         |  

(g)

    |  

to  the knowledge of MDS, no Non-Controlled Operator has authorized,  agreed
or  otherwise become committed to do any of the matters set forth in 
paragraphs (d) and (e) above.

    
---|---|--- 
    

 

 

**4.1.10** **Compliance  with Applicable Law**

 

 

MDS,  each  Operator and, to the knowledge of MDS, each Non-Controlled
Operator has operated  that part of the Diagnostics Business presently
operated by it and currently  operates such Diagnostics Business in
compliance with all Applicable Laws in  all  material respects.

 

 

**4.1.11** **Sufficiency  of Purchased Assets**

 

 

The  Purchased Assets owned, leased or otherwise held by the Sellers are,
together  with the Migrating Assets, the Replacement Contracts and the
Limited Trade  Mark  Licence, sufficient to carry on the Diagnostics
Business as presently conducted  by the Sellers, subject to clauses (a), (d),
(k), (o) and, to the extent used  in  the Diagnostics Business, (e) of the
definition of the Excluded Assets, all  Employees, and any services to be
provided by MDS or a third party to the Buyer  and/or any Designated Buyer
Affiliates after the BC Closing under the Migration  Agreement. It being
acknowledged that the Parties have agreed to the Migrating  Assets and the
Replacement Contracts under Sections 5.10  and 5.14  and MDS  makes no
representation or warranty as to the sufficiency of the Migrating  Assets and
the Replacement Contracts and shall have no liability therefor.  Except as
set forth in Schedule F1 to the Disclosure Letter, Schedule F to  the 
Disclosure Letter lists all employees necessary to carry on the Diagnostics 
Business as presently conducted by each such Seller.

 

 

**4.1.12** **Licences**

 

 

Except  as  set forth in Section 4.1.12 of the Disclosure Letter, each
Operator and, to  the  knowledge of MDS, each Non-Controlled Operator,
possesses all Licences material  to the conduct of the Diagnostics Business
carried on by it and each such  Licence of any Operator and, to the knowledge
of MDS, a Non-Controlled Operator  is in full force and effect and each
Operator and, to the knowledge of MDS,  each  Non-Controlled Operator is in
compliance with the terms and conditions of such  Licences in all material
respects and, to the knowledge of MDS, no proceeding  is  pending or
threatened to revoke or limit any such Licence. Each Licence of  an 
Operator material to the conduct of the Diagnostics Business carried on by 
it is  listed in Section 4.1.12 of the Disclosure Letter.

 

 

**4.1.13** **Employees,  Labour Matters**

 

 

         |  

(a)

    |  

Schedule  F annexed to the Disclosure Letter contains as at August 28, 
2006:

    
---|---|--- 
    

 

 

         |  

(i)

    |  

the  employee identification number and titles of all Employees together 
with  the location of their employment;

    
---|---|--- 
    

 

 

         |  

(ii)

    |  

the  date each Employee was hired;

    
---|---|--- 
    

 

 

         |  

(iii)

    |  

a  list of all employment offers made by MDS or an Operator to an executive 
Employee or an Employee with a total annual salary which exceeds  $150,000;

    
---|---|--- 
    

 

 

         |  

(iv)

    |  

the  rate of annual remuneration or hourly wage of each Employee at the 
date  hereof and all bonuses, incentive schemes, benefits and other
compensation  to which such Employee is entitled;

    
---|---|--- 
    

 

 

         |  

(v)

    |  

the  amount of vacation pay to which each Employee is entitled on the 
date  hereof; and

    
---|---|--- 
    

 

 

         |  

(vi)

    |  

the  contractor identification letter of all independent contractors that 
regularly provide material services to an Operator (or, to the extent  the 
services relate exclusively to the Diagnostics Business, MDS) pursuant  to 
a consulting arrangement and their annual  remuneration.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

Except  as disclosed in Section 4.1.13 of the Disclosure Letter, no
Employee  is  employed under a contract which cannot be terminated by his or
her  employer with appropriate notice and there are no retention, change 
of  control or deal bonuses or other compensation or benefits payable  by
the  Buyer or the Operators pertaining to the sale of the Diagnostics 
Business.  MDS and each Operator has withheld and remitted or paid to the
relevant  Governmental Authority all income Taxes, employment insurance 
contributions, Canada Pension Plan contributions and any Taxes or  other 
amounts which it is required by statute to withhold and remit or  pay to 
any Governmental Authority in respect of its  Employees.

    
---|---|--- 
    

 

 

         |  

(c)

    |  

Except  as disclosed in Section 4.1.13 of the Disclosure Letter, there are 
no  outstanding charges or inspection Orders made under the Occupational 
Health and Safety Act (Ontario) or similar legislation of any jurisdiction 
in which the Diagnostics Business is carried on by an Operator in  respect 
of the Diagnostics Business carried on by such Operator nor, to the 
knowledge of MDS, are any charges pending or threatened in writing  under 
such legislation.

    
---|---|--- 
    

 

 

         |  

(d)

    |  

There  are no outstanding notices of assessment, provisional assessment, 
reassessment, supplementary assessment, penalty assessment or increased 
assessment (collectively, " **assessments** ")  which any Operator has
received from any workers' compensation board or  similar authority and there
are no material assessments which are  unpaid  on the date hereof or which
will be unpaid at the Closing  Time.

    
---|---|--- 
    

 

 

**4.1.14** **Collective  Agreements**

 

 

No  Operator, or to the knowledge of MDS, any Non-Controlled Operator, is a
party  to  a collective agreement. No trade union, council of trade unions,
employee  bargaining agency or affiliated bargaining agent holds bargaining
rights with  respect to any Employees by way of certification, interim
certification,  voluntary recognition, or successor rights, or, to the
knowledge of MDS, has  applied or threatened to apply to be certified as the
bargaining agent of any  of  such employees. To the knowledge of MDS, no
material work stoppage or other  material labour dispute in respect of the
Diagnostics Business is pending or  threatened.

 

 

**4.1.15** **Benefit  Plans**

 

 

         |  

(a)

    |  

Section  4.1.15 of the Disclosure Letter contains a true and complete list 
of all  Benefit Plans of the Diagnostics Business and identifies which of 
such  Benefit Plans is a Pension Plan. Except as disclosed at Section
4.1.15  of  the Disclosure Letter, neither MDS nor any Operator has a
formal  plan or  commitment to create any additional Benefit Plan or to
modify, amend  or  change any existing Benefit Plan that would affect any
Employee or  former  employee of the Diagnostics Business, except such
modification, amendment  or change as may be required to be made to secure
the continued  registration of any existing Benefit Plan with any applicable
Governmental  Authority or to reflect annual premium changes in the ordinary
course  of  business.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

With  respect to each of the Benefit Plans, MDS has made available to Buyer 
true, correct and complete copies of each of the following  documents:

    
---|---|--- 
    

 

 

         |  

(i)

    |  

a  copy of the current terms of the Benefit  Plan;

    
---|---|--- 
    

 

 

         |  

(ii)

    |  

if  the Benefit Plan is funded through a trust or any third party funding 
arrangement, a copy of the current trust or other funding agreement 
(including all amendments thereto) and the most recent financial  statements
thereof;

    
---|---|--- 
    

 

 

         |  

(iii)

    |  

all  current material Contracts relating to the Benefit Plan with respect 
to  which MDS or an Operator may have any Liability, including insurance 
contracts, investment management agreements, subscription and  participation
agreements and record keeping  agreements;

    
---|---|--- 
    

 

 

         |  

(iv)

    |  

the  most recent financial, accounting, actuarial valuation or other
report,  as  applicable, of each Benefit Plan whether or not such report is
required  by  Applicable Law; and

    
---|---|--- 
    

 

 

         |  

(v)

    |  

the  most recent annual information returns filed with Governmental
Authorities  in respect of each Benefit Plan for which such filing is
required  by  Applicable Law.

    
---|---|--- 
    

 

 

         |  

(c)

    |  

Except  as disclosed in Section 4.1.15 of the Disclosure Letter, no
material  changes have occurred in respect of any Benefit Plan since the
date  of the  most recent financial, accounting, actuarial or other report,
as  applicable, issued in connection with any Benefit Plan, which could 
reasonably be expected to adversely affect the relevant report (including 
rendering it misleading in any material respect), other than changes  arising
as a result of the experience of the Benefit Plan or changes  in  the
assumptions or methods used in the most recent  report.

    
---|---|--- 
    

 

 

         |  

(d)

    |  

None  of the Sellers has received, or applied for, any payment of surplus 
out of  any Benefit Plan or any payment in respect of the demutualization 
of the  insurer of any Benefit Plan.

    
---|---|--- 
    

 

 

         |  

(e)

    |  

All  Employee data necessary to administer each Benefit Plan is in the 
possession of the Sellers or the Operators, will be included in the 
Purchased Assets and is complete, correct and in a form which is  sufficient
for the proper administration of the Benefit Plan in accordance  with its
terms and all Applicable  Laws.

    
---|---|--- 
    

 

 

         |  

(f)

    |  

None  of the Benefit Plans require or permit a retroactive increase in 
premium  or payments or require additional premiums or payments upon
termination  of  the Benefit Plan or any insurance contract relating
thereto, and  the level  of insurance reserves, if any, under any insured
Benefit Plan is  reasonable and sufficient to provide for all incurred but
unreported  claims.

    
---|---|--- 
    

 

 

         |  

(g)

    |  

The  Liabilities of the Diagnostics Business in respect of all Benefit 
Plans  are properly reflected in the Financial Statements according to
GAAP,  other than Liabilities related to the MDS Option Plan which
Liabilities  are not reflected on the Financial  Statements.

    
---|---|--- 
    

 

 

         |  

(h)

    |  

Except  as disclosed at Section 4.1.15  of  the Disclosure Letter, no
Benefit Plan provides benefits, including  death  or medical benefits
(whether or not insured), with respect to Employees  or  former employees of
the Diagnostics Business beyond retirement or  other  termination of
service, other than:

    
---|---|--- 
    

 

 

         |  

(i)

    |  

coverage  required by Applicable Law,

    
---|---|--- 
    

 

 

         |  

(ii)

    |  

death  or retirement benefits under any Pension  Plan,

    
---|---|--- 
    

 

 

         |  

(iii)

    |  

deferred  compensation benefits accrued as Liabilities in the Financial
Statements,  or

    
---|---|--- 
    

 

 

         |  

(iv)

    |  

benefits  the full cost of which is borne by the Employee or former
employee  (or his  beneficiary).

    
---|---|--- 
    

 

 

         |  

(i)

    |  

All  employer contributions required to be made by an Operator that are 
due  under Applicable Law to the Pension Plans as of the date hereof have 
been  made or properly accrued. All employee contributions to such Pension 
Plans  required to be contributed prior to the most recent pay period
ending  prior to the date hereof have been properly withheld by the
applicable  Operator and have been fully paid into the funding arrangements
for  the  respective Pension Plan.

    
---|---|--- 
    

 

 

         |  

(j)

    |  

Neither  MDS nor, to the knowledge of MDS, any Operator has received any
written  notice of any material claims or proceedings involving MDS or any 
Operator  or, to the knowledge of MDS, any of the Employees before any
Governmental  Authority relating to any Benefit  Plan.

    
---|---|--- 
    

 

 

**4.1.16** **Residence  of Sellers**

 

 

Each  Seller is not a non-resident of Canada within the meaning of the ITA
and MDS  ONT  LP is a "Canadian partnership" for the purposes of the ITA.

 

 

**4.1.17** **Insurance**

 

 

The  Purchased Assets owned or used by the Operators in the operation of
the  Diagnostics Business are insured pursuant to the insurance policies
listed  at  Section 4.1.17 of the Disclosure Letter. All such policies of
insurance are  in  full force and effect and MDS is not in material default,
whether as to the  payment of premium or otherwise, under the terms of any
such policy. All claims  of MDS or any Operator relating to the Diagnostics
Business under such insurance  policies and other policies held over the past
three (3) years and all losses  covered by any insurance policy deductible or
self insurance are listed at  Section 4.1.17 of the Disclosure Letter.

 

 

**4.1.18** **Intellectual  Property Rights and Information Systems**

 

 

         |  

(a)

    |  

Other  than any (i) unregistered copyrights and unregistered trade marks 
and  common law rights in trade marks; (ii) moral rights, all rights of 
priority, rights to file applications for inventions and derivative 
applications and patents in any and all jurisdictions; and (iii)  industrial
design rights other than industrial design registrations  and  pending
applications for same (all of which for greater certainty  are  included in
the Purchased Assets in accordance with the terms and  conditions hereof),
Schedule E annexed to the Disclosure Letter sets  forth  a true and complete
list of all Intellectual Property Rights which  are  proprietary to the
Operators or MDS and which are included in the  Purchased Assets including
all Software which is proprietary to the  Operators or MDS and which is
included in the Purchased Assets (such  Intellectual Property Rights
including such Software collectively  the  " **Proprietary  IP** ").

    
---|---|--- 
    

 

 

         |  

(b)

    |  

Schedule  E annexed to the Disclosure Letter sets forth a true and complete 
list of  all Intellectual Property Rights licensed from third parties that 
is used  in whole or in part in the Diagnostics Business (the " **Licensed 
IP** ").

    
---|---|--- 
    

 

 

         |  

(c)

    |  

Except  pursuant to the license agreements disclosed on Schedule D to the 
Disclosure Letter, neither MDS nor the Operators have licensed or  granted 
any material interest in or right to use, access or exploit all or  any 
portion of any Proprietary IP to any other  Person.

    
---|---|--- 
    

 

 

         |  

(d)

    |  

All  registrations and filings necessary to preserve the rights of MDS  or
such  Operator in and to such Proprietary IP, in each case federally in 
Canada  and in the United States, as at the date hereof have been made
other  than  those that the failure to make has not had and would not
reasonably  be  expected to have a Material Adverse Effect. Except as set
forth in  Schedule E to the Disclosure Letter there have been no patents
applied  for  and no other intellectual property registrations of any nature
made,  by  MDS or an Operator, in any jurisdiction concerning all or any
part  of the  Proprietary IP.

    
---|---|--- 
    

 

 

         |  

(e)

    |  

To  the knowledge of MDS, none of: (i) the Proprietary IP; (ii) MDS' or an 
Operator's ownership, use, operation, copying, licensing or other  commercial
exploitation of the Proprietary IP; and (iii) the carrying  on  of the
Diagnostics Business infringes, violates or breaches the  intellectual
property or other proprietary rights in Canada or the  United  States of any
other Person. MDS is not aware of any misappropriation,  breach, violation or
material interference with such Proprietary  IP by any  third parties and
neither MDS nor any Operator has received any written  notice expressly
claiming that any Proprietary IP is, or may be,  invalid  or unenforceable
other than where such claim, if decided adversely  to any  of MDS or an
Operator, would not have a Material Adverse  Effect.

    
---|---|--- 
    

 

 

         |  

(f)

    |  

Except  as disclosed in Schedule E to the Disclosure  Letter:

    
---|---|--- 
    

 

 

         |  

(i)

    |  

all  of the Proprietary IP are in full force and effect and have not been 
used  or enforced or failed to be used or enforced in a manner that would 
result  in their abandonment, cancellation or unenforceability;  and

    
---|---|--- 
    

 

 

         |  

(ii)

    |  

all  of the Proprietary IP consisting of issued registrations, or in the 
case  of inventions, issued patents, are valid and enforceable (with
respect  to  Canadian registrations and issued patents, in Canada, and, with
respect  to  U.S. registrations and issued patents, in the United  States).

    
---|---|--- 
    

 

 

         |  

(g)

    |  

The  Proprietary IP was developed either by contractors retained by MDS  or
an  Operator or by employees of MDS or an Operator and, to the knowledge 
of  MDS, does not: (i) contain any third party software, technology or 
third  party intellectual property or other proprietary rights or property; 
and  (ii) require any other Person's license, authorization, consent or
waiver  of any kind in connection with the use or commercial exploitation 
of the  Proprietary IP by Buyer (or any transferee of all or substantially 
all of  the MDS Diagnostics Division) in the carrying on of the diagnostics 
business after the Closing Time.

    
---|---|--- 
    

 

 

         |  

(h)

    |  

Intentionally  deleted.

    
---|---|--- 
    

 

 

         |  

(i)

    |  

Neither  MDS nor any Operator is a party to any claim (i) for trade mark, 
trade  name, industrial design, patent or copyright, trade secret or other 
intellectual property right infringements as to any services provided,  or 
any products produced or sold by, or concerning the Software of,  MDS or an 
Operator in the Diagnostics Business; or (ii) relating to trade marks,  trade
names, industrial designs, patents or copyrights, trade secret  or  other
intellectual property right owned or licensed by any of MDS  or an  Operator
exclusively in connection with the Diagnostics  Business.

    
---|---|--- 
    

 

 

         |  

(j)

    |  

MDS  and the applicable Operators have:

    
---|---|--- 
    

 

 

         |  

(i)

    |  

not  intentionally incorporated, and the Software does not to the knowledge 
of  MDS, contain any disabling mechanisms or protection features, including 
computer viruses, time locks or any code, instruction or device which  are 
designed to or may disrupt or prevent the use of the Software or  computer 
hardware or render any data inaccessible or that may be used without 
authority to access, modify or delete or damage any of the Software  or 
computer hardware data in the Software;  and

    
---|---|--- 
    

 

 

         |  

(ii)

    |  

implemented  industry standard software to detect computer viruses. 

    
---|---|--- 
    

 

 

         |  

(k)

    |  

MDS  and the applicable Operators have taken commercially reasonable steps 
to  safeguard and maintain the proprietary rights of MDS and the Operators 
in  and to the Proprietary IP and the trade secrets and confidential 
information of the Diagnostics  Business.

    
---|---|--- 
    

 

 

         |  

(l)

    |  

To  the knowledge of MDS, the Software is free from defects or deficiencies 
that would materially interfere with the ordinary course operation  of the 
Software.

    
---|---|--- 
    

 

 

         |  

(m)

    |  

MDS  or the applicable Operators have registered each of the domain names 
set  forth in Schedule E to the Disclosure Letter and have paid all fees 
required to maintain each registration, and there are no other domain  names
used in the Diagnostics Business except as set forth in Schedule  E.  None
of such domain names have been placed "on  hold".

    
---|---|--- 
    

 

 

         |  

(n)

    |  

Buyer  will not suffer or incur any Liability to the applicable third party 
under  any AutoLabs Contract as a direct result of an MDS Contracting
Party's  misrepresentation or breach of any covenant, agreement or
representation  made by the MDS Contracting Party under the applicable
AutoLabs Contract  (i) in respect of the intellectual property rights related
to the  APX  (AutoLab Process eXpert), and (ii) that the APX (AutoLab
Process  eXpert)  system complies with or conforms to the requirements,
specifications  or  documentation as set out in the applicable AutoLabs
Contract. 

    
---|---|--- 
    

 

 

**4.1.19** **Environmental  Matters**

 

 

         |  

(a)

    |  

Each  of the Operators possesses all material environmental licences,
permits  and other governmental approvals and authorizations (collectively 
the  " **Environmental  Permits** ")  necessary to conduct the Diagnostics
Business carried on by it and  is in  compliance with the Environmental
Permits and applicable Environmental  Laws except for non-compliance which
either individually or in the  aggregate has not had and would not reasonably
be expected to  have **** a  Material Adverse Effect. The Environmental
Permits are listed in  Section  4.1.19 of the Disclosure Letter, are in full
force and effect and,  subject  to receipt of any approval, consent or
authorization of any Governmental  Authority required by Applicable Law in
respect of the transfer of  such  Environmental Permits to Buyer, will not
become void or voidable  as a  result of the Closing. To the knowledge of
MDS, there are no material  proceedings or investigations in progress or
threatened in writing,  which  may result in the cancellation, revocation,
suspension, or modification  of  any Environmental Permit of the 
Operators.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

Neither  MDS nor any Operator has used or, since the date of ownership by 
the  applicable Operator or MDS, permitted to be used, except in material 
compliance with all Environmental Laws, the Real Property and the  Leased 
Premises included in the Purchased Assets to generate, manufacture,  process,
distribute, use, treat, store, dispose of, transport or  handle  any
Hazardous Materials except for any non-compliance that has not  had and 
would not reasonably be expected to have **** any  Material Adverse Effect.
Except as set forth in Section 4.1.19 of  the  Disclosure Letter, to the
knowledge of MDS, no underground storage  tanks  are located on the Real
Property included in the Purchased Assets  and the  Leased Premises.

    
---|---|--- 
    

 

 

         |  

(c)

    |  

Within  the last 36 months, neither MDS nor any Operator has received any 
written  notice of, or been prosecuted for, non-compliance of any
Environmental  Law  in respect of the Diagnostics Business or the Purchased
Assets owned  or  used by it. There are no outstanding written notices,
orders or directions  relating to environmental matters requiring, or
notifying MDS or  any  Operator that it is or may be responsible for, any
containment, clean-up,  remediation or corrective action to be made under
Environmental Laws  with  respect to the Diagnostics Business or the
Purchased Assets owned  or used  by it in the Diagnostics Business. To the
knowledge of MDS, there  are no  material proceedings or investigations in
progress or threatened  relating  to environmental matters in respect of the
Diagnostics Business,  the Real  Property or the Leased Premises.

    
---|---|--- 
    

 

 

         |  

(d)

    |  

Neither  MDS nor any of the Operators has caused, nor to the knowledge of 
MDS, has  there been, any Release in contravention of any Environmental Law 
on, in,  or from the Real Property or the Leased Premises included in the 
Purchased  Assets that has resulted in or would reasonably be expected to
result  in **** a  Material Adverse Effect. All Hazardous Materials used in
whole or  in part  by MDS or any Operator in connection with the Diagnostics
Business  or  resulting from the Diagnostics Business have been disposed of,
treated  and  stored by such Person in material compliance with all
Environmental  Laws  except for any non-compliance that has not had and
would not reasonably  be  expected to have **** any  Material Adverse
Effect.

    
---|---|--- 
    

 

 

         |  

(e)

    |  

Sellers  have provided to the Buyer a copy of all environmental audits,
studies  or  reports on the Real Property and, to the knowledge of MDS, the
Leased  Premises included in the Purchased Assets in the possession of 
Sellers.

    
---|---|--- 
    

 

 

**4.1.20** **Real  Property**

 

 

         |  

(a)

    |  

All  Land included in the Purchased Assets is listed in Section 4.1.20  of
the  Disclosure Letter including the legal description  thereof.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

To  the knowledge of MDS, there are no work orders outstanding against 
the  Real Property included in the Purchased Assets and neither MDS nor 
any  Operator has received any written deficiency notices of any material 
breach of any Applicable Law in respect of the foregoing which could,  if 
not corrected, become a work order.

    
---|---|--- 
    

 

 

         |  

(c)

    |  

To  the knowledge of MDS, the Buildings included in the Purchased Assets 
have  not been insulated with urea formaldehyde foam insulation, nor have 
they  been fireproofed or insulated with any asbestos fibre product nor 
are  there PCB's stored on any such Real  Property.

    
---|---|--- 
    

 

 

         |  

(d)

    |  

With  respect to the Real Property included in the Purchased Assets: 

    
---|---|--- 
    

 

 

         |  

(i)

    |  

the  applicable owner of the Land holds no registered and/or beneficial 
interest in any lands adjoining the Land, as contemplated in the  _Planning 
Act_   (Ontario);

    
---|---|--- 
    

 

 

         |  

(ii)

    |  

to  the knowledge of MDS, the Land has unobstructed access to and from 
adjoining public highways, streets and/or roads; 

    
---|---|--- 
    

 

 

         |  

(iii)

    |  

the  Land is adequately serviced by public or private utilities or its 
own  services to permit the Diagnostics Business operated at the Lands  to
be  carried on substantially as currently carried on;  and

    
---|---|--- 
    

 

 

         |  

(iv)

    |  

save  as set forth in Section 4.1.20 of the Disclosure Letter, there are 
no  leases, subleases, licenses, concessions, or other agreements, written 
or  oral, granting to any Person other than an Operator the right of  use
or  occupancy of any portion of such Real  Property.

    
---|---|--- 
    

 

 

         |  

(e)

    |  

Except  as may be disclosed by the International Survey, the Building at 
100  International Boulevard, Toronto is erected within the boundaries  of
the  Land municipally known as 100 International Boulevard, Toronto, no 
part of  such Building encroaches upon any adjoining lands, and to the
knowledge  of  MDS there are no encroachments of any buildings, structures
or  improvements situate on any adjoining lands onto such  Land.

    
---|---|--- 
    

 

 

**4.1.21** **No  Expropriation**

 

 

No  Operator or MDS has received any written notice of expropriation of all
or  any  material part of the Purchased Assets and MDS is not aware of any
expropriation  proceeding pending or threatened in respect of any of the
Purchased  Assets.

 

 

**4.1.22** **Leases**

 

 

Except  as  set forth in Section 4.1.22 of the Disclosure Letter, each of
the Leases  included in the Purchased Assets is listed in Schedule C annexed
to the  Disclosure Letter and is in full force and effect. No Operator or MDS
nor,  to  the knowledge of MDS, the lessor, is currently in breach of any
material  provision of any such Lease and each such Lease is otherwise in
good standing.  MDS has made available to Buyer true, complete and correct
copies of all such  Leases. The possession and quiet enjoyment by the
applicable Seller or Operator  of the Leased Premises has not been disturbed
in any material respect and there  are no material disputes with the lessors
under any of the Leases included  in  the Purchased Assets. Except as set
forth in Section 4.1.22  of the  Disclosure Letter, there are no subleases,
licenses or other rights of  occupation which have been granted by any
Operator to any Person other than  an  Operator the right to use or occupy
any such Leased Premises or any portion  thereof.

 

 

**4.1.23** **Material  Contracts**

 

 

         |  

(a)

    |  

Each  of the material Contracts of MDS pertaining exclusively to the
Diagnostics  Business, including for greater certainty the partnership
agreements  that  govern MDS ONT LP and Toronto Labs and the shareholders'
agreements of  Windsor Labs and Toronto GP and each of the material Contracts
to  which  the Operators are party included in the Purchased Assets is
listed  in  Schedule D annexed to the Disclosure Letter. Neither MDS nor
any  Operator  is currently in breach of any material provision of such
material  Contract **** and  each such material Contract is otherwise in
good standing. To the  knowledge of MDS, there exists no condition, event or
fact that,  with  giving of notice or lapse of time or both, would
constitute a material  default of any such material Contract. MDS has made
available to  Buyer  true, complete and correct copies of all such material
Contracts.  Except  as set forth in Section 4.1.23  of  the Disclosure
Letter, no Seller is a party to or bound by any guarantee,  surety or similar
obligation which pertains to or affects the Diagnostics  Business or the
Purchased Assets.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

In  respect of each of the AutoLabs Contracts that involves the
installation  and implementation of an APX (AutoLab Process eXpert) system,
MDS  or the  applicable MDS Contracting Party has installed and implemented
such  APX  (AutoLab Process eXpert) system such that it complies in all
material  respects with, and it has been accepted by the applicable
customer  as  being in compliance with, the terms and conditions of the
applicable  AutoLabs Contract. ****

    
---|---|--- 
    

 

 

         |  

(c)

    |  

Except  in respect of the specified project work remaining to be completed 
pursuant to the U.S. Transition Services Contract as set out in Subsection 
4.1.23(c)  of  the Disclosure Letter, MDS does not have knowledge of, and
does not  anticipate that, the applicable third party requires or will
require  the  applicable MDS Contracting Party to perform any other services
under  any  of the U.S. Transition Services Contracts. 

    
---|---|--- 
    

 

 

         |  

(d)

    |  

In  respect of certain of the U.S. Non-Competition Agreements: (i) neither 
MDS  nor MDS Laboratories Georgia Inc. are in violation of the Non-
Competition  Agreement dated March 15, 2004 between MDS and MDS Laboratories
Georgia,  Inc. for the benefit of Laboratory Corporation of America
Holdings;  and  (ii) neither MDS nor MDS Hudson Valley Laboratories, Inc.
are in  violation  of the Non-Competition Agreement dated March 15, 2004
between MDS  and MDS  Hudson Valley Laboratories Inc. for the benefit of
Laboratory Corporation  of America Holdings.

    
---|---|--- 
    

 

 

**4.1.24** **Books  and Records**

 

 

The  Books  and Records of the Sellers included in the Purchased Assets
fairly and correctly  set out and disclose the financial position of the MDS
Diagnostics Division  of  the Sellers as at the date hereof in all material
respects, and all material  financial transactions of MDS Quebec and MDS ONT
LP relating exclusively to  the  Diagnostics Business have been accurately
recorded in such Books and Records.  The Books and Records of the Ontario GP
fairly and correctly set out and  disclose the financial position of the
Diagnostics Business carried on by the  Ontario GP as at the date hereof in
all material respects, and all material  financial transactions of the
Ontario GP have been accurately recorded in such  Books and Records.

 

 

**4.1.25** **Accounts  Receivable**

 

 

Each  Seller has the full right and authority to assign to Buyer the
Accounts  Receivable of the Seller included in the Purchased Assets. The
Accounts  Receivable reflected in the Quarterly Statements are bona fide,
enforceable  and  fully collectible (subject to a reasonable allowance,
consistent with past  practice, for doubtful accounts as reflected in the
Quarterly Statements in  accordance with GAAP). Except as set forth in
Section 4.1.25  of the  Disclosure Letter, such Accounts Receivable are not
subject to any defence,  set-off or counterclaim.

 

 

**4.1.26** **Tax  Matters**

 

 

         |  

(a)

    |  

There  are no Encumbrances, other than Permitted Encumbrances, on account 
of  Taxes on the Purchased Assets.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

There  are no proceedings, investigations, audits or claims now pending 
or  threatened against the Sellers or Operators in respect of any Taxes 
in  respect of the Diagnostics Business or Operators, and there are no 
matters  under discussion, audit or appeal with any Governmental Authority 
relating  to Taxes in respect of the Diagnostics Business or Operators,
which  will  result in an Encumbrance on any of the Purchased Assets or
Replacement  Contracts other than Permitted Encumbrances. 

    
---|---|--- 
    

 

 

**4.1.27** **GST  Registration**

 

 

Ontario  GP is registered for purposes of Part IX of the Excise Tax Act
(Canada). Ontario  GP's GST Registration Number is [REDACTED]. MDS Quebec is
registered under  Division I of Chapter VIII of Title I of the Quebec Sales
Tax Act with respect  to Quebec sales Tax and its registration number is
[REDACTED].

 

 

**4.1.28** **Share  Capital**

 

 

To  the  knowledge of MDS, the authorized and issued capital of Toronto GP
is as set  forth in Section 4.1.28 of the Disclosure Letter.

 

 

**4.1.29** **Subsidiaries  and Joint Venture Interests**

 

 

Except  as  set forth in Section 4.1.29 of the Disclosure Letter, no
Operator owns any  shares in or securities of any other body corporate nor is
any Operator a  partner, member, owner, proprietor or equity investor of or
in any partnership,  joint venture, co-tenancy or other similar jointly-owned
business undertaking  nor has it agreed to become any of the foregoing.

 

 

**4.1.30** **Privacy  Matters**

 

 

Except  as  set forth in Section 4.1.30  of the  Disclosure Letter,
neither MDS nor any Operator has received any written  complaint or notice of
any complaint, breach or violation of any Privacy Law  in  respect of the
Diagnostics Business carried on by it which has had a Material  Adverse
Effect.

 

 

**4.1.31** **Condition  of Purchased Assets**

 

 

To  the  knowledge of MDS, except as set forth in Section 4.1.31  of the 
Disclosure Letter, the Buildings included in the Purchased Assets are free 
from  significant mechanical, electrical or **** structural  defects and the
material Equipment and other tangible personal property included  in the
Purchased Assets are in good working order, subject to reasonable wear  and
tear. To the knowledge of MDS, except as set forth in Section 4.1.31  of
the  Disclosure Letter, none of such Buildings or Equipment or other
tangible  personal property material to the operation of the Diagnostics
Business are  in  need of maintenance or repairs except for maintenance and
repairs in the  ordinary course of business.

 

 

**4.1.32** **Related  Party Transactions**

 

 

Except  as  set forth in Section 4.1.32  of the  Disclosure Letter, all
Contracts included in the Purchased Assets have been  entered into on arm's
length terms (within the meaning of the ITA). Any accounts  due and payable
by the Operators to MDS or any Affiliate of MDS or by MDS or  any  Affiliate
of MDS to any Operator, are recorded on the Books and Records of  the 
Operators at their fair market value. Since the date of the Financial 
Statements, there has been no forgiveness or similar release or, except in 
the  ordinary course of business, repayment of a debt owed by or to a Person
not  at  arms-length with the Operators or the Sellers.

 

 

**4.2** **Representations  and Warranties of Buyer**

 

 

Buyer  represents and warrants to MDS and the other Sellers as set forth in
the  following Subsections of this Section 4.2.

 

 

**4.2.1** **Incorporation**

 

 

Buyer  is  a corporation duly incorporated and validly existing under the
laws of its  jurisdiction of incorporation. No proceedings have been taken or
authorized  by  Buyer or, to the best of Buyer's knowledge, by any other
Person, with respect to  the bankruptcy, insolvency, liquidation, dissolution
or winding up of  Buyer.

 

 

**4.2.2** **Corporate  Power and Due Authorization**

 

 

Buyer  has  all necessary corporate power and capacity to execute and
deliver, and to  observe and perform its covenants and obligations under,
this Agreement and  the  Closing Documents to which it will be a party.
Buyer has taken all corporate  action necessary to authorize the execution
and delivery of, and the observance  and performance of its covenants and
obligations under, this Agreement and  such  Closing Documents.

 

 

**4.2.3** **Absence  of Conflicting Agreements**

 

 

None  of  the execution and delivery of, or the observance and performance
by Buyer of  any  covenant or obligation under, this Agreement or any
Closing Document to which  it  will be a party contravenes or results in or
will contravene or result in a  violation of or a default under (with or
without the giving of notice or lapse  of time, or both) or in the
acceleration of any material obligation  under:

 

 

         |  

(a)

    |  

the  articles or by-laws of Buyer;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

any  agreement, lease, mortgage, security document, obligation or
instrument  to  which Buyer is a party or by which Buyer or its assets is
affected  or  bound; or

    
---|---|--- 
    

 

 

         |  

(c)

    |  

Applicable  Law.

    
---|---|--- 
    

 

 

**4.2.4** **Enforceability  of Obligations**

 

 

This  Agreement has been, and the Closing Documents to be entered into by
Buyer will  be, duly executed and delivered by Buyer and this Agreement
constitutes and  each  such Closing Document will constitute a valid and
binding obligation of Buyer  enforceable against Buyer in accordance with its
terms.

 

 

**4.2.5** **Investment  Canada Act**

 

 

Buyer  is  not a "non-Canadian" for the purposes of the Investment Canada
Act and no  approval or consent is required under such Act in connection with
the execution,  delivery and performance of this Agreement by Buyer.

 

 

**4.2.6** **Status  of Buyer**

 

 

None  of  the Buyer or any Designated Buyer Affiliate is or will be a Person
the taxable  income of which is exempt from income Tax under Part I of the
ITA by virtue  of  subsection 149(1) of the ITA (a " **149  Person** "), 
and  where a Designated Buyer Affiliate is a partnership, its partners will
be (i)  entities other than 149 Persons or (ii) partnership, the partners of
which  are  persons other than 149 Persons.

 

 

**4.2.7** **GST  Registration**

 

 

Buyer  is  registered for purposes of Part IX of the Excise Tax Act
(Canada). Buyer's GST  Registration Number is [REDACTED].

 

 

**4.2.8** **Consents  and Approvals**

 

 

Other  than the Regulatory Consents, no consent, approval, or authorization
of or  registration or filing with any Governmental Authority is required by
Buyer  in  connection with the execution and delivery by Buyer of this
Agreement or any  of  the Closing Documents to be entered into by Buyer, or
the observance and  performance by Buyer of its obligations under this
Agreement or such Closing  Documents.

 

 

**4.2.9** **Financing**

 

 

Buyer  is  able to finance the entire Purchase Price from its existing cash
on hand, liquid  assets, credit facilities and other binding financial
commitments.

 

 

**4.2.10** **Eligibility**

 

 

Buyer  is  able to satisfy each of the representations and warranties
required to be given  by it in order to become a limited partner or
shareholder, as applicable, of  Toronto Labs, Toronto GP and Windsor Labs as
set forth in the partnership  agreement, shareholders' agreement or
constating documents governing each such  Operator.

 

 

**4.3** **Commission**

 

 

Each  Party represents and warrants to the other Party that the other Party
will  not  be liable for any brokerage commission, finder's fee or other
like payment in  connection with the transactions contemplated hereby because
of any action  taken  by, or agreement or understanding reached by, that
Party.

 

 

**4.4** **Qualification  of Representations and Warranties**

 

 

Any  representation or warranty made by a Party as to the enforceability of
this  Agreement or any Closing Document against a Person is subject to the
following  qualifications:

 

 

         |  

(a)

    |  

specific  performance, injunction and other equitable remedies are
discretionary  and, in particular, may not be available where damages are
considered  an  adequate remedy; and

    
---|---|--- 
    

 

 

         |  

(b)

    |  

enforcement  may be limited by bankruptcy, insolvency, liquidation,
reorganization,  reconstruction and other laws generally affecting
enforceability  of  creditors' rights.

    
---|---|--- 
    

 

 

**4.5** **Survival  of Representations and Warranties of MDS**

 

 

All  representations and warranties made by MDS in this Agreement and in any
Closing  Document shall survive the Closing for a period of eighteen (18)
months after  the Closing Date other than representations and warranties of
MDS set forth  in  Section 4.1.4  regarding title of Purchased Assets which
representations and warranties shall  survive Closing for a period of six
years after the Closing Date. The  representations and warranties of MDS set
forth in Section 4.1.26  shall,  to the extent it relates to a particular
Tax Liability of a Person or a Seller,  survive closing until 90 days after
the expiration of the limitation period  contained in the applicable Tax laws
subsequent to the expiry of which an  assessment or reassessment or other
form or recognized document assessing such  Tax Liability cannot be issued.
After each such period, MDS shall have no  further liability hereunder with
respect to such representations and warranties  except with respect to claims
properly made pursuant to Article 8  hereof  within such period.

 

 

**4.6** **Survival  of Representations and Warranties of Buyer**

 

 

All  representations and warranties made by Buyer in this Agreement and in
any  Closing Document shall survive for a period of eighteen (18) months
after the  Closing Date. After such period, Buyer shall have no further
liability hereunder  with respect to such representations and warranties
except with respect to  claims properly made pursuant to Article 8  hereof 
within such period.

 

 

**4.7** **Knowledge  of MDS**

 

 

Where  any  representation or warranty contained in this Agreement, other
than one regarding  a Non-Controlled Operator, is expressly qualified by
reference to the "knowledge" or "awareness" of MDS, it shall be deemed to
refer to the actual  knowledge or awareness of any one of (i) Kenneth L.
Horton, Executive  Vice-President, Corporate Development and General Counsel,
James A.H. Garner,  Executive Vice-President and Chief Financial Officer,
Peter Winkley,  Vice-President, Finance and Global Controller, Rob Breckon,
Senior  Vice-President, Corporate Development, William Chung, Director,
Strategic  Initiatives, Corporate Development, Hans K. Thunem, President, MDS
Diagnostics  Services, Michael McTeague, Senior Vice-President, Legal, MDS
Diagnostics and  Frank Amodeo, Senior Vice-President, Finance, MDS
Diagnostics Services, in  each  case without any enquiry other than
reasonable enquiry of appropriate senior  officers of the Sellers in respect
of the Diagnostics Business and the Purchased  Assets; (ii) Anne Louise
Aboud, General Manager, Ontario and Quebec, MDS  Diagnostic Services, Anna
Filipopoulos, Senior Vice-President, Human Resources,  MDS Diagnostic
Services, Craig Taylor, Leasing Manager, Nigel Terrett,  Vice-President, BC
Operations, Maurizio Laudisa, Senior Vice-President,  Information Technology
and Richard Goddard, Director, Facility Operations in  respect of that
portion of the operations of the Diagnostics Business that  such  individual
is responsible for, without any enquiry. Where any representation  or 
warranty contained in this Agreement regarding a Non-Controlled Operator is 
expressly qualified by reference to the "knowledge" or "awareness" of MDS,
it  shall be deemed to refer to the actual knowledge or awareness of Frank
Amodeo  after reasonable enquiry and Anne Louise Aboud and Hans K. Thunem
without any  enquiry.

 

 

**4.8** **No  Breach**

 

 

Any  matter or thing done or omitted to be done prior to the Closing by MDS
or any  Operator in substantial compliance with the request of or with the 
informed **** approval  of Buyer or any of its Representatives or as
contemplated by this Agreement  or  the BC Agreement, shall not constitute a
breach of any representation, warranty,  covenant or other provision of this
Agreement.

 

 

**ARTICLE 5**

 

 

**OTHER  COVENANTS OF THE PARTIES**

 

 

**5.1** **Conduct  Prior to Closing**

 

 

During  the Interim Period, the Parties shall act as set forth in this
Section 5.1.

 

 

**5.1.1** **Conduct  Business in Ordinary Course**

 

 

Except  as  otherwise contemplated or permitted by this Agreement, the BC
Agreement, the  Rix  Agreement or the Migration Agreement or set forth in
the Disclosure Letter,  MDS  shall and shall cause the other Sellers to:

 

 

         |  

(a)

    |  

use  commercially reasonable efforts to:

    
---|---|--- 
    

 

 

         |  

(i)

    |  

preserve  and protect the Diagnostics Business and its income and the
goodwill and  reputation of the Diagnostics  Business;

    
---|---|--- 
    

 

 

         |  

(ii)

    |  

retain  or cause to be retained the Employees necessary for the operation 
of the  Diagnostics Business in the manner it is currently being  operated;

    
---|---|--- 
    

 

 

         |  

(iii)

    |  

maintain  its and the Operators' material business relationships with its and
the  Operators' respective customers, suppliers, landlords and governments,
and  promote and preserve for Buyer such  relationships;

    
---|---|--- 
    

 

 

         |  

(iv)

    |  

ensure  that any material **** Contracts  entered into or amended by the
Sellers or the Operators with respect  to  the Diagnostics Business shall
include provisions permitting the  assignment of such Contracts to the Buyer
or a Designated Buyer Affiliate  and a change of control of the Diagnostics
Business as a result of  the  transactions contemplated hereunder, as
applicable, without having  to  obtain the consent of any other party to
such Contracts, the payment  of  any fee, penalty or liquidated damages or
any other limitation or  restriction;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

carry  on the Diagnostics Business with reasonable diligence and in the 
ordinary  course and not make any material modification in its accounting
or  management practices;

    
---|---|--- 
    

 

 

         |  

(c)

    |  

confer  with Buyer concerning operational matters of a material nature
relating  to  the Diagnostics Business;

    
---|---|--- 
    

 

 

         |  

(d)

    |  

promptly  inform Buyer in writing of (i) any material change in the
Purchased  Assets, the Replacement Contracts, the Migrating Assets, Assumed 
Liabilities, business, affairs, operations, financial condition,  or 
capital of the Diagnostics Business, and (ii) any fact, change, condition, 
circumstance or occurrence of any event that MDS believes will, or  is 
reasonably likely to, result in a failure to satisfy the conditions  in 
favour of Buyer hereunder to be complied with or satisfied by Sellers; 
provided, however, that the delivery of any such notice pursuant  to this 
paragraph shall not limit or otherwise affect the remedies available 
hereunder to Buyer;

    
---|---|--- 
    

 

 

         |  

(e)

    |  

not,  directly or indirectly, through any officer, director, Employee, 
representative (including, without limitation and for greater certainty,  any
investment banker, financial advisor, lawyer or accountant) or  agent  of
the Sellers, a Seller or other Affiliate (excluding the BC Operators)  (i)
solicit, initiate, encourage or otherwise facilitate (including  by way  of
furnishing information or entering into any form of agreement,  arrangement
or understanding) the initiation of any inquiries or  proposals  regarding
(A) any sale of all or a substantial part of the Diagnostics  Business or the
Purchased Assets to any Person other than Buyer and  its  permitted assigns;
or (B) any business combination, reorganization,  recapitalization,
amalgamation, merger or consolidation of a Seller  (other  than MDS) or an
Operator or, only to the extent it materially adversely  affects the ability
of MDS to perform its material obligations under  this  Agreement, MDS,
including the sale of any securities of a Seller  (other  than MDS) or an
Operator or, only to the extent it materially adversely  affects the ability
of MDS to perform its material obligations under  this  Agreement, MDS to
any Person other than Buyer and its permitted assigns  (each an "
**Acquisition  Proposal** "),  (ii) participate in any discussions or
negotiations regarding any  Acquisition Proposal, (iii) approve or recommend
any Acquisition  Proposal,  (iv) publicly disclose in any manner any
Acquisition Proposal, or  (v)  enter into any agreement, arrangement or
understanding related to  any  Acquisition Proposal, except as contemplated
by this Agreement. For  greater certainty, (a) an Acquisition Proposal does
not include (i)  the  furnishing of information to Rix, entities controlled
by him, his  agents  and representatives to the extent necessary to
facilitate the transactions  contemplated in the BC Purchase Agreement or
(ii) any action required  by a  partnership or shareholder agreement or
constating document of an  Operator, Toronto Labs, Toronto GP or Windsor Labs
or any action  contemplated or permitted by this Agreement (each, a "
**Permitted  Proposal** ");  (b) MDS may continue to provide such
information and enter into  discussions and negotiations with other Persons
regarding a Permitted  Proposal; (c) MDS may enter into a binding agreement
in respect of  a  Permitted Proposal including a Regional Purchase Agreement
and any  other  agreements contemplated by either such agreement provided
that it  does not  materially adversely affect the ability of MDS to perform
its material  obligations under this Agreement, and may approve, recommend
and  publicly  announce same, in each case without violating this 
Agreement;

    
---|---|--- 
    

 

 

         |  

(f)

    |  

except  for any Permitted Proposals, MDS shall, and shall use commercially 
reasonable efforts to cause the officers, directors, employees, 
representatives and agents of the Sellers to, cease immediately all 
discussions and negotiations regarding any proposal that constitutes,  or 
may reasonably be expected to lead to, an Acquisition Proposal; 

    
---|---|--- 
    

 

 

         |  

(g)

    |  

ensure  that its officers, directors, Employees, representatives and agents 
and  those of the other Sellers are aware of the provisions of Subsection 
5.1.1(e),  and it shall be responsible for any breach of Subsection
5.1.1(e)  by  its and the other Sellers' and Operators' officers, directors,
Employees,  representatives or agents other than Rix or Rixco or any
nominees,  representatives or agents of Rix or  Rixco;

    
---|---|--- 
    

 

 

         |  

(h)

    |  

not  enter into any new Leases or offers to lease in respect of the
Diagnostics  Business or any renewal or extension of an existing Lease or
prepay  any  rent in respect of a Lease without the prior written consent of
Buyer,  which shall not be unreasonably withheld or  delayed.

    
---|---|--- 
    

 

 

Notwithstanding  the foregoing, Buyer acknowledges and agrees that on or
prior to the Closing  Time, MDS may, whether conditional upon the Closing or
not, terminate certain  related party agreements as set forth at Section
5.1.1 of the Disclosure Letter. 

 

 

**5.1.2** **Action  to Satisfy Closing Conditions**

 

 

Each  Party shall take all such commercially reasonable action as is within
its power  to control, and shall use its commercially reasonable efforts to
cause other  actions to be taken which are not within its power to control,
so as to ensure  compliance with all conditions which are for the benefit of
any Party. Subject  to and in compliance with Applicable Law, including the
Competition Act, and  the  Confidentiality Agreement, the Parties will co-
operate in exchanging such  information and providing such assistance as may
be reasonably required in  connection with the foregoing.

 

 

**5.1.3** **MDS  Consents and Waivers**

 

 

MDS  shall, and shall cause the other Sellers to, at their own expense,
subject  to  obtaining all commercially reasonable co-operation and
assistance of Buyer,  use  all commercially reasonable efforts to obtain by
the Closing Time the LPBP  Consent, all consents or waivers of applicable
third parties, including other  shareholders and partners, required to
transfer the Regional Assets owned by  them and all material consents or
waivers of the landlords and other third  parties in respect of the Non-
Assignable Contracts and the Non-Assigned Leases,  and shall provide and
deliver all notices, if any, required by the terms of  the  Contracts, the
Leases, the Equipment Leases, the Warranty Rights and the  Transferable
Licences included in the Purchased Assets in connection with the 
transactions contemplated herein. For greater certainty, this Section shall 
not  obligate any Seller to make payment to any such shareholder, partner or
other  third party nor any payment, other than to cover administrative,
processing  or  similar fees or any other amounts contemplated in any Non-
Assignable Contracts  in connection with the assignment thereof, to any
landlord or other third party  or to institute legal or arbitration or other
proceedings to obtain such  consents or waivers.

 

 

**5.1.4** **Privacy**

 

 

MDS  and  Buyer acknowledge and agree that certain information provided to
Buyer or any  Designated Buyer Affiliate in connection with the transactions
contemplated  hereunder constitutes Personal Information (the " **Disclosed 
Personal Information** ")  the  disclosure of which is necessary for the
purposes (the " **Purposes** ")  of  both determining if Buyer or the
Designated Buyer Affiliate shall proceed with,  and completing, the
transactions, and thereafter for carrying on the Diagnostics  Business and
that:

 

 

         |  

(a)

    |  

the  Disclosed Personal Information may not be used or disclosed by Buyer 
or  the Designated Buyer Affiliate for any purpose other than the  Purposes;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

the  Disclosed Personal Information must be kept strictly confidential 
and  Buyer or the Designated Buyer Affiliate shall ensure that access  to
the  Disclosed Personal Information shall be restricted to those 
representatives of Buyer who have a bona fide need for access to  the 
Disclosed Personal Information for the Purposes and shall instruct  those 
representatives to protect the confidentiality of such information  in a 
manner consistent with the obligations of Buyer and or the Designated  Buyer
Affiliate hereunder and under the Confidentiality Agreement; 

    
---|---|--- 
    

 

 

         |  

(c)

    |  

if  the transactions contemplated hereby do not proceed or are not
completed,  Buyer and the Designated Buyer Affiliate shall destroy or
return  to MDS,  as directed by MDS, the Disclosed Personal Information; 
and

    
---|---|--- 
    

 

 

         |  

(d)

    |  

if  the transactions contemplated hereby are completed, (i) Buyer and  the 
Designated Buyer Affiliate shall only use or disclose the Disclosed  Personal
Information for the same purposes for which it was collected,  used or
disclosed by MDS or the Operators; and (ii) Buyer and the  Designated Buyer
Affiliate shall (A) not use or communicate the Quebec  Personal Information
to a third party unless and until, and to the  extent,  the Buyer obtains
the consent of such individual to do so, and (B)  develop  and implement
such policies and procedures as Buyer considers appropriate  to ensure that
the Buyer meets the commitment set forth in (A) of  this  Subsection
5.1.4(d).

    
---|---|--- 
    

 

 

**5.1.5** **Injunctions**

 

 

If  any  court having jurisdiction over the Parties or any Seller issues any
injunction,  decree or similar order before the Closing Time which would
prohibit or  materially restrict or hinder the Closing, the Parties shall use
their  respective commercially reasonable efforts to have such injunction,
decree  or  order dissolved or otherwise eliminated as promptly as possible
and, in any  event, prior to the Closing Time.

 

 

**5.1.6** **Access  for Investigation**

 

 

         |  

(a)

    |  

Subject  to and in compliance with Applicable Law, including the
Competition  Act,  and the Confidentiality Agreement during the Interim
Period, MDS  shall  permit Buyer and its Representatives to have access
during normal  business  hours to the Purchased Assets, such portions of the
Shared Contracts  as  relate to the Diagnostics Business, the Replacement
Contracts and  the  Migrating Assets, in each case, once acquired, and the
Books and  Records  over which it or an Operator exercises control on
condition that  no Person  given access interferes with the ordinary conduct
of the Diagnostics  Business by MDS or any Operator and MDS shall furnish to
Buyer such  operating data and other information with respect to the
Diagnostics  Business, the Purchased Assets, such portions of the Shared
Contracts  as  relate to the Diagnostics Business, to the extent related to
the  Diagnostics Business, the Replacement Contracts and the Migrating 
Assets  in the possession or control of MDS as Buyer shall from time to
time  reasonably request. MDS agrees that Buyer may conduct such
environmental  investigations and tests on the Real Property included in the
Purchased  Assets as Buyer, acting reasonably, considers necessary, at
Buyer's  expense and provided that no damage is caused to such Real
Property  and  the condition of the Real Property is restored substantially
to its  pre-investigation condition and that such investigations and tests 
do not  interfere with the ordinary conduct of the Diagnostics Business. 
Buyer  shall indemnify and hold harmless MDS and the Operators of and from 
and  against all actions, causes of actions, suits, claims, demands,
damages,  losses, costs or expenses suffered or incurred by any of them to 
the  extent Buyer does not comply with the foregoing obligations with 
respect  to the conduct of any such investigations and tests. Buyer shall 
forthwith  provide to MDS a copy of the results of such investigations and
tests  and  shall not disclose and shall cause any Person who prepared a
report  based  on such investigations and tests not to disclose, any
information  relating  to such investigations and tests or contained in any
such report  to any  Person unless compelled to do so by Applicable Law.
Except as set  forth in  this Agreement, the exercise of any rights of
access or inspection  by or  on behalf of Buyer under this Section 5.1.6 
will not affect or mitigate the covenants, representations and warranties  of
MDS in this Agreement which will continue in full force and effect  as 
provided in this Agreement.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

Subject  to the terms of the Confidentiality Agreement and Section 5.1.4, 
both prior to the Closing Date and, if the sale and purchase of the 
Purchased Assets hereunder fails to occur for whatever reason, thereafter 
Buyer will not disclose to anyone or use for its own or for any purpose 
other than the purpose contemplated by this Agreement any confidential 
information concerning MDS or an Operator or the Diagnostics Business 
obtained by Buyer pursuant hereto, will hold all such information  in the 
strictest confidence and, if the sale and purchase of the Purchased  Assets 
hereunder fails to occur for whatever reason, will return to MDS  or, at 
the request of MDS, destroy all documents, records and all other  information
or data relating to MDS or the Operators or to the Diagnostics  Business
which Buyer obtained pursuant to this  Agreement.

    
---|---|--- 
    

 

 

         |  

(c)

    |  

From  and after the Closing Date, Sellers will not disclose to anyone or 
use for  any purpose any confidential information concerning the Purchased 
Assets,  the Replacement Contracts, the Migrating Assets or the Diagnostics 
Business purchased by Buyer pursuant to this Agreement and will hold  all 
such information in the strictest confidence, in each case, except,  upon 
prior notice to Buyer, to defend any claim or other proceeding as 
contemplated in Section 7.2,  the filing of Tax Returns or dealing with any
other matters contemplated  in Section 7.4  or  7.5,  or as required by
Applicable Law.

    
---|---|--- 
    

 

 

**5.1.7** **75  and 100 International Blvd.**

 

 

At  the  Closing Time and conditional upon Closing, MDS and Buyer and/or the
applicable  Designated Buyer Affiliates shall execute and deliver a license
of certain  premises at each of 75 and 100 International Boulevard
(collectively, the " **International  Boulevard Licenses** ")  on 
mutually acceptable terms to the extent the applicable real estate Migration 
Projects are not completed by the Closing Time.

 

 

**5.2** **Regulatory  Consents**

 

 

**5.2.1** **Competition  Act Filings**

 

 

Buyer  shall use its best efforts to obtain Competition Act Clearance. Buyer
shall  co-operate with MDS and keep MDS informed as to the status of the
proceedings  related to all applications, notifications and filings relating
to Competition  Act Clearance. MDS will co-operate with Buyer and provide
reasonable assistance  to Buyer in obtaining Competition Act Clearance.

 

 

Without  limiting the generality of the foregoing, as soon as practicable and
in any  event within ten (10) Business Days after the date of this Agreement
(or within  such other period of time as the Parties may agree), on the
written election  of  Buyer, the Parties will prepare and file with the
Commissioner:

 

 

         |  

(a)

    |  

an  application for an advance ruling certificate under section 102 of 
the  _Competition  Act_   in  respect of the transactions contemplated by
this Agreement, together  with  a request that a No-Action Letter be issued
and a waiver under subsection  113(c) of the _Competition  Act_   be 
granted if an advance ruling certificate is not issued. Where a waiver  under
subsection 113(c) of the Competition Act is not granted, on  the  written
election of Buyer given at any time, Buyer and the Sellers  shall  promptly
prepare and file a short-form pre-merger notification (and  if the 
Commissioner requests a long-form, they shall prepare and file a  long-form 
in addition to or in lieu of a short-form) pursuant to Part IX of  the 
Competition Act in respect of the transactions contemplated by this 
Agreement; or

    
---|---|--- 
    

 

 

         |  

(b)

    |  

a  short-form pre-merger notification (and if the Commissioner requests  a 
long-form, they shall file a long-form in addition to or in lieu  of a 
short-form) pursuant to Part IX of the Competition Act in respect  of the 
transactions contemplated by this Agreement, together with a competitive 
impact submission and a request that an advance ruling certificate  or  No-
Action Letter be issued.

    
---|---|--- 
    

 

 

**5.2.2** **Competition  Act Clearance Process**

 

 

Buyer  and  MDS shall promptly furnish to the Commissioner, or her
authorized representative  under the Competition Act, any additional
information required or reasonably  requested under the Competition Act. All
requests and enquiries from the  Commissioner or her authorized
representative under the Competition Act will  be  dealt with by MDS and
Buyer in consultation with the other. MDS and Buyer  will:

 

 

         |  

(a)

    |  

not  extend or consent to any extension of any waiting period under the 
Competition Act or enter into any agreement with the Commissioner,  or her 
authorized representative under the Competition Act, to not consummate  any 
of the transactions contemplated in this Agreement, including under  any 
Regional Purchase Agreement, except with the consent of the  other;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

promptly  notify the other of written communications of any nature from the 
Commissioner, or her authorized representative under the Competition  Act, 
relating to such transactions and provide the other with copies thereof, 
except to the extent of competitively sensitive information, which 
competitively sensitive information will be provided only to the  external 
legal counsel and/or external expert of the other and will not be  shared 
by such counsel or expert with any other  Person;

    
---|---|--- 
    

 

 

         |  

(c)

    |  

permit  the other to review in advance any proposed written communications 
of any  nature with the Commissioner, or her authorized representative
under  the  Competition Act, relating to such transactions, and provide the
other  with  final copies thereof, except to the extent of competitively
sensitive  information, which competitively sensitive information will be
provided  only to the external legal counsel and/or external expert of the 
other and  will not be shared by such counsel with any other Person;  and

    
---|---|--- 
    

 

 

         |  

(d)

    |  

not  participate in any substantive meeting or discussion (whether in 
person,  by telephone or otherwise) with the Commissioner, or her
authorized  representative under the Competition Act, in respect of any
filings,  investigation or inquiry concerning such transactions unless it
consults  with the other in advance and gives the other the opportunity to 
attend  and participate thereat (except where the Commissioner, or her
authorized  representative under the Competition Act, expressly requests
that  the  other should not be present at the meeting or discussion or
part  or parts  of the meeting or discussion).

    
---|---|--- 
    

 

 

**5.2.3** **Filing  Fees**

 

 

The  responsibility for payment of the required filing fees and applicable
Taxes  thereon payable in connection with the Competition Act Clearance will
be for  the  account of Buyer and such expenses will include any fines,
penalties and other  costs resulting from the failure to make any such
filings as a result of the  Buyer's actions or failure to act.

 

 

**5.2.4** **Other  Regulatory Consents**

 

 

In  addition to its obligations in respect of Regulatory Consents under the 
Competition Act, Buyer shall, at its own expense, subject to obtaining the 
reasonable cooperation and assistance of MDS, use all commercially
reasonable  efforts to obtain by the Closing Time all other Regulatory
Consents in respect  of the Diagnostics Business in Ontario and Quebec. MDS
shall cause the Sellers  to reasonably co-operate with and assist Buyer
during the Interim Period in  order to permit Buyer to obtain such Regulatory
Consents. Subject to Applicable  Law and the Confidentiality Agreement, the
Parties will coordinate and  co-operate with one another in exchanging such
information and supplying such  assistance as may be reasonably requested by
each in connection with the  foregoing including providing each other with
all notices and information  supplied or filed with any Governmental
Authority after the date hereof (except  for notices and information which
MDS or Buyer in each case acting reasonably,  considers confidential and
competitively sensitive which may be filed on a  confidential basis) and all
notices or correspondence received from any  Governmental Authority.

 

 

**5.3** **Bulk  Sales**

 

 

Buyer  waives compliance with the provisions of the _Bulk  Sales Act_  
(Ontario) and any other applicable bulk sales legislation in connection with 
the  purchase and sale of the Purchased Assets contemplated in this 
Agreement.

 

 

**5.4** **Buyer 's  Covenants**

 

 

**5.4.1** **Employees**

 

 

         |  

(a)

    |  

Prior  to the Closing Time, but conditional upon the completion of the
Closing,  Buyer or the applicable Designated Buyer Affiliate shall offer
employment  to all the Ontario Employees and Quebec Employees on terms and
conditions  which are substantially comparable in the aggregate to those
upon  which  such Employees are employed by the relevant Seller at the
Closing  Time  including under the short-term incentive plan applicable to
each  such  Employee provided that it is agreed that such offer by Buyer
will  not  include any stock option or stock purchase plan entitlement.
Buyer  will  develop and implement a long-term performance based incentive
plan  or  other compensation scheme to be effective on or about January 1, 
2007, for  senior management of the Diagnostics Business in recognition
that  Buyer is  not able to offer a stock option or stock purchase plan.
Buyer neither  represents nor warrants that such long-term performance based
incentive  plan or other compensation scheme will be equivalent to any
stock  option  or stock purchase plan currently provided by MDS. In making
such  offer,  Buyer or the applicable Designated Buyer Affiliate shall take
into  account  the aggregate compensation and benefits (including, as
applicable,  the  short term incentive plan) enjoyed by the Ontario
Employees and Quebec  Employees and the existing seniority and length of
service of the  Ontario  Employees and Quebec Employees.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

Until  the Closing Time, each Seller shall be responsible for all wages, 
bonuses,  earned vacations, sick leave, termination and severance pay, and 
other  remuneration and benefits for all of their Employees. On and after 
the  Closing Time, Buyer or the applicable Designated Buyer Affiliate  shall
be  responsible for all wages, bonuses, earned vacations, sick leave, 
termination and severance pay and other remuneration and benefits  under 
Buyer's Benefits Plans with respect to the Employees who accept Buyer's or 
the applicable Designated Buyer Affiliate's offer of employment. For  greater
certainty, each Seller shall be responsible for all termination  and
severance costs related to the termination by such Seller of  any  Ontario
Employee or Quebec Employee who refuses the offer of employment  made in
accordance with Subsection 5.4.1(a).

    
---|---|--- 
    

 

 

         |  

(c)

    |  

If  Buyer, a Designated Buyer Affiliate or an Operator acquired by Buyer  or
a  Designated Buyer Affiliate terminates any Employee within six (6) 
months  of the Closing Time, Buyer shall, or shall cause the applicable
Designated  Buyer Affiliate or Operator to, provide such Employee with
termination  and  severance pay at least as favourable as that for which
such Employee  would  have been entitled to receive under the severance
policy or employment  contract applicable to such Employee immediately prior
to the Closing  Time  other than with respect to any entitlement under an
employee stock  option  plan or employee share purchase plan or any
retention, change of  control  or deal bonus pertaining to the sale of the
Diagnostics  Business.

    
---|---|--- 
    

 

 

**5.4.2** **Cooperation**

 

 

Buyer  shall co-operate with and assist Sellers during the Interim Period in
order  to  permit the Closing to be consummated. In particular, Buyer shall
provide to  the  applicable third party partners and shareholders in respect
of the Regional  Assets and the lessors and other third parties under the
Leases, Equipment  Leases and Contracts included in the Purchased Assets all
such information  relating to Buyer and the applicable Designated Buyer
Affiliate including  financial information, information relating to its
business experience and  the  business experience of the individuals who
ultimately control and operate Buyer  and the applicable Designated Buyer
Affiliate and with respect to their ability  to perform their obligations
under the applicable partnership agreement and  shareholders' agreement
relating to such Purchased Assets and such Leases,  Equipment Leases and
Contracts and operate the Diagnostics Business, as may  be  reasonably
required by such Persons in order to obtain the consents of such  Persons to
the transfer of such Purchased Assets to Buyer or the applicable  Designated
Buyer Affiliate.

 

 

**5.5** **Benefit  Plans**

 

 

         |  

(a)

    |  

As  soon as practicable after the Closing Date, but effective as of the 
Closing Time, Buyer or the applicable Designated Buyer Affiliate  shall 
establish and register with the applicable Governmental Authorities,  or 
shall otherwise cause to be provided, one or more pension plans or  other 
retirement savings arrangements for those Ontario Employees and Quebec 
Employees who accepted the Buyer's or the Designated Buyer Affiliate's, as 
the case may be, offer of employment who participated in a Pension  Plan 
immediately prior to the Closing Time (the " **Buyer 's  Pension Plans**") 
each of which shall contain benefit provisions which are substantially 
comparable, in the aggregate, to those provided under the Pension  Plan in 
which the Ontario Employees and Quebec Employees who accepted the  Buyer's 
or Designated Buyer Affiliate's, as the case may be, offer of employment, 
respectively, participated immediately prior to the Closing Time.  Buyer or 
the applicable Designated Buyer Affiliate shall also establish or  otherwise
provide a pension fund or other funding arrangement for  each  Buyer's
Pension Plan. Buyer's Pension Plans shall provide that for the  purposes of
eligibility for membership, vesting and continued benefit  accrual, service
by Ontario Employees and Quebec Employees who accepted  the Buyer's or
Designated Buyer Affiliate's, as the case may be, offer of  employment
recognized under a Pension Plan shall be recognized as  continuous unbroken
service with Buyer or the applicable Designated  Buyer  Affiliate. Buyer or
the applicable Designated Buyer Affiliate further  agrees to provide the
applicable Seller with such documentation and  information as it may
reasonably require to satisfy itself that the  Buyer's Pension Plans and the
pension funds therefor have been properly  established or otherwise provided,
as applicable, in accordance with  this  Section. For those Ontario
Employees and Quebec Employees who join  a  Buyer's Pension Plan that is a
"registered pension plan" as that term is  defined in subsection 248(1) of
the ITA, MDS shall cause the Pension  Plans  in which such employees
participated immediately prior to the Closing  Time  to recognize service of
such employees with Buyer or the applicable  Designated Buyer Affiliate after
the Closing Time for purposes of  vesting  and eligibility for benefits.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

At  the Closing Time, Buyer or the applicable Designated Buyer Affiliate 
shall  make available to the Ontario Employees and Quebec Employees who 
accepted  the Buyer's or the applicable Designated Buyer Affiliate's, as the
case  may be, offer of employment benefits, in addition to those provided 
under  the Buyer's Pension Plans, which are substantially comparable, in
the  aggregate to those provided under the Benefit Plans which currently 
are  applicable to such Employees (" **Buyer 's  Benefit Plans**").  For
the purposes of Buyer's Benefit Plans, Buyer or the applicable  Designated
Buyer Affiliate agrees to credit the Employees who accepted  the  Buyer's or
the applicable Designated Buyer Affiliate's offer of employment  with
eligibility and vesting service on and after the Closing Time  for  such
Employees' service prior to the Closing Time recognized by the  applicable
Benefit Plans. Buyer or the applicable Designated Buyer  Affiliate agrees to
waive any pre-existing medical condition or similar  restriction in any
Buyer's Benefit Plans only to the extent an Employee  has coverage on the
Closing Date under the Benefit Plans which currently  are applicable to such
Employee notwithstanding such pre-existing  medical  condition or similar
restriction. Buyer or the applicable Designated  Buyer  Affiliate will
credit amounts paid by such Employees during the 2006  plan  year as
deductibles or co-payments under the applicable Benefit Plan  toward the
total deductible and/or co-payment requirements under  the  applicable
Buyer's Benefit Plan after the Closing Time. With respect to  any flexible
benefit arrangements, Buyer or the applicable Designated  Buyer Affiliate
will provide credit under the applicable Buyer's Benefit  Plan after the
Closing Time for the net unused benefits remaining  including, for greater
certainty, the balance in the health spending  account of any such Employee.
MDS or the applicable Seller shall  remain  responsible for those
Liabilities under any Benefit Plan in connection  with claims incurred with
respect to Employees before the Closing  Time. No  Seller shall be
responsible for any Liabilities under any Benefit  Plan in  connection with
claims incurred at or after the Closing Time with  respect  to any Ontario
Employees or Quebec Employees who accepted the offer  of  employment of the
Buyer or applicable Designated Buyer  Affiliate.

    
---|---|--- 
    

 

 

         |  

(c)

    |  

Effective  as of the Closing Time, each Employee who is a participant in
any  Benefit  Plan shall cease to be an active participant in such Benefit
Plan  and the  applicable Seller shall be responsible for any benefits
accrued by  or  payable to any Employee under such Benefit Plan up to the
Closing  Time.

    
---|---|--- 
    

 

 

         |  

(d)

    |  

Effective  as of the Closing Time, each Seller shall assign to Buyer or the 
applicable Designated Buyer Affiliate, and Buyer or the applicable 
Designated Buyer Affiliate shall assume all of Sellers' Liabilities and 
responsibilities with respect to death or medical benefits (whether  or not 
insured), with respect to Ontario Employees and Quebec Employees  who 
accepted the Buyer's or applicable Designated Buyer Affiliate's, as the  case
may be, offer of employment beyond retirement or other termination  of 
service.

    
---|---|--- 
    

 

 

         |  

(e)

    |  

For  greater certainty, effective as of the Closing Time, each Seller 
shall  cease to have any Liabilities or obligations in respect of those 
Benefit  Plans to which it did not contribute or was not required to
contribute  and  for which its obligations were limited to providing
administrative  services in respect thereto, provided that nothing in this
Subsection  5.5(e)  shall relieve any obligation of a Seller to provide
benefits after  the  Closing Time as provided by this Agreement to Ontario
Employees and  Quebec  Employees who do not accept Buyer's or the applicable
Designated Buyer  Affiliate's, as the case may be, offer of  employment.

    
---|---|--- 
    

 

 

**5.6** **Limited  Trade Mark Licence**

 

 

At  the  Closing Time and conditional upon Closing, MDS and Buyer and/or the
Designated  Buyer Affiliates shall execute and deliver a limited trade mark
licence  agreement (the " **Limited  Trade Mark Licence** ")  in the  form
of agreement attached as Schedule 5.6 hereto.

 

 

**5.7** **Migration  Agreement**

 

 

Contemporaneously  with the execution of this Agreement by the Parties, MDS
and Buyer and/or the  Designated Buyer Affiliates have executed and delivered
a migration agreement  (the " **Migration  Agreement** ")  in the  form of
agreement attached as Schedule 5.7(a) hereto. At the Closing Time and 
conditional upon Closing, MDS and Buyer and/or the Designated Buyer
Affiliates  shall execute and deliver a licence agreement in respect of the
CBS IP (the  " **CBS  License Agreement** ")  in the  form of agreement
attached as Schedule 5.7(b)  hereto.

 

 

**5.8** **Non-Competition  Agreement**

 

 

At  the  Closing Time and conditional upon Closing, MDS and Buyer and/or the
Designated  Buyer Affiliates shall execute and deliver a non-competition
and  non-solicitation agreement (the " **Non-Competition  Agreement** ") 
in the  form of agreement attached as Schedule 5.8 hereto.

 

 

**5.9** **Support  Services Agreement**

 

 

At  the  Closing Time and conditional upon Closing, MDS and Buyer and/or the
Designated  Buyer Affiliates shall execute and deliver a support services
agreement (the  " **Support  Services Agreement** "),  which  agreement
shall be consistent with the term sheet attached hereto at Schedule  5.9 
(the " **Support  Services Agreement Term Sheet** ")  and on  terms and
conditions mutually agreed to by the Parties.

 

 

**5.10** **Shared  Contracts**

 

 

Buyer  and  MDS shall use commercially reasonable efforts to cause each of
the Shared  Contracts to be split into two contracts, one with respect to the
rights  relating to the Diagnostics Business in Ontario and Quebec and, as
applicable  British Columbia, in favour of Buyer or the applicable Designated
Buyer  Affiliate and the other with respect to the rights not relating to
such  Diagnostics Business in favour of MDS. Each Shared Contract will only
be split  upon the mutual agreement of MDS, Buyer (or, as applicable, the
Designated  Buyer  Affiliate) and the applicable third party as to the terms
of each of the  contracts resulting from the split thereof. Subject to the
foregoing, the  Parties acknowledge and agree that: (i) each of the Parties
(and in the case  of  Buyer, any Designated Buyer Affiliate, as applicable)
shall co-operate and  work  together with the other Party and the applicable
third party to achieve such  splitting; (ii) no Seller shall be obliged to
commence arbitration or any other  legal proceeding or make any payments to
third parties other than any  administrative, processing or similar fee in
connection with such splitting;  (iii) for any Shared Contract, the Parties
may not be able to obtain terms  and  conditions in each of the contracts
resulting from a split thereof that are  identical to or as favourable as the
terms and conditions of such Shared  Contract prior to the split; and (iv)
MDS shall not be obligated to amend,  terminate, extend, renew or replace any
Shared Contract to effect any split  of  such Shared Contract until such
time as it is satisfied as to the terms and  conditions of such amendment or
new, extended, renewed or replacement contract,  if any, as the case may be.
Each reference in this Agreement relating to the  assignment or non-
assignment of Non-Assignable Contracts shall, as it pertains  to Shared
Contracts, be deemed to be a reference to the intended splitting  of  such
Shared Contracts as described in this Section.

 

 

**5.11** **Designated  Buyer Affiliates**

 

 

MDS  acknowledges that Buyer shall, prior to Closing, designate in writing
one or  more Affiliates of Buyer or OMERS Administration Corporation,
acceptable to  MDS,  acting reasonably or as set forth in Schedule 2.5 ****
(each  a " **Designated  Buyer Affiliate** ")  to  become party to this
Agreement so as to acquire certain of the Purchased Assets,  Replacement
Contracts and Migrating Assets as contemplated under Schedule 2.5.  Each
Designated Buyer Affiliate shall execute a contract of adhesion agreeing 
to  be bound by this Agreement as if an original party hereto, containing 
representations and warranties of the Designated Buyer Affiliate in favour 
of  MDS and the Operators the same as those of Buyer set forth in
Section 4.2,  _mutatis  mutandis_ ,  and  otherwise in form and substance
satisfactory to the Parties. Upon such  Designated Buyer Affiliate executing
and delivering to MDS such contract of  adhesion, such Designated Buyer
Affiliate shall be a Party and all references  herein to Buyer (other than in
Sections 3.2,  3.4,  3.5,  3.6,  4.2  and  6.2.1) shall include such
Designated Buyer Affiliate as the context requires.  Notwithstanding the
foregoing, Buyer shall remain jointly and severally liable  with such
designated Affiliates of Buyer and shall cause all of its covenants  and
obligations hereunder to be observed and performed by such  Affiliates.

 

 

**5.12** **Confidentiality **

 

 

         |  

(a)

    |  

Prior  to the Closing Time, MDS shall request that the other parties to  the
Other  Confidentiality Agreements return and destroy all Confidential
Information  (as defined in the Other Confidentiality Agreements) and
provide  evidence  of having done so to Buyer at Closing. 

    
---|---|--- 
    

 

 

         |  

(b)

    |  

Prior  to the Closing Time, the Sellers and Buyer shall enter into a 
confidentiality agreement in the form of agreement attached as Schedule 
5.12.

    
---|---|--- 
    

 

 

**5.13** **Transaction** **Structure**

 

 

Prior  to  the Closing, the Parties agree to co-operate in structuring the
sale of the  Purchased Assets as set forth in Schedule 2.5 and, to the extent
necessary,  any  amendments made thereto with the consent of the Parties
prior to the Closing  Time, subject to the following:

 

 

         |  

(a)

    |  

the  Buyer will structure the implementation of steps 2 and 13 (the  "
**Buyer  Purchase Structure** ")  as set forth in Schedule 2.5 in a manner
so that no costs and expenses  (including, without limitation, legal fees and
disbursements) will  be  borne by MDS or any of the other Sellers and Buyer
will be solely  responsible for any and all Taxes actually incurred by MDS in
connection  with or in any way related to the implementation of the Buyer
Purchase  Structure and any costs and expenses (including, without
limitation,  legal  fees and disbursements) actually incurred by MDS or the
Sellers in  the  event of the termination or unwinding of such steps of the
Buyer  Purchase  Structure should Closing not occur (unless Closing does not
occur  as a  result of the failure of MDS to satisfy any conditions
precedent  within  its control), and the Buyer shall indemnify and reimburse
MDS and  the  Sellers forthwith, on an as incurred basis, for any and all
such  Taxes,  costs and expenses;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

without  restricting the application of paragraph (a) above, MDS agrees to 
reasonably cooperate with Buyer in respect of any required or desired 
amendment to Schedule 2.5 following the date of this Agreement; provided, 
however, that (i) if MDS or any of the Operators incurs  incremental ****
Taxes  in connection with or in any way related to the subject matter of 
the  amendment, or (ii) if such amendment materially increases the risk 
for  liability to Tax to MDS or any of the Operators, and MDS or any of 
the  Operators incurs Taxes in connection with or in any way related to 
the  subject matter of such amendment, in both (i) and (ii) as determined 
by  MDS, acting reasonably, Buyer shall be solely responsible for any  and
all  such Taxes. In the event of any such amendment, Buyer shall be
responsible  for all costs and expenses (including, without limitation, all
legal  fees  and disbursements) actually incurred by MDS or any of the
Operators  in  connection with or in any way related to implementation of
the subject  matter of any such amendment to Schedule 2.5. Buyer shall
indemnify  and  reimburse each of MDS and the Operators forthwith, on an as
incurred  basis, for any and all such Taxes, costs and expenses so
incurred; 

    
---|---|--- 
    

 

 

         |  

(c)

    |  

without  restricting the application of paragraph (a) above, Buyer agrees 
to  reasonably cooperate with MDS in respect of any required or desired 
amendment to Schedule 2.5 following the date of this Agreement; provided, 
however, that (i) if Buyer or any Designated Buyer Affiliate incurs 
incremental **** Taxes  in connection with or in any way related to the
subject matter of  the  amendment, or (ii) if such amendment materially
increases the risk  for  liability to Tax to Buyer or any Designated Buyer
Affiliate, and  Buyer or  any Designated Buyer Affiliate incurs Taxes in
connection with or  in any  way related to the subject matter of such
amendment, in both (i)  and (ii)  as determined by Buyer, acting reasonably,
MDS shall be solely responsible  for any and all such Taxes. In the event of
any such amendment, MDS  shall  be responsible for all costs and expenses
(including, without limitation,  all legal fees and disbursements) actually
incurred by Buyer or any  Designated Buyer Affiliate in connection with or in
any way related  to  implementation of the subject matter of any such
amendment to Schedule  2.5. MDS shall indemnify and reimburse each of Buyer
or any Designated  Buyer Affiliate forthwith, on an as incurred basis, for
any and all  such  Taxes, costs and expenses so incurred;  and

    
---|---|--- 
    

 

 

         |  

(d)

    |  

the  obligation of the Parties set forth in this Section 5.13  shall,
notwithstanding any other provision of this Agreement to the  contrary,
survive completion or termination of this Agreement and  the  transactions
contemplated hereby and shall continue in full force  and  effect for the
benefit of the other Party until 60 days after the  expiration of the period
during which, in the absence of any waiver  or  other document extending
such period, an assessment, reassessment  or other  form of recognized
document assessing liability for Taxes could be  issued  under applicable
Tax laws.

    
---|---|--- 
    

 

 

**5.14** **Replacement** **Material** **Contracts**

 

 

Notwithstanding  anything in this Agreement, including Section 5.1.1,  in 
proceeding to seek any necessary consent to the assignment of any Contracts 
contemplated in Subsection 6.1.5(b),  if, in  MDS' reasonable estimation,
after having made commercially reasonable efforts to  do so (which efforts
shall not include commencing arbitration or any other  legal  proceeding),
the applicable third party to any particular Contract other than,  for the
avoidance of doubt, a Lease (a " **Subject  Contract** ")  will  not, on or
prior to the Closing Time, provide its consent to the assignment  of  the
Subject Contract to Buyer or the applicable Designated Buyer Affiliate  or 
will not provide such consent without requiring MDS to pay any amount other 
than  an amount contemplated to be payable by MDS under Section 2.3,  then 
MDS may satisfy the condition in Subsection 6.1.5(b)  by  securing on or
prior to the Closing an equivalent substitute for such Subject  Contract and
assigning such equivalent substitute Contract to the Buyer or  the 
applicable Designated Buyer Affiliate on the Closing and the provisions of 
Subsection 2.3(b)  shall  not apply to such Subject Contract. Whether MDS
shall have secured, on or before  the BC Closing, an equivalent substitute
for a Subject Contract shall be (i)  determined by the President, Senior
Vice-President, Finance and, in respect  of a  Subject Contract pertaining
to information technology, by the Senior  Vice-President, Information
Technology of the management team of the MDS  Diagnostics Division, and (ii)
evidenced by the delivery to Buyer on or before  the BC Closing of an
officers' certificate executed by each of such Persons  certifying such
determination in their respective view. Each such Person shall  act
reasonably in his determination under this Section.

 

 

**ARTICLE 6**

 

 

**CONDITIONS  PRECEDENT**

 

 

**6.1** **Buyer 's  Conditions**

 

 

Subject  to Section 2.2,  Buyer  shall be obliged to complete the Closing
only if each of the conditions  precedent set forth in the following
Subsections of this Section 6.1  have  been satisfied in full at or before
the Closing Time and the Closing is  completed on or before March 15, 2007.
Each of such conditions precedent is  for  the exclusive benefit of Buyer
and Buyer may waive any of them in whole or  in  part in writing.

 

 

**6.1.1** **Accuracy  of Representations and Performance of Covenants**

 

 

At  the  Closing Time, all of the representations and warranties of MDS made
in or  pursuant to this Agreement shall be true and correct in all material
respects  as  if made at and as of the Closing Time, except: (i) with
respect to Subsection  4.1.19(a)  only, to  the extent that any inaccuracy
thereof does not individually or in the aggregate  have a Material Adverse
Effect; (ii) as such representations and warranties  may be affected by
events or transactions expressly permitted by this Agreement  or the BC
Purchase Agreement or by Buyer, including, for greater certainty,  the 
implementation of the Buyer Purchase Structure; and (iii) that the 
representations and warranties of MDS made in Subsections 4.1.13(c), 
4.1.15(j),  4.1.20(b)  and 4.1.26  shall be  true and correct as if made
at and as of the Closing Time subject to any changes  in the disclosure
contained in the Disclosure Letter with respect to such  representations
which shall have been disclosed in writing to the Buyer prior  to  the
Closing. At the Closing Time, MDS and its Affiliates shall have observed 
or  performed in all material respects all of the obligations, covenants
and  agreements that they must perform at or before the Closing Time. Buyer
shall  have received immediately prior to Closing Time a certificate from a
senior  officer of MDS (without personal liability) certifying, to the best
of such  officer's knowledge, information and belief that the conditions in
this Section 6.1.1  have  been satisfied.

 

 

**6.1.2** **Receipt  of Closing Documentation**

 

 

All  documentation relating to the due authorization of the sale of the
Purchased  Assets, the Replacement Contracts and the Migrating Assets by the
applicable  Seller under this Agreement and the Closing Documents to which it
is a party  shall be mutually satisfactory to the Parties, acting reasonably.

 

 

**6.1.3** **Transfer  of Real Property**

 

 

The  transfers of the Real Property included in the Purchased Assets shall be
in  such  forms as are customary for conveyances of real property on an "as
is, where is" basis, but in Ontario shall contain the statements contemplated
in clauses  50(22)(a) and (b) of the _Planning  Act_ (Ontario).  Buyer
shall pay the cost of registration of the transfers to it and any land 
transfer Taxes payable with respect thereto. This Agreement is subject to 
compliance with the subdivision control provisions of the _Planning  Act_
(Ontario)  and any similar provisions under Applicable Law, and the Sellers
covenant to  comply with such provisions and obtain at their own expense any
consents  required in that regard prior to Closing. The Sellers and Buyer
acknowledge  and  agree that in Ontario the transfer of real property will
be completed by  electronic registration pursuant to Part III of the _Land 
Registration Reform Act_ ,  R.S.O.  1990, c.L4, as amended, and that the
delivery of documents and the release  thereof to the Buyer and Sellers shall
be governed by a "Document Registration  Agreement" to be entered into
between the respective solicitors for the Buyer  and the Sellers
substantially in the current form prescribed by the _Law  Society of Upper
Canada_.

 

 

**6.1.4** **BC  Closing**

 

 

All  conditions precedent to the BC Closing shall have been satisfied or
waived,  as  applicable, save and except for the release from escrow of all
BC Documents  delivered in connection with the BC Closing, the [REDACTED]
prior to the BC  Closing as contemplated in Step 19 of Schedule 2.5 and the
payment of the Cash  Closing Amount (as defined in and under the BC Purchase
Agreement).

 

 

**6.1.5** **Consents  and Other Conditions**

 

 

         |  

(a)

    |  

All  Regulatory Consents shall have been obtained or made on or before 
the  Closing Time.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

Subject  to Section 5.14,  the Sellers shall have given or obtained, as the
case may be, all  of the  notices, consents and approvals described in
Schedule 6.1.5(b),  in all cases in form and substance satisfactory to the
Buyer, acting  reasonably.

    
---|---|--- 
    

 

 

         |  

(c)

    |  

Each  of the transactions included in Schedule 2.5 that are to have
occurred  prior to the Closing Time shall have been completed in the
sequence  contemplated therein to the satisfaction of the Buyer, acting 
reasonably.

    
---|---|--- 
    

 

 

**6.1.6** **Litigation**

 

 

There  shall not be in force any Applicable Law or Order, and there shall not
have  been  any action taken under any Applicable Law or by any Governmental
Authority,  that  makes it illegal or otherwise restrains, enjoins or
prohibits the Closing  contemplated herein in accordance with the terms
hereof in any material  respect.

 

 

**6.1.7** **Material  Adverse Change**

 

 

No  change  which would constitute a Material Adverse Effect shall have
occurred since  the  date hereof and Buyer shall have received immediately
prior to the Closing  Time  a certificate from a senior officer of MDS
(without personal liability)  confirming to the best of his knowledge,
information and belief that no Material  Adverse Effect has occurred. For
avoidance of doubt, the failure to obtain  the  necessary consent from the
applicable third parties in respect of the transfer  to Buyer of any of the
Regional Assets or the exercise by any such third party  of any right of
first refusal shall not constitute a Material Adverse  Effect.

 

 

**6.1.8** **Deliveries  of MDS**

 

 

At  the  Closing Time, MDS shall, and shall cause MDS Quebec and subject to
LPBP Consent,  MDS ONT LP as applicable to, execute and deliver to Buyer in
form and substance  mutually satisfactory to the Parties, acting reasonably,
all certificates,  agreements, documents and instruments as required under
this Agreement including  the following:

 

 

         |  

(a)

    |  

a  statutory declaration of each Seller that it is not a non-resident  of 
Canada within the meaning of the  ITA;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

the  Land transfers, Document Registration Agreements and Acknowledgements 
and  Directions permitting electronic registration contemplated by Section 
6.1.3,  together with all duplicate keys, combinations and codes in the
possession  or control of the Sellers to the locks in the buildings,
offices,  security  devices and storage facilities relating to the Real
Property and  all  permits, licences, contracts, agreements, records,
drawings, plans,  drawings, operating manuals, reports, studies, warranties
and all  other  documents and information relating to the operation,
maintenance  and  repair of the Real Property in the possession or control
of the  Sellers;

    
---|---|--- 
    

 

 

         |  

(c)

    |  

a  general conveyance or bill of sale duly executed by each Seller, 
conveying  to Buyer all of such Seller's right, title, and interest in the
Quebec  Assets, the Ontario Assets, the Replacement Contracts and the
Migrating  Assets relating to or arising from each Migration Project that
has  been  completed in accordance with the Migration Agreement,
respectively  (" **General  Conveyance** ");

    
---|---|--- 
    

 

 

         |  

(d)

    |  

an  assignment and assumption agreement duly executed by each Seller 
under  which such Seller assigns its right, title and interest in and to 
the  Leases, Contracts and Equipment Leases included in the Purchased 
Assets,  the Replacement Contracts and the Migrating Assets relating to or 
arising  from each Migration Project that has been completed in accordance 
with the  Migration Agreement to Buyer and Buyer assumes the Assumed
Liabilities  (each an " **Assignment  and Assumption Agreement** "), 
together with all lessor consents to the assignments of the Leases  obtained
by the Closing Time, and an assignment of such Seller's right,  title and
interest in any warranties relating to the Real  Property;

    
---|---|--- 
    

 

 

         |  

(e)

    |  

assignments  duly executed by each Seller for the Intellectual Property
Rights  and  Transferable Licences of such Seller included in the Purchased
Assets  or  Migrating Assets in appropriate form for  registration;

    
---|---|--- 
    

 

 

         |  

(f)

    |  

an  application for transfer of the motor vehicle registration permit 
duly  executed by a Seller, as applicable, for each motor vehicle used 
exclusively in the Diagnostics Business and registered in the name  of the 
Seller;

    
---|---|--- 
    

 

 

         |  

(g)

    |  

the  Limited Trade Mark Licence;

    
---|---|--- 
    

 

 

         |  

(h)

    |  

the  CBS License Agreement;

    
---|---|--- 
    

 

 

         |  

(i)

    |  

the  Non-Competition Agreement;

    
---|---|--- 
    

 

 

         |  

(j)

    |  

the  Support Services Agreement;

    
---|---|--- 
    

 

 

         |  

(k)

    |  

subject  to Subsection 2.1(b)  and Section 2.2,  the stock transfers,
Partnership Interest transfers, resignations,  releases and other documents
to be delivered to Buyer on the Closing  Date  under the Regional Purchase 
Agreements;

    
---|---|--- 
    

 

 

         |  

(l)

    |  

an  opinion of counsel to MDS customary for a transaction of this nature; 

    
---|---|--- 
    

 

 

         |  

(m)

    |  

if  required under Section 5.1.7  or  the Migration Agreement, the
International Boulevard Licenses and  Post-Closing Services Agreement,
respectively;  and

    
---|---|--- 
    

 

 

         |  

(n)

    |  

such  other certificates, instruments of conveyance and documents as may 
be  reasonably requested by Buyer prior to the Closing Date to carry  out
the  intent and purposes of this Agreement. 

    
---|---|--- 
    

 

 

**6.1.9** **LPBP  Consent**

 

 

The  LPBP  Consent shall have been obtained on or before the Closing Time.

 

 

**6.1.10** **Migration  Condition**

 

 

The  condition set forth in Section 9.1 of the Migration Agreement shall have
been  satisfied or waived by the Buyer on or before the Closing Time.

 

 

**6.2** **Conditions** **  of MDS**

 

 

Subject  to Section 2.2,  MDS  shall be obliged to complete the Closing
only if each of the conditions  precedent set forth in the following
Subsections of this Section 6.2  has been  satisfied in full at or before
the Closing Time and the Closing is completed  on  or before March 15, 2007.
Each of such conditions precedent is for the exclusive  benefit of MDS and
MDS may waive any of them in whole or in part in writing. 

 

 

**6.2.1** **Accuracy  of Representations and Performance of Covenants**

 

 

At  the  Closing Time, all of the representations and warranties of Buyer
and each  Designated Buyer Affiliate made in or pursuant to this Agreement
shall be true  and correct in all material respects as if made at and as of
the Closing Time,  except as such representations and warranties may be
affected by events or  transactions expressly permitted by this Agreement. At
the Closing Time, Buyer  and each Designated Buyer Affiliate shall have
observed or performed in all  material respects all of the obligations,
covenants and agreements that it  must  perform at or before the Closing
Time. MDS shall have received immediately  prior  to Closing Time a
certificate from a senior officer of Buyer certifying, to  the  best of such
officer's knowledge, information and belief, and without personal  liability,
that the conditions in this Section 6.2.1  have  been satisfied.

 

 

**6.2.2** **Receipt  of Closing Documentation**

 

 

All  documentation relating to the due authorization of the purchase of the
Purchased  Assets, the Replacement Contracts and the Migrating Assets by the
Buyer and  each  Designated Buyer Affiliate under this Agreement and the
Closing Documents to  which it is a party shall be mutually satisfactory to
the Parties, acting  reasonably.

 

 

**6.2.3** **Litigation**

 

 

There  shall not be in force any Applicable Law or Order, and there shall not
have  been  any action taken under any Applicable Law or by any Governmental
Authority,  that  makes it illegal or otherwise restrains, enjoins or
prohibits the Closing  contemplated herein in accordance with the terms
hereof in any material  respect.

 

 

**6.2.4** **Consents  and Other Conditions**

 

 

         |  

(a)

    |  

All  Regulatory Consents **** shall  have been obtained or made on or before
the Closing  Time.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

The  conditions set forth in Schedule 6.2.4(b)  shall have been satisfied.

    
---|---|--- 
    

 

 

         |  

(c)

    |  

Each  of the transactions included in Schedule 2.5 that are to have
occurred  prior to the Closing Time shall have been completed in the
sequence  contemplated therein to the satisfaction of MDS, acting 
reasonably.

    
---|---|--- 
    

 

 

         |  

(d)

    |  

The  Buyer Purchase Structure shall not have resulted in any incremental 
Taxes  for MDS or any Operator as a result of any change effective on or 
before  11:59 p.m. on the day prior to the Closing in any applicable Tax 
law or  the interpretation thereof by any applicable Governmental 
Authority.

    
---|---|--- 
    

 

 

**6.2.5** **Deliveries  of Buyer**

 

 

At  the  Closing Time, Buyer and each Designated Buyer Affiliate as
applicable shall  execute and/or deliver to the applicable Seller in form and
substance mutually  satisfactory to the Parties, acting reasonably, all
certificates, agreements,  documents and instruments as required under this
Agreement including the  following:

 

 

         |  

(a)

    |  

payment  of the Closing Cash Amount in accordance with Subsection 3.9(b);

    
---|---|--- 
    

 

 

         |  

(b)

    |  

the  General Conveyance, the Document Registration Agreements and 
Acknowledgements and Directions permitting electronic registration  in 
respect of the transfer of the  Lands;

    
---|---|--- 
    

 

 

         |  

(c)

    |  

a  GST undertaking and indemnity regarding the self-assessment and
remittance  of GST applicable to the purchase of the Lands, as applicable,
in  lieu of  the payment of GST on the Lands to the applicable Seller; 

    
---|---|--- 
    

 

 

         |  

(d)

    |  

the  Assignment and Assumption Agreements, together, if requested by a 
party to  any Lease, Contract or Equipment Lease, the agreement of Buyer
directly  with such party to assume all obligations thereunder from the
Closing  Time;

    
---|---|--- 
    

 

 

         |  

(e)

    |  

the  Limited Trade Mark Licence;

    
---|---|--- 
    

 

 

         |  

(f)

    |  

the  CBS License Agreement;

    
---|---|--- 
    

 

 

         |  

(g)

    |  

the  Non-Competition Agreement;

    
---|---|--- 
    

 

 

         |  

(h)

    |  

the  Support Services Agreement;

    
---|---|--- 
    

 

 

         |  

(i)

    |  

subject  to Subsection 2.1(b)  and Section 2.2,  the assumption agreements
in respect of the partnership agreements  and  shareholders' agreements and
other documents to be delivered by Buyer to  the applicable Seller on Closing
under the Regional Purchase  Agreements;

    
---|---|--- 
    

 

 

         |  

(j)

    |  

the  opinion of counsel to Buyer and any Designated Buyer Affiliates,  as 
applicable;

    
---|---|--- 
    

 

 

         |  

(k)

    |  

if  required under Section 5.1.7  or  the Migration Agreement, the
International Boulevard Licenses and  Post-Closing Services Agreement,
respectively; 

    
---|---|--- 
    

 

 

         |  

(l)

    |  

any  costs payable by Buyer to MDS pursuant to Sections 4.1  and 4.2  of 
the Migration Agreement; and

    
---|---|--- 
    

 

 

         |  

(m)

    |  

such  other certificates, instruments of conveyance and documents as may 
be  reasonably requested by MDS prior to the Closing Date to carry out 
the  intent and purposes of this  Agreement.

    
---|---|--- 
    

 

 

**6.2.6** **LPBP  Consent**

 

 

The  LPBP  Consent shall have been obtained on or before the Closing Time.

 

 

**6.2.7** **BC  Closing**

 

 

All  conditions precedent to the BC Closing shall have been satisfied or
waived,  as  applicable, save and except for the release from escrow of all
BC Documents  delivered in connection with the BC Closing, [REDACTED] prior
to the BC Closing  as contemplated in Step 19 of Schedule 2.5 and the payment
of the Cash Closing  Amount (as defined in and under the BC Purchase
Agreement).

 

 

**6.3** **Waiver**

 

 

Either  Party may waive, by written notice to the other Party, any condition
set forth  in this Article 6  which is  for its sole benefit. No waiver by
a Party of any condition, in whole or in  part, shall operate as a waiver of
any other condition.

 

 

**6.4** **Failure  to Satisfy Conditions**

 

 

Subject  to Section 2.2,  if any  condition set forth in Section 6.1 
or 6.2  is not  satisfied at the Closing Time, or if it becomes apparent
that any such condition  cannot be satisfied at the Closing Time, the Party
entitled to the benefit  of  such condition (the " **First  Party** ") 
may  terminate this Agreement by notice in writing to the other Party and in
such  event:

 

 

         |  

(a)

    |  

unless  the other Party can show that the condition or conditions which
have  not  been satisfied and for which the First Party has terminated
this  Agreement  are reasonably capable of being performed or caused to be
performed  by the  First Party or have not been satisfied by reason of a
default by  the First  Party hereunder, the First Party shall be released
from all obligations  hereunder, except as contemplated in Section 10.10; 
and

    
---|---|--- 
    

 

 

         |  

(b)

    |  

unless  the First Party can show that the condition or conditions which
have  not  been satisfied and for which the First Party has terminated
this  Agreement  are reasonably capable of being performed or caused to be
performed  by the  other Party or have not been satisfied by reason of a
default by  the other  Party hereunder, then the other Party shall also be
released from  all  obligations hereunder, except as contemplated in Section
10.10.

    
---|---|--- 
    

 

 

**ARTICLE 7**

 

 

**POST-CLOSING  PROVISIONS**

 

 

The  provisions of this Article 7 shall apply conditional upon Closing.

 

 

**7.1** **Insurance  and Risk of Loss**

 

 

         |  

(a)

    |  

From  and after the Closing Time, Buyer shall place its own insurance on 
the  Purchased Assets, the Replacement Contracts conveyed at that time  and
the  Migrating Assets and the Diagnostics Business and none of MDS or  the 
Operators shall have any obligation or Liabilities in respect of  the 
Purchased Assets, the Replacement Contracts, the Migrating Assets,  the 
Diagnostics Business or the Assumed Liabilities thereafter except  as 
otherwise expressly provided in this Agreement. 

    
---|---|--- 
    

 

 

         |  

(b)

    |  

MDS  shall use commercially reasonably efforts to recover any Losses in 
respect  of the Disclosed Matter under its policies of insurance. To the
extent  that such Losses are not covered by MDS' insurance policies, it
shall  notify Buyer and Buyer shall use commercially reasonable efforts  to
seek  coverage for any such Loss under applicable workers' compensation 
legislation.

    
---|---|--- 
    

 

 

**7.2** **Litigation**

 

 

Buyer  and  the applicable Designated Buyer Affiliate shall reasonably co-
operate with  each  Seller but, subject to the terms of Article 8,  at
the  expense of such Seller in order that such Seller may properly defend any
claim,  demand, suit, action, cause of action, dispute, proceeding,
litigation,  investigation, grievance, arbitration, governmental proceeding
or other  proceeding including appeals and applications for review, in
progress against,  by or relating to such Seller with respect to the
Purchased Assets, the  Replacement Contracts, the Migrating Assets, the
Diagnostics Business or the  Excluded Liabilities (including with respect to
the partnerships and  corporations in which the Seller holds an interest
directly or indirectly)  or  any diagnostics business formerly operated by
any Seller or any of its  Affiliates or in which any Seller or an Affiliate
thereof had any equity  interest prior to the Closing Time in respect of a
period of time prior to  the  Closing Time, whether brought before or after
the Closing Time. In this  connection, Buyer shall make reasonably available
to Sellers those Employees  knowledgeable about the matter in question and
all books and records relating  thereto and shall permit such employees to
testify in all proceedings with  respect thereto.

 

 

**7.3** **Post-Closing  Access**

 

 

After  the  Closing, upon reasonable notice, Buyer and the applicable
Designated Buyer  Affiliate and MDS and the other Sellers will give, or cause
to be given, to  the  Representatives of the other, access, during normal
business hours, to the  books  and records which relate exclusively to the
Diagnostics Business (including  with  respect to the underlying
partnerships and corporations of the Diagnostics  Business) for the periods
prior to the Closing Time, and will permit such  persons to examine and copy
such books and records to the extent reasonably  requested by the other Party
in connection with the preparation of Tax and  financial reporting matters,
audits, legal proceedings, governmental  investigations and other business
purposes. Each of Buyer and the applicable  Designated Buyer Affiliate and
MDS and the other Sellers will preserve such  books and records for a period
of seven years from Closing Date, or such longer  period as is required by
Applicable Law or a Governmental Authority in  connection with a Licence or
related audit, including an Ontario Health  Insurance Plan audit. However,
none of such Persons shall be obligated to take  any action pursuant to this
Section that would unreasonably disrupt the normal  course of its business,
violate the terms of any contract to which it is a  party  or to which it or
any of its assets is subject or grant access to any of its  proprietary,
confidential or classified information. MDS, Buyer and any  Designated Buyer
Affiliate will co-operate with one another in the conduct  of  any Tax audit
or similar proceedings involving or otherwise relating to the  Diagnostics
Business (or the income therefrom or assets thereof).

 

 

**7.4** **Excluded  Asset Adjustment**

 

 

To  the  extent a rebate, refund, royalty, credit or other amount
contemplated by  subsection (m) of the definition of "Excluded Assets" (each
a " **Excluded  Refund** ")  is  paid to Buyer, a Designated Buyer
Affiliate or an Operator and such Excluded  Refund is not included in the
Accounts Receivable on the Closing Balance Sheet  and has not been received
by MDS or Operator **** prior  to  the Closing Time (an " **Unaccounted 
Excluded Refund** "),  and  the Buyer, applicable Designated Buyer Affiliate
or an Operator, or other Person  to which the applicable Diagnostics Business
has been transferred receives  the  Unaccounted Excluded Refund, directly or
indirectly, after the Closing Time,  Buyer, the applicable Designated Buyer
Affiliate, Operator or other Person  shall  receive such Unaccounted
Excluded Refund in trust for MDS, to the extent of  the  interest of MDS
therein, and shall promptly notify MDS of such payment, provide  to MDS an
accounting of such Unaccounted Excluded Refund and pay to MDS all  money
received by such Person in respect of such Unaccounted Excluded Refund 
without any deduction, withholding or off set.

 

 

**7.5** **Tax  Matters**

 

 

         |  

(a)

    |  

After  the Closing, Buyer or the applicable Designated Buyer Affiliate
shall  provide to MDS such information and assistance as is reasonably
requested  by MDS for the purposes of preparing any Tax Returns of Ontario
GP,  MDS  ONT LP and MDS Quebec in respect of periods ending on or before
the  Closing Date and determining MDS' (or its Affiliates) liability for
Taxes. 

    
---|---|--- 
    

 

 

         |  

(b)

    |  

After  the Closing Date, each Party shall provide to the other Party, at 
such  other Party's expense, such information and assistance as is
reasonably  requested by the other Party for the purpose of completing and
filing  any  Tax Returns, claiming any refunds or credits and responding to,
defending  against or conducting any action, suit, proceeding, audit,
investigation  or claim in respect of Taxes.

    
---|---|--- 
    

 

 

**7.6** **Privacy  Notification**

 

 

Buyer  and  each Designated Buyer Affiliate shall notify the employees,
customers, patients,  directors, officers, securityholders and other Persons
whose Personal  Information is included within the Disclosed Personal
Information that the  Closing has taken place and Personal Information about
them has been disclosed  to Buyer and each Designated Buyer Affiliate to the
extent and in the manner  required by Applicable Law.

 

 

**7.7** **Other  Confidentiality Agreements**

 

 

MDS  shall, at the expense and reasonable request of Buyer, diligently
enforce any  and all rights and remedies available to it under the terms of
the Other  Confidentiality Agreements in respect of confidential information
of the  Diagnostics Business purchased by Buyer hereunder including by
injunction or  specific performance.

 

 

**7.8** **Post-Closing  Reimbursements**

 

 

After  the  Closing Time, should a Seller receive payment of any amount on
account of any  Accounts Receivable or Prepaid Expenses of the MDS
Diagnostics Division  reflected on the Closing Balance Sheet, such Seller
shall receive such payment  in trust for Buyer or the applicable Designated
Buyer Affiliate and shall,  within fifteen (15) Business Days after the end
of each month in which any  such  payment was received, notify the Buyer or
the applicable Designated Buyer  Affiliate of such payment and pay to the
Buyer or the applicable Designated  Buyer Affiliate an amount equal to the
money received by such Seller in respect  of such payment without any
deduction, withholding or off set.

 

 

After  the  Closing Time, should a Seller make a payment of any amount on
account of any  Assumed Liability **** reflected  on the Closing Balance
Sheet, including for greater certainty any Employee  wages, health, dental or
other benefits and other remuneration, the Seller  shall  provide Buyer or
the applicable Designated Buyer Affiliate with evidence of  the  payment and
Buyer or the applicable Designated Buyer Affiliate shall, within  fifteen
(15) Business Days of receipt of such evidence, reimburse the Seller  an 
amount equal to the amount paid without any deduction, withholding or off
set. 

 

 

**7.9** **No  MDS Guarantees on Lease Renewals**

 

 

Buyer  and  the applicable Designated Buyer Affiliate shall not extend the
term of any  Lease  or renew any Lease included in the Purchased Assets or
the Replacement Contracts  acquired in connection with this Agreement without
the prior written consent  of  MDS unless no Seller shall have any Liability
thereunder surviving beyond a  period of twelve (12) months following
Closing.

 

 

**7.10** **Post-Closing  Conveyance of Migrating Assets**

 

 

MDS  shall  as soon as reasonably practicable after any Migrating Project is
completed  after  Closing in accordance with the Migration Agreement,
transfer and convey to  the  Buyer or a Designated Buyer Affiliate all of
MDS' right, title and interest in  and to the Migrating Assets relating to or
arising from such Migration Project  pursuant to a general conveyance or bill
of sale, in form and substance mutually  satisfactory to the Parties, acting
reasonably.

 

 

**7.11** **Survival  of Covenants**

 

 

All  covenants and agreements of the Parties set forth in this Agreement to
be  performed after the Closing Date shall survive the Closing and remain in
full  force and effect indefinitely until fully performed.

 

 

**7.12** **U.S.  Non-Competition and Non-Solicitation Agreements**

 

 

The  Buyer  and each Designated Buyer Affiliate hereby agrees to (and to
cause their  respective Affiliates to) adhere to and be bound by each non-
competition  covenant and non-solicitation covenant, the waivers of defences
relating thereto  and the remedies for breach thereof, to which the
applicable MDS Contracting  Party (and its Affiliates) is subject pursuant to
the agreements executed in  connection with the sale of the MDS diagnostics
business in the United States,  as such agreements are listed in Section
7.12  of the  Disclosure Letter (the " **U.S.  Non-Competition Agreements**
"),  to  the same extent (including for the periods of time) as the
applicable MDS  Contracting Party (and its Affiliates), as if Buyer and the
Designated Buyer  Affiliates were the original MDS Contracting Party under
such U.S.  Non-Competition Agreements. For certainty, such non-competition
covenants,  non-solicitation covenants, the waivers of defences relating
thereto and the  remedies for breach thereof consist of those provisions set
out opposite the  applicable U.S. Non-Competition Agreements in Section
7.12  of the  Disclosure Letter. The Buyer and its Designated Buyer
Affiliates acknowledge  and  agree that the covenants set forth in this
Section are reasonable, properly  required in the circumstances and are
necessary in connection with the purchase  of the Purchased Assets and
assumption of the Assumed Liabilities by Buyer  and  its Designated Buyer
Affiliates pursuant to this Agreement and the BC Purchase  Agreement.

 

 

**ARTICLE 8**

 

 

**INDEMNIFICATION**

 

 

**8.1** **Definitions**

 

 

As  used  in this Article 8:

 

 

" **Claim** " means  any act, omission or state of facts and any demand,
action, investigation,  inquiry, suit, proceeding, claim, assessment,
judgment or settlement or  compromise relating thereto which may give rise to
a right to indemnification  under Section 8.2  or 8.3;

 

 

" **Direct  Claim** " means  any Claim by an Indemnified Party against an
Indemnifier which does not result  from a Third Party Claim;

 

 

" **Indemnifier** " means  any Party obligated to provide indemnification
under this  Agreement;

 

 

" **Indemnified  Party** " means  any Person entitled to indemnification
under this Agreement;

 

 

" **Indemnity  Payment** " means  any amount of Loss required to be paid
pursuant to Sections 8.2  or 8.3;

 

 

" **Loss** " means  any and all loss, Liability, damage, cost, expense,
charge, fine, penalty or  assessment, suffered or incurred by the Person
seeking indemnification directly  resulting from or arising out of any Claim,
including the costs and expenses  of  any action, suit, proceeding,
investigation, inquiry, arbitration award,  grievance, demand, assessment,
judgment, settlement or compromise relating  thereto, but (i) excluding loss
of profits, indirect, incidental, special,  punitive and consequential
damages (which, for greater certainty, are deemed  to  include any Taxes
payable by the Indemnified Party as a consequence of the  receipt of an
amount pursuant to Article 8  hereof  and provided that a Loss shall not be
deemed an indirect Loss solely because  the  Loss is incurred by Buyer
through a diminution in the value of its direct or  indirect investment in an
Operator); (ii) excluding any contingent Liability  until it becomes actual;
(iii) reduced by any net Tax benefit; and (iv) reduced  by any recovery,
settlement or otherwise under or pursuant to any insurance  coverage, or
pursuant to any claim, recovery, settlement or payment by or  against any
other Person; and

 

 

" **Third  Party Claim** " means  any Claim asserted against an Indemnified
Party by any Person who is not a  Party  or a Seller or an Affiliate of such
a Person.

 

 

**8.2** **Indemnification  by MDS**

 

 

Subject  to the limits set forth in Section 8.10,  MDS  shall indemnify,
defend and save harmless Buyer, each Designated Buyer Affiliate  and the
Representatives of the Buyer and Designated Buyer Affiliate from and  against
any and all Loss suffered or incurred by any of them, as a result of,  or 
arising in connection with:

 

 

         |  

(a)

    |  

subject  to Section 4.5,  any misrepresentation or breach of any warranty
made or given by  MDS in  this Agreement or in any Closing  Document;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

any  failure by any Seller to observe or perform any covenant, agreement 
or  obligation of such Seller contained in this Agreement or in any Closing 
Document; or

    
---|---|--- 
    

 

 

         |  

(c)

    |  

any  Excluded Liability including for greater certainty, (i) all claims 
for  severance or termination pay made by any Ontario Employee or Quebec 
Employee who does not accept Buyer's offer of employment made in  accordance
with Subsection 5.4.1(a)  and (ii) any Liability incurred by Buyer, a
Designated Buyer Affiliate  or  the Operator of the Diagnostics Business
[REDACTED] arising from  the  failure of the Sellers or Operators to obtain
the consent of [REDACTED]  to  the Buyer or a Designated Buyer Affiliate
prior to Closing;  or

    
---|---|--- 
    

 

 

         |  

(d)

    |  

subject  to compliance by Buyer with Subsection 7.1(b), any Claim related 
to the  matter set forth in Section 4.1.6(3)(g) of the Disclosure Letter 
(the  " **Disclosed  Matter** ").

    
---|---|--- 
    

 

 

**8.3** **Indemnification  by Buyer**

 

 

Buyer  shall indemnify, defend and save harmless each Seller and the
Representatives  of  each Seller from and against any and all Loss suffered
or incurred by any of  them, as a result of, or arising in connection with:

 

 

         |  

(a)

    |  

subject  to Section 4.6,  any misrepresentation or breach of any warranty
made or given by  Buyer or  any Designated Buyer Affiliate in this Agreement
or in any Closing  Document;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

any  failure by Buyer or any Designated Buyer Affiliate to observe or 
perform  any covenant, agreement or obligation of Buyer or such Designated 
Buyer  Affiliate contained in this Agreement or in any Closing Document;  or

    
---|---|--- 
    

 

 

         |  

(c)

    |  

any  Assumed Liability, including for greater certainty, those resulting 
from  any Claim, which may be asserted by any Ontario Employee or Quebec 
Employee who accepts Buyer's or the applicable Designated Buyer  Affiliate's
offer of employment against any Seller in respect of the  employment or
termination of employment of such Employee by Buyer  or the  applicable
Designated Buyer Affiliate or an Operator or any changes  to the  duties,
terms and conditions of their employment at or after the  Closing  Time.

    
---|---|--- 
    

 

 

**8.4** **Agency  for Representatives**

 

 

Each  Party agrees that it accepts each indemnity in favour of any of its 
Representatives as agent and trustee of that Representative and MDS accepts 
each  indemnity in favour of the other Sellers and their Representatives as
agent  and  trustee of that Seller and Representative. Each Party agrees
that a Party may  enforce an indemnity in favour of any of that Party's
Representatives on behalf  of that Representative (and in the case of MDS, on
behalf of the other Sellers  and their Representatives).

 

 

**8.5** **Notice  of the Defence of Third Party Claims**

 

 

If  an  Indemnified Party receives notice of the commencement or assertion
of any Third  Party Claim, the Indemnified Party shall give the Indemnifier
reasonably prompt  written notice thereof, but in any event no later than 30
days after receipt  of  such notice of such Third Party Claim. Such notice
to the Indemnifier shall  describe the Third Party Claim in reasonable detail
and shall indicate, if  reasonably practicable, the estimated amount of the
Loss that has been or may  be  sustained by the Indemnified Party. The
Indemnifier shall have the right to  participate in or, by giving notice to
that effect to the Indemnified Party  not  later than 30 days after receipt
of such notice of such Third Party Claim and  subject to the rights of any
insurer or other third party having potential  liability therefor, to elect
to assume the defence of any Third Party Claim  at  the Indemnifier's own
expense and by such Indemnifier's own counsel, and the  Indemnified Party
shall co-operate in good faith in such defence. The  Indemnified Party shall
have the right to participate in the defence of any  Third Party Claim
assisted by counsel of its own choosing at the Indemnified  Party's expense.
The Indemnified Party shall not settle or compromise any Third  Party Claim
without the prior written consent of the Indemnifier.

 

 

**8.6** **Assistance  for Third Party Claims**

 

 

The  Indemnifier and the Indemnified Party will use all reasonable efforts to
make  available to the Party which is undertaking and controlling the defence
of  any  Third Party Claim,

 

 

         |  

(a)

    |  

those  employees whose assistance, testimony or presence is necessary to 
assist  such Party in evaluating and in defending any Third Party Claim; 
and 

    
---|---|--- 
    

 

 

         |  

(b)

    |  

all  documents, records and other materials in the possession of such 
Party  reasonably required by such Party for its use in defending any Third 
Party  Claim,

    
---|---|--- 
    

 

 

and  shall  otherwise co-operate with the Party defending such Third Party
Claim. The  Indemnifier shall be responsible for all reasonable expenses
associated with  making such documents, records and materials available and
for all reasonable  expenses of any employees made available by the
Indemnified Party to the  Indemnifier hereunder, which expense shall be equal
to an amount to be mutually  agreed upon per person per hour or per day for
each day or portion thereof  that  such employees are assisting the
Indemnifier but such expenses shall not exceed  the actual direct out-of
pocket cost to the Indemnified Party associated with  such employees.

 

 

**8.7** **Settlement  of Third Party Claims**

 

 

If  an  Indemnifier elects to assume the defence of any Third Party Claim as
provided  in  Section 8.5,  the  Indemnifier shall not be liable for any
legal expenses subsequently incurred  by  the Indemnified Party in
connection with the defence of such Third Party Claim.  However, if the
Indemnifier fails to take reasonable steps necessary to defend  diligently
such Third Party Claim within 15 days after receiving notice from  the 
Indemnified Party that the Indemnified Party bona fide believes on
reasonable  grounds that the Indemnifier has failed to take such steps, the
Indemnified  Party may, at its option, elect to assume the defence of and to
compromise  or  settle the Third Party Claim assisted by counsel of its own
choosing and the  Indemnifier shall be liable for all reasonable costs and
expenses paid or  incurred in connection therewith; provided that the
Indemnified Party shall  not  enter into any compromise or settlement of any
Third Party Claim without the  prior written consent of the Indemnifier,
which shall not be unreasonably  withheld, delayed or conditioned.

 

 

**8.8** **Direct  Claims**

 

 

Any  Direct Claim shall be asserted by giving the Indemnifier reasonably
prompt  written notice thereof, but in any event not later than 30 days after
the  Indemnified Party becomes aware of such Direct Claim. The Indemnifier
shall  then  have a period of 15 days within which to respond in writing to
such Direct  Claim. If the Indemnifier does not so respond within such 15 day
period, the  Indemnifier shall be deemed to have rejected such Claim, and in
such event  the  Indemnified Party shall be free to pursue such remedies as
may be available  to  the Indemnified Party.

 

 

**8.9** **Failure  to Give Timely Notice**

 

 

A  failure  to give timely notice as provided in this Article 8  shall 
not affect the rights or obligations of the Indemnifier or Indemnified Party 
except and only to the extent that, as a result of such failure, any such
party  which was entitled to receive such notice was deprived of its right to
recover  any payment under its applicable insurance coverage or was otherwise
directly  and materially damaged as a result of such failure or whose rights
were  materially prejudiced by such failure.

 

 

**8.10** **Limitation**

 

 

Claims  for indemnification made by Buyer, any Designated Buyer Affiliate or
the  Representative of Buyer or a Designated Buyer Affiliate against any
Seller  shall  be limited as follows:

 

 

         |  

(a)

    |  

in  respect of Claims made under Subsection 8.2(a)  (other than a Claim
resulting from a misrepresentation or breach  of  warranty in respect of a
representation or warranty in Subsection  4.1.26)  no Losses shall be
recoverable until the aggregate of all Losses  suffered  or incurred by
Buyer, any Designated Buyer Affiliate or the Representative  of Buyer or a
Designated Buyer Affiliate in respect of all  misrepresentations or breaches
of warranty made or given by MDS in  this  Agreement or in any Closing
Document exceeds 0.5% of the Purchase  Price in  the aggregate in which
event the amount of all such Losses in excess  of  such amount may be
recovered by Buyer or the applicable Designated  Buyer  Affiliate or
Representative, as applicable; 

    
---|---|--- 
    

 

 

         |  

(b)

    |  

the  maximum aggregate liability of Sellers to Buyer, any Designated Buyer 
Affiliate and their Representatives for Losses pursuant to Section  8.2 
shall not exceed 30% of the Purchase Price other than Losses resulting 
directly from the intentional breach of this Agreement or any Closing 
Document by a Seller or a Seller's fraudulent or deceitful act;  and

    
---|---|--- 
    

 

 

         |  

(c)

    |  

if  any Applicable Law would give Buyer, any Designated Buyer Affiliate  or
the  Representative of Buyer or a Designated Buyer Affiliate the right, 
notwithstanding the express terms of Section 4.5  or  8.2  to  the
contrary, to make a claim in respect of a breach of a representation  or
warranty made or given by a Seller in this Agreement or in any  Closing 
Document after the expiry of the survival period set forth in Section  4.5 
with respect to such representation and warranty, the Parties agree  that 
the aggregate Losses suffered or incurred by Buyer, any Designated  Buyer 
Affiliate or the Representative of Buyer or a Designated Buyer Affiliate  as
a result of, or arising in connection with, any such Claim shall  be  deemed
to be limited to $1.00 and Buyer and each Designated Buyer  Affiliate hereby
forever waives, releases and discharges each Seller  from  any Loss in
excess of such deemed  amount.

    
---|---|--- 
    

 

 

**8.11** **Reductions  and Subrogation**

 

 

If  the  amount of any Loss incurred by an Indemnified Party at any time
subsequent  to  the making of an Indemnity Payment is reduced by

 

 

         |  

(a)

    |  

any  net Tax benefit to the Indemnified Party;  or

    
---|---|--- 
    

 

 

         |  

(b)

    |  

any  recovery, settlement or otherwise under or pursuant to any insurance 
coverage, or pursuant to any claim, recovery, settlement or payment  by or 
against any other Person,

    
---|---|--- 
    

 

 

the  Indemnified Party shall promptly notify the Indemnifier in writing of
the nature  and amount of such reduction (and any costs, expenses (including
Taxes) or  premiums incurred in connection therewith), and the amount of such
reduction  (less any such costs, expenses (including Taxes) or premiums)
shall promptly  be  repaid by the Indemnified Party to the Indemnifier. Upon
making an Indemnity  Payment, the Indemnifier shall, to the extent of such
Indemnity Payment, be  subrogated to all rights of the Indemnified Party
against any third party in  respect of the Loss to which the Indemnity
Payment relates. Until the  Indemnified Party recovers full payment of its
Loss, any and all claims of  the  Indemnifier against any such third party
on account of such Indemnity Payment  shall be postponed and subordinated in
right of payment to the Indemnified  Party's rights against such third party.

 

 

**8.12** **Exclusive  Remedy**

 

 

The  rights of indemnity set forth in this Article 8  are the  sole and
exclusive remedy of Buyer and each Designated Buyer Affiliate on the  one
hand and the Sellers on the other in respect of any misrepresentation, 
breach of warranty or breach of covenant by the other hereunder or under any 
Closing Document (other than the rights of termination in Section 6.4  or a 
claim for specific performance or injunctive relief).

 

 

**8.13** **Duty  to Mitigate**

 

 

Nothing  in this Agreement shall in any way restrict or limit the general
obligation  at  law of an Indemnified Party to mitigate any Loss which it
may suffer or incur  by  reason of the breach by an Indemnifier of any
representation, warranty or  covenant of the Indemnifier hereunder or under
any Closing Document. If any  Loss  can be reduced by any recovery,
settlement or otherwise under or pursuant to  any  insurance coverage, or
pursuant to any claim, recovery, settlement or payment  by  or against any
other Person, the Indemnified Party shall take all appropriate  steps to
enforce such recovery, settlement or payment.

 

 

**8.14** **General  Limitations**

 

 

An  Indemnifier shall have no liability to an Indemnified Party hereunder or
under  any Closing Document:

 

 

         |  

(a)

    |  

for  any Liability which arises solely by reason of a proposed or actual 
enactment or change of any applicable Tax legislation or any proposed  or 
actual change in the interpretation or administration of such legislation 
after the date hereof;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

for  any Liability that arises as a result of any legislation not in force 
on  the date hereof which takes effect retrospectively or occurs as a 
consequence of a change in the interpretation of the law after the  date 
hereof;

    
---|---|--- 
    

 

 

         |  

(c)

    |  

in  respect of any matter or thing done or omitted to be done by or at 
the  direction or with the consent of the Indemnified  Party;

    
---|---|--- 
    

 

 

         |  

(d)

    |  

in  respect of any Claim arising in connection with or in any way related 
to  the implementation by the Indemnifier of the Indemnified Party's 
structuring of the purchase and sale of the Purchased Assets as  contemplated
herein;

    
---|---|--- 
    

 

 

         |  

(e)

    |  

in  respect of more than one representation, warranty or covenant that 
relates  to the same matter or thing in this Agreement or a Closing 
Document;

    
---|---|--- 
    

 

 

         |  

(f)

    |  

for  any Loss or matter to the extent arising from a change in the
accounting  policies or practices of the Operator after the Closing; 

    
---|---|--- 
    

 

 

         |  

(g)

    |  

to  the extent that a Seller is unable to challenge or dispute any Claim 
due  to the loss or destruction, in each case by Buyer, a Designated Buyer 
Affiliate or an Operator, of any relevant Books and  Records;

    
---|---|--- 
    

 

 

         |  

(h)

    |  

for  any Loss or matter to the extent accrued, provided for or reserved 
for, or  otherwise taken into account in the Closing Balance Sheet or an
adjustment  to the Purchase Price (otherwise than under Section 8.15);  and

    
---|---|--- 
    

 

 

         |  

(i)

    |  

for  any Loss for a breach of or inaccuracy in any representation or
warranty  if the Indemnified Party was aware, at or before the Closing
Date,  of the  facts as a result of which such representation or warranty
was breached  or  inaccurate.

    
---|---|--- 
    

 

 

**8.15** **Adjustment  to the Purchase Price**

 

 

For  greater certainty, the amount of any payment required to be made by an 
Indemnifier to an Indemnified Party shall be deemed to constitute an
adjustment  to the Purchase Price and the Parties agree to allocate the
adjustment to the  appropriate Purchased Asset, acting reasonably.

 

 

**ARTICLE 9**

 

 

**ARBITRATION**

 

 

**9.1** **Arbitration**

 

 

Any  dispute between the Parties concerning any matter arising under or in
connection  with Sections 3.4,  3.5  and 3.6  and  Schedule 3.1 of this
Agreement shall be submitted to arbitration in accordance  with the
provisions of this Article.

 

 

**9.2** **Laws  of Ontario**

 

 

The  law  to be applied in connection with the arbitration shall be the law
of Ontario,  including its conflict of law rules.

 

 

**9.3** **Arbitration  Act**

 

 

The  arbitration shall be governed by the Rules of Procedure (the " **Rules**
")  set  forth in Schedule 9.3. The rules and procedures of the
_Arbitration  Act, 1991_   (Ontario) shall apply except to the extent that
they are modified by the express  provisions of this Article or such Rules.
The decision of the arbitrator shall  be conclusive, final and binding on the
Parties and no appeal shall lie  therefrom.

 

 

**ARTICLE 10**

 

 

**GENERAL**

 

 

**10.1** **Expenses**

 

 

Except  as  set forth in this Agreement, each Party shall pay all expenses
it incurs (and  in  the case of MDS, any expenses that MDS Quebec incurs) in
authorizing, preparing,  executing and performing this Agreement and the
Closing Documents and the  transactions contemplated under this Agreement and
the Closing Documents,  whether or not the Closing occurs, including all fees
and expenses of its legal  counsel, bankers, investment bankers, brokers,
accountants or other  representatives or consultants.

 

 

**10.2** **Time**

 

 

Time  is  of the essence of each provision of this Agreement.

 

 

**10.3** **Notices**

 

 

Any  notice, demand or other communication (in this Section, a " **notice**
")  required or permitted to be given or made hereunder shall be in writing
and  shall be sufficiently given or made if:

 

 

         |  

(a)

    |  

delivered  in person during normal business hours of the recipient on a
Business  Day  and left with a receptionist or other responsible employee of
the  recipient at the applicable address set forth below;  or

    
---|---|--- 
    

 

 

         |  

(b)

    |  

sent  by any electronic means of sending messages, including facsimile 
transmission (excluding e-mail), which produces a paper record  ("
**Transmission** ")  during normal business hours on a Business Day; 

    
---|---|--- 
    

 

 

in  the  case of a notice to MDS, addressed to it at:

 

 

MDS  Inc.

 

100  International Blvd.

 

Toronto,  Ontario

 

M9W  6J6

 

 

Attention: Executive  Vice-President,

 

Corporate  Development and General Counsel

 

Fax  No.: (416)  213-4222

 

 

with  a  copy to (which shall not constitute notice):

 

 

Fasken  Martineau DuMoulin LLP

 

66  Wellington Street West

 

Suite  4200, Toronto Dominion Bank Tower

 

Box  20,  Toronto-Dominion Centre

 

Toronto,  Ontario

 

M5K  1N6

 

 

Attention:  Scott  Conover

 

Fax  No.:  (416)  364-7813

 

 

and  in  the case of a notice to Buyer or any applicable Designated Buyer
Affiliate,  addressed to it at:

 

 

200  Bay  Street

 

P.O.  Box  56

 

Suite  2100

 

Royal  Bank Plaza, South Tower

 

Toronto,  ON

 

M5J  2J2

 

 

Attention:  President  and Chief Executive Officer

 

Fax  No.:  (416)  361-6075

 

 

with  a  copy to (which shall not constitute notice):

 

 

Ogilvy  Renault LLP

 

200  Bay  Street

 

Royal  Bank Plaza, South Tower

 

Suite  3800

 

P.O.  Box  84

 

Toronto,  ON

 

M5J  2Z4

 

 

Attention:  Jacques Demers

 

Fax  No.:  (416) 216-3930

 

 

Each  notice sent in accordance with this Section shall be deemed to have
been  received:

 

 

         |  

(a)

    |  

on  the day it was delivered in person as  aforesaid;

    
---|---|--- 
    

 

 

         |  

(b)

    |  

on  the same day that it was sent by Transmission, or on the first Business 
Day thereafter if the day on which it was sent by Transmission was  not a 
Business Day or if it was sent after normal business hours on a Business 
Day.

    
---|---|--- 
    

 

 

Any  Party  may change its address for notice by giving notice to the
other  Parties.

 

 

**10.4** **Assignment,  Successors**

 

 

         |  

(a)

    |  

Buyer  (and, as applicable, any Designated Buyer Affiliate) may, without 
the  consent of MDS but upon prior written notice to MDS, assign this 
Agreement  and its rights and obligations hereunder, in whole or in part,
to  one or  more Affiliates of Buyer or OMERS Administration Corporation.
Upon  notification to MDS of any such assignment by Buyer (or, as
applicable,  any Designated Buyer Affiliate), the applicable Affiliate (to
which  such  assignment is made) shall become liable for the performance of
the  obligations assigned by Buyer (or, as applicable, any Designated 
Buyer  Affiliate) to it. Notwithstanding the foregoing, Buyer shall remain 
jointly and severally liable with such designated Affiliates of Buyer  or 
OMERS Administration Corporation (or, as applicable, any Designated  Buyer 
Affiliate) and shall cause all of its covenants and obligations hereunder  to
be observed and performed by such Affiliates. Notwithstanding  the 
foregoing, any assignee which will acquire property pursuant to Section  2.1
must satisfy the conditions in Section  5.11.

    
---|---|--- 
    

 

 

         |  

(b)

    |  

MDS  may, without the consent of Buyer (and, as applicable, any Designated 
Buyer Affiliate), but upon prior written notice to Buyer, assign  this 
Agreement and its rights and obligations hereunder, in whole or in  part, 
to one or more direct or indirect subsidiaries of MDS. Upon notification  to
Buyer (and, as applicable, any Designated Buyer Affiliate) of  any such 
assignment by MDS, the designated subsidiary of MDS shall become  liable 
for the performance of the obligations assigned to them. Notwithstanding  the
foregoing, MDS shall remain jointly and severally liable with  such 
designated subsidiaries of MDS and shall cause all of its covenants  and 
obligations hereunder to be observed and performed by such  subsidiaries.

    
---|---|--- 
    

 

 

         |  

(c)

    |  

Subject  to paragraphs (a) and (b),

    
---|---|--- 
    

 

 

         |  

(i)

    |  

no  Party may assign any rights or benefits under this Agreement to any 
Person;

    
---|---|--- 
    

 

 

         |  

(ii)

    |  

each  Party agrees to perform its obligations under this Agreement itself, 
and  not to arrange in any way for any other Person to perform those 
obligations; and

    
---|---|--- 
    

 

 

         |  

(iii)

    |  

no  assignment of benefits or arrangement for substituted performance  by
one  Party shall be of any effect against the other Party except to the 
extent  that the other Party has consented to it in  writing.

    
---|---|--- 
    

 

 

         |  

(d)

    |  

This  Agreement shall enure to the benefit of and be binding upon the
Parties  and their respective successors (including any successor by reason 
of  amalgamation or statutory arrangement of any Party) and permitted 
assigns.

    
---|---|--- 
    

 

 

**10.5** **Further  Assurances**

 

 

Each  Party shall do such acts and shall execute such further documents,
conveyances,  deeds, assignments, transfers, elections and the like, and will
cause the doing  of such acts and will cause the execution, filing and
registration of such  further documents as are within its power, as the other
Party may in writing  at  any time and from time to time reasonably request
be done and or executed,  in  order to give full effect to the provisions of
this Agreement and each Closing  Document.

 

 

**10.6** **Public  Announcements**

 

 

Subject  to Applicable Law, no Party shall make or cause to be made, any
public statement  or public announcement or issue any press release or
otherwise communicate  with  any news media concerning this Agreement or the
transactions contemplated by  this Agreement without the prior written
consent of the other Party, and the  Parties shall co-operate as to the
timing and content of any such press release,  public announcement or
communication. Notwithstanding the foregoing, Buyer  acknowledges that MDS is
a reporting issuer under Applicable Laws and is  obligated to make immediate
public disclosure of the entering into of this  Agreement and the material
terms hereof and will be required to file a copy  of  this Agreement on the
System for Electronic Document Analysis and Retrieval  (SEDAR) and EDGAR, and
Buyer consents to the making of such disclosure and  such  filing and any
related communications (including in connection with analyst  conference
calls) and shall co-operate in the content of such disclosure  provided,
however, that Buyer has a reasonable opportunity to comment on the 
disclosure related to such filing.

 

 

**10.7** **Counterparts**

 

 

This  Agreement may be executed in any number of counterparts. Each
executed  counterpart shall be deemed to be an original. All executed
counterparts taken  together shall constitute one agreement.

 

 

**10.8** **Facsimile  Execution**

 

 

To  evidence the fact that it has executed this Agreement, a Party may send a
copy  of its executed counterpart to the other Party by Transmission. That
Party  shall  be deemed to have executed this Agreement on the date it sent
such Transmission.  In such event, such Party shall forthwith deliver to the
other Party the  counterpart of this Agreement executed by such Party.

 

 

**10.9** **No  Partnership**

 

 

Nothing  contained in this Agreement shall be deemed in any way or for any
purpose to  constitute any Party a partner or agent or legal representative
of the other  Party in the conduct of any business or otherwise or a member
of a joint venture  or joint enterprise with the other, or to authorize one
Party to bind the other  or to create any fiduciary relationship between
them.

 

 

**10.10** **Survival**

 

 

Notwithstanding  any provision herein to the contrary, Sections 5.1.4, 
5.1.6(a),  5.1.6(b)  and 5.13  and  Articles 1, 8 and 10 shall survive the
termination of this  Agreement.

 

 

[THE  REMAINDER OF THIS PAGE HAS BEEN INTENTIONALLY  LEFT BLANK]

 

 

 

**TO  WITNESS THEIR AGREEMENT** ,  the  Parties have duly executed this
Agreement.

 

        

**MDS  INC.**

 

    
--- 
     

Per:

    |  

__/s/  Stephen P. DeFalco__

    
     

Name:

    |  

Stephen  P. DeFalco

    
     

Title:

    |  

Chief  Executive Officer

    
      |   
     

Per:

    |  

__/s/  Jim Garner__

    
     

Name:

    |  

Jim  Garner

    
     

Title:

    |  

Executive  Vice President and Chief Financial Officer

    
     

We  have authority to bind the  Corporation

    
    

 



 



 

        

**BOREALIS  INFRASTRUCTURE MANAGEMENT INC.**

 

    
--- 
     

Per:

    |  

__/s/J.  Michael Rolland__

    
     

Name:

    |  

J.  Michael Rolland

    
     

Title:

    |  

Senior  Vice President

    
      |   
     

Per:

    |  

__/s/John  Knowlton__

    
     

Name:

    |  

John  Knowlton

    
     

Title:

    |  

Secretary

    
     

We  have authority to bind the  Corporation

    
    

  * * *

 

 

 

 

 

**Schedule  2.5 
Transaction Structure and Closing  Sequence**

 

**[REDACTED]**

 


 

 

**Schedule  3.1 
Holdback Amount**

 

**[REDACTED]**

 


 

**Schedule  3.8 
Purchase Price Allocation**

 

**[REDACTED]** 

  * * *

 

 



 

 

 

**Schedule  5.6**

 

**M** **DS  INC.**

 

 

**-  AND  -**

 

 

**BOREALIS  INFRASTRUCTURE MANAGEMENT INC.**

 

 

**-  AND  -**

 

 

**[DESIGNATED  BUYER AFFILIATES]**

 

 

        

**LIMITED  TRADE-MARK LICENCE  AGREEMENT 

**

    
--- 
    

**Dated  this <*> day of <*>, 2006**

 

**Prepared  by:**

 

![](fasken.jpg)

 

Fasken  Martineau DuMoulin LLP

 

Toronto, Ontario

 

 


 

 

**Article 1.........  INTERPRETATION**

 

1.1.......... Definitions

 

1.2.......... Headings, etc

 

1.3.......... Plurality and Gender

 

1.4.......... Including, etc.

 

1.5.......... Construction

 

1.6.......... Severability

 

1.7.......... Time of the Essence

 

1.8.......... No Third Party  Beneficiaries.

 

**Article 2......... GRANT OF  LICENCE**

 

2.1.......... Grant

 

**Article 3......... QUALITY  CONTROL**

 

3.1.......... Compliance with Quality  Control Guidelines

 

3.2.......... Preserve Goodwill

 

3.3.......... Access for Inspection

 

3.4.......... Compliance with Applicable  Laws

 

3.5.......... Notice of Default

 

3.6.......... Remedy

 

**Article 4.........  AGREEMENT NOT ASSIGNABLE**

 

4.1.......... Not Assignable

 

**Article 5.........  TRADE-MARK OWNERSHIP**

 

5.1.......... MDS Owner of MDS  Marks

 

5.2.......... Negative Covenant

 

5.3.......... No Challenge

 

5.4.......... Defending the MDS  Marks

 

**Article 6......... TERM AND  TERMINATION**

 

6.1.......... Term and Termination

 

6.2.......... Termination with Respect  to  a Licensee

 

**Article 7......... EFFECT  OF TERMINATION**

 

7.1.......... Discontinue Use on  Termination

 

7.2.......... Destruction of  Materials

 

7.3.......... Survival

 

**Article 8.........  SUB-LICENSING**

 

8.1.......... Permitted  Sub-Licensees

 

8.2.......... Sub-Licenses

 

**Article 9.........  INDEMNITY**

 

9.1.......... Indemnity

 

**Article 10.......  REMEDIES**

 

10.1........ Remedies

 

**Article 11.......  GENERAL**

 

11.1........ Notices

 

11.2........ Waiver of Rights

 

11.3........ Amendments

 

11.4........ Governing Law

 

11.5........ Entire Agreement

 

11.6........ Further Assurances

 

11.7........ Counterparts

 

11.8........ Facsimile Execution

 

11.9........ Binding Agreement

 

11.10...... No Partnership

 

**SCHEDULE "A"MDS  Marks**

 ** SCHEDULE "B"Form  of  Sub-License**


 

 

**TRADE-MARK  LICENSE AGREEMENT**

 

**THIS LIMITED TRADE-MARK LICENSE  AGREEMENT** (" **Agreement** ") is made
and entered into as of <*>, 2006, by and between MDS Inc., a corporation 
incorporated under the  laws of Canada (the " **Licensor** ") and Borealis
Infrastructure  Management Inc., a corporation incorporated under the laws of
Canada (the  " **Buyer** ") **[NTD: The Designated Buyer Affiliates  will be
added as Licensees.]** (the Buyer and l, land l  are collectively 
referred to herein as the " **Licensees** ")

 

**RECITALS:**

 

**A.  **Licensor  is the owner of all right, title and interest in and to
the  registered trade-marks in Canada, shown in Schedule "A" attached hereto.

 

**B.  **Licensor  and Buyer have entered into an asset purchase agreement
with  respect to the portion of the Diagnostics Business conducted in
Ontario  and  Quebec dated l,  2006 (as such  agreement may be amended
from time to time, the " **Ontario Purchase  Agreement** "), as well as an
asset purchase agreement with respect to the  portion of the Diagnostics
Business conducted in British Columbia dated l,  2006 (as such  agreement
may be amended from time to time, the " **BC Purchase  Agreement** ") (the
Ontario Purchase Agreement and the BC Purchase  Agreement are collectively
referred to herein as the " **Purchase  Agreements** "), pursuant to which,
among other things, Buyer is  purchasing from Licensor and the other Sellers
the Purchased Assets (as  defined  in both of the Purchase Agreements) on
the terms and subject to the conditions  set forth in each of the Purchase
Agreements.

 

**C.  **The  MDS Marks are used by Licensor and its Affiliates in
connection  with its Pharma Services, Nordion and Sciex businesses and, prior
to the  Closing, the MDS Marks have been used by Licensor and its Affiliates
in  connection with the Diagnostics Business. The goodwill associated with
the  MDS Marks is extremely valuable to Licensor and its Affiliates and all 
right,  title and interest in and to the MDS Marks shall remain with Licensor
and  shall  not be transferred to Buyer pursuant to or in connection with
the Purchase  Agreements.

 

**D.  **Buyer  requires a transition period to re-brand and adopt new marks
in  connection with the operation of the Diagnostics Business by the
Licensees  and  their Affiliates after Closing.

 

**E.  **It  is a condition of Closing under the Ontario Purchase Agreement
that  the Parties enter into this Agreement on the Closing Date.

 

**IN CONSIDERATION** of the  premises, the Purchase Price paid by Buyer to
the Sellers pursuant to the  Purchase Agreements, the respective covenants
and agreements contained  herein  and of other consideration (the receipt
and sufficiency of which are hereby  acknowledged by each Party) the Parties
agree as follows:

 

**Article 1** ** 
INTERPRETATION**

 

**1.1   ****Definitions**

 

As used in this Agreement, unless the  context  otherwise requires
capitalized terms not expressly defined in this Agreement  shall have the
meanings ascribed thereto in the Ontario Purchase Agreement,  and  the
following terms shall have the following meanings:

 

(a)  " **Affiliate** " means, with respect  to any Person,

 

(i)  any other Person who directly or  indirectly controls, is controlled
by, or is  under direct or indirect common control with, such Person; or

 

(ii)  any other Person that directly or  indirectly owns all of the
participating  equity of such Person or for which all of the participating
equity is directly  or indirectly owned by such Person; and

 

a  Person shall be deemed to "control" a Person if such Person possesses
directly  or indirectly the power to direct or cause the direction of the
management  and  policies of such Person, whether through the ownership of
voting securities,  by  contract or otherwise, and "controlled" shall have a
similar meaning;

 

(b)  " **Agreement** " has the meaning  ascribed thereto in the preamble 
hereof and includes all attached schedules;

 

(c)  " **AutoLabs Business** " means the business  carried on by the 
Licensor and its Affiliates prior to Closing and by Licensees and their 
Affiliates after Closing relating to the hardware system and related
software  known as APX (AutoLab Process eXpert) that provides specimen
management,  storage, results and instrument interfacing capabilities at
testing locations,  consisting of the licensing, maintenance and support of
such system;  

 

(d)  " **BC Purchase Agreement** " has the meaning  ascribed thereto in
the  recitals;

 

(e)  " **Defaulting Licensee** " has the meaning  ascribed thereto in 
Section 6.2;

 

(f)  " **Diagnostics Business** " means the specimen  collection and 
diagnostic services businesses carried on, prior to the date hereof, by 
Licensor  and the BC Operators, the Operators and the Non-Controlled
Operators as  defined  in both of the Purchase Agreements and after Closing
by Licensees and their  Sub-Licensees, consisting of the provision of
clinical laboratory testing  for  physicians, hospitals, non-hospital health
care institutions, employers  or  insurance companies, management of
hospital laboratories and other support  services for clinical diagnostics
and the Auto Labs Business;

 

(g)  " **MDS Marks** " means the registered  trade-marks in Canada set out 
in Schedule "A" attached hereto, including any and all common law rights  and
goodwill attaching thereto;

 

(h)  " **notice** " has the meaning  ascribed thereto in Section  11.1;

 

(i)  " **Ontario Purchase Agreement** " has the meaning  ascribed thereto 
in the recitals;

 

(j)  " **Parties** " means, collectively  Licensor and Licensees and "
**Party** " means any one of them;

 

(k)  " **Permitted Assignee** " has the meaning  ascribed thereto in 
Section 4.1;

 

(l)  " **Permitted Sub-Licensee** " has the meaning  ascribed thereto in 
Section 8.1;

 

(m)  " **Person** " shall be broadly  interpreted and includes an 
individual, body corporate, partnership, joint venture, trust, association, 
unincorporated organization, the Crown, any Governmental Authority or any 
other  entity recognized by law;

 

(n)  " **Purchase Agreements** " has the meaning  ascribed thereto in the 
recitals;

 

(o)  " **Representative** " has the meaning  ascribed thereto in Section 
9.1;

 

(p)  " **Sub-License** " has the meaning  ascribed thereto in Section  8.2;

 

(q)  " **Territory** " means (a) Canada,  (b) and, to the extent required 
to perform the obligations of the Licensees under the US Support Services 
Contracts as contemplated by the Ontario Purchase Agreement, the U.S.A.  ;

 

(r)  " **Transition Period** " means the period  commencing on the date 
hereof and ending on the date that is 12 months after the date of this 
Agreement; and

 

(s)  " **Transmission** " has the meaning  ascribed thereto in Section 
11.1(b).

 

**1.2   ****Headings, etc**.

 

The division of this Agreement into articles,  sections, subsections and
schedules and the insertion of headings are for  convenience of reference
only and shall not affect the construction or  interpretation of this
Agreement. The article, section, subsection and  schedule headings in this
Agreement are not intended to be full or precise  descriptions of the text to
which they refer and are not to be considered  part  of this Agreement. All
uses of the words "hereto", "herein", "hereof", "hereby" and "hereunder" and
similar expressions refer to this Agreement and not  to any particular
section or portion of it. References to an Article,  Section, Subsection or
Schedule refer to the applicable article, section,  subsection or schedule of
this Agreement.

 

**1.3   ****Plurality and Gender**

 

In this Agreement, words in the singular  include the plural and vice-versa
and words in one gender include all  genders.

 

**1.4   ****Including, etc**.

 

Reference in this Agreement to the term  "including" shall mean "including
without limitation" and shall not be construed  to limit any general
statement which it follows to the specific or similar  items  or matters
immediately following it.

 

**1.5   ****Construction**

 

This Agreement is the joint product of  Licensor and Licensees, has been
subject to mutual consultation, negotiation  and  agreement of the Parties
and shall not be construed for or against any  Party.

 

**1.6   ****Severability**

 

If any provision of this Agreement is  determined by a court of competent
jurisdiction to be invalid, illegal  or  unenforceable in any respect, such
determination shall not impair or affect  the  validity, legality or
enforceability of the remaining provisions hereof,  and  each provision is
hereby declared to be separate, severable and distinct.

 

**1.7   ****Time of the Essence**

 

Time shall be of the essence of this Agreement  and each provision hereof.

 

**1.8   ****No Third Party Beneficiaries**

 

Nothing in this Agreement is intended  expressly or by implication to, or
shall, confer upon any Person other  than  Licensor and Licensees and,
solely in respect of Article 9, Licensor's  Representatives, any rights or
remedies of any kind. Licensor accepts each  covenant in favour of each
Representative as agent and trustee of such  Representative, and Licensor may
enforce such covenants on behalf of each  Representative.

 

**Article 2** ** 
GRANT  OF  LICENCE**

 

**2.1   ****Grant**

 

Subject to the terms and conditions of  this  Agreement, Licensor grants to
Licensees a non-exclusive, non-transferable,  royalty-free licence to use the
MDS Marks solely in association with the  Diagnostics Business for the
Transition Period in the Territory (provided  that,  notwithstanding any
other statement in this Agreement, Licensees may only  use  the MDS Marks in
the U.S.A to the extent required to perform the obligations  of  the
Licensees under the US Support Services Contracts as contemplated by  the 
Ontario Purchase Agreement).

 

**Article 3** ** 
QUALITY  CONTROL**

 

**3.1   ****Compliance with Quality Control Guidelines**

 

Licensees shall use the MDS Marks only  in  connection with the Diagnostics
Business and only in the Territory.  Licensees shall operate the Diagnostics
Business and provide diagnostic  services  of substantially the same
character and quality as the Licensor prior to  Closing  and shall ensure
that the use of the MDS Marks conforms to and complies  with a  character
and quality substantially the same as the character and quality  standards of
Licensor prior to Closing.

 

**3.2   ****Preserve Goodwill**

 

Licensees shall ensure that all  representations of the MDS Marks shall be
used in a manner so as to ensure  the  preservation and enhancement of the
goodwill attaching to the MDS Marks.  Licensees shall not advertise, exploit,
promote, market or otherwise operate  the  Diagnostics Business using the
MDS Marks in any manner which will or is  reasonably likely to adversely
affect the reputation of Licensor or the  validity  or distinctiveness of
the MDS Marks.

 

**3.3   ****Access for Inspection**

 

Licensees will permit Licensor and its  authorized representatives access to
Licensees' operating facilities during  normal business hours upon Licensor
providing a Licensee with two (2) Business  Days prior written notice of its
request for such access, for the purpose  of  inspecting the Diagnostics
Business operated in association with the MDS  Marks  and full disclosure of
all uses of the MDS Marks by such Licensee.  Licensees shall provide samples
of all proposed uses of the MDS Marks including  with any trade-marks of
Licensees, in each case together with reasonable  details  as to the
proposed usage, and shall not use the MDS Marks in any advertising, 
promotional or other materials, including without limitation in any press 
release, prepared by or on behalf of a Licensee after the date hereof, 
without  the prior written approval of Licensor, which approval shall not be
unreasonably  withheld. Approval or non-approval shall be given within three
(3)  Business Days of a request for approval having been made.

 

**3.4   ****Compliance with Applicable Laws**

 

Licensees shall operate the Diagnostics  Business and use the MDS Marks in
compliance with all Applicable Laws and  shall  obtain and at all times
maintain any and all Licences necessary for the  operation of the Diagnostics
Business in the Territory.

 

**3.5   ****Notice of Default**

 

Each Licensee shall give prompt notice  to  Licensor of (i) any violation of
this Agreement by such Licensee or violation  of  any Sub-License by any
Sub-Licensee; (ii) any unauthorized use of the MDS  Marks  in the Territory
or any confusingly similar marks or names adopted by third  parties of which
a Licensee becomes aware and (iii) the occurrence of any  of the  matters or
events described in Section 6.1(b) or Section 6.2(a), (b), (c)  or (d) with
respect to such Licensee.

 

**3.6   ****Remedy**

 

Upon notice to or other discovery by a  Licensee of any misuse of the MDS
Marks or non-compliance by such Licensee  or a  Permitted Sub-Licensee with
the provisions of this Agreement or the applicable  Sub-License, such
Licensee shall (and shall cause the applicable Sub-Licensee  to, as the case
may be) promptly notify Licensor and remedy such misuse  or  non-compliance
and notify Licensor of the remedial steps taken.

 

**Article 4** ** 
AGREEMENT  NOT  ASSIGNABLE**

 

**4.1   ****Not Assignable**

 

No Licensee shall have the right to assign,  divide, mortgage, pledge, charge
or otherwise encumber this Agreement in  whole  or in any part, or any
licensed right granted herein, to any Person, other  than  the right to
assign this Agreement to an Operator or BC Operator (each,  a " **Permitted
Assignee** "), provided that (a) the Licensee shall  provide reasonable prior
written notice of such assignment to Licensor,  the  Licensees shall remain
jointly and severally liable with such Permitted  Assignee, and shall cause
all of its covenants and obligations hereunder  to be  observed and
performed by such Permitted Assignee, and (b) such Licensee  shall, 
promptly upon the Permitted Assignee ceasing to be an Affiliate of such 
Licensee  or OMERS Administration Corporation or ceasing to operate the
applicable  part of  the Diagnostics Business within the Territory, (i)
provide Licensor with  written  notice of same, and (ii) cause such
Permitted Assignee to assign this Agreement  to another Permitted Assignee,
such assignment to be subject to this Section  4.1.

 

**Article 5** ** 
TRADE-MARK  OWNERSHIP**

 

**5.1   ****MDS Owner of MDS Marks**

 

Licensees recognize the significant value  of  the goodwill associated with
the MDS Marks and acknowledge that the MDS  Marks  and all rights therein,
including the goodwill, belong exclusively to  Licensor. Licensees agree not
to commit any act or omission adverse or  injurious to Licensor's rights in
the MDS Marks.

 

**5.2   ****Negative Covenant**

 

Licensees shall not associate intellectual  property belonging to third
parties with the MDS Marks (other than the  intellectual property of
Affiliates of Licensees, to the extent such association  is reasonably
required in connection with the use of the MDS Marks permitted  to  such
Affiliates by this Agreement) except with the prior written consent  of 
Licensor, such consent not to be unreasonably withheld. Licensees shall  not
(and shall cause each Affiliate of Licensees not to) use any of the  MDS 
Marks as, or as part of, its corporate, partnership, business or trade-name 
or  style.

 

**5.3   ****No Challenge**

 

Neither during the term of this Agreement,  nor  at any time after
termination hereof, shall any Licensee, either directly  or  indirectly, (i)
dispute, challenge or contest the ownership, validity,  distinctiveness or
enforceability of the MDS Marks, (ii) attempt any  registration thereof or of
any other mark or name that is similar phonetically  or visually to the MDS
Marks or is so similar thereto as to suggest association  with, confusion
with or sponsorship by Licensor, or (iii) depreciate, impair,  dilute or
otherwise adversely affect or attempt to depreciate, impair,  dilute or 
otherwise adversely affect the value of the goodwill attaching to the MDS 
Marks.

 

**5.4   ****Defending the MDS Marks**

 

Licensor shall have the sole and exclusive  right and discretion to determine
whether or not any action shall be taken  by  itself on account of any
infringements of, use of, imitations of or interference  with the MDS Marks
or any right confusingly similar thereto. Licensor may  at any time commence
proceedings in respect of the MDS Marks. Licensees  shall assist Licensor in
the proof and enforcement of the rights of Licensor  at  Licensor's expense
as required by Licensor. In no event shall a Licensee  have any recourse
against Licensor for costs or damages as a result of  Licensor's failure to
act or as a result of any action brought by  Licensor. Licensor may at its
sole discretion assume the defense of any  action or proceeding of any kind
brought against a Licensee which relates  to the  use, distinctiveness or
validity of, or otherwise to, the MDS Marks.

 

**Article 6** ** 
TERM  AND  TERMINATION**

 

**6.1   ****Term and Termination**

 

This Agreement shall expire and terminate  upon  the expiry of the
Transition Period as defined in this Agreement. However,  in addition to and
without limiting or prejudicing any rights or remedies  of  Licensor
hereunder, at law or in equity, this Agreement shall automatically  terminate
before the expiry of the Transition Period, upon the happening  of any  of
the following events:

 

(a)  A Licensee or any of its Sub-Licensees  commits a breach of this
Agreement or the  applicable Sub-License and the Licensee or Sub-Licensee, as
the case may  be, is  so notified in writing by Licensor of such breach
occurring and, in the  case of  a breach capable of remedy, fails to remedy
the same within ten (10) days  after  receipt of such notice from Licensor;
or

 

(b)   A Licensee or any of its Sub-Licensees disputes, contests or
challenges  (i) the validity or enforceability of any MDS Marks, (ii) the
ownership of  any MDS Marks by Licensor, its successors and assigns, (iii)
the entitlement  of  Licensor or any of its Affiliates or licensees to use
or licence any MDS  Marks  or (iv) opposes any application by Licensor or
any of its Affiliates for  any MDS  Marks or any associated or similar
trade-marks.

 

**6.2   ****Termination with Respect to a Licensee**

 

This Agreement shall automatically terminate  before the expiry of the
Transaction Period with respect to a Licensee  (a " **Defaulting Licensee**
") upon the happening of any of the  following events:

 

(a)   A change of control of such Licensee occurs. For the purpose hereof,
a  change of control shall occur if (i) all or substantially all of the
assets  of  such Licensee are sold, distributed or otherwise disposed or in
one or  more  transactions to a Person other than an Affiliate of the
Licensee or OMERS  Administration Corporation or (ii) a Licensee ceases to be
an Affiliate of  either Borealis Capital Corporation or OMERS Administration
Corporation;

 

(b)   Such Licensee ceases or threatens to cease to carry on business or
takes  any  action to dissolve, wind-up or liquidate;

 

(c)   Such Licensee stops making payments in the normal course of business,
makes  a  general assignment for the benefit of creditors, makes a bulk sale
of its  assets, institutes any proceedings relating to insolvency or
bankruptcy,  or such  proceedings are instituted against such Licensee; or

 

(d)   A custodian, receiver, manager, receiver-manager, lessor,
encumbrancer  or any  other entity is appointed to take charge of or takes
possession of any  material  part of such Licensee's business, property or
assets, or a distress or execution  is levied against such Licensee.

 

**Article 7** 
 **EFFECT  OF TERMINATION**

 

**7.1   ****Discontinue Use on Termination**

 

(a)  Upon expiry or termination of this  Agreement pursuant to Section 6.1,
the  licensed rights granted herein shall immediately cease and be null and 
void,  Licensees shall immediately discontinue any and all use, display or 
advertisement of any kind in any medium or manner of the MDS Marks, or  any 
confusingly similar names or marks including any brochures, pamphlets, 
signs  (including, appearing on, in or around any building or any vehicle),
business  cards, letterhead, internet sites or web pages and Licensee shall
not adopt  any  other mark, name, logo, acronym or any other identification
of source that  may  be considered confusingly similar with the MDS Marks or
suggest a relationship,  association or affiliation with Licensor or the MDS
Marks.

 

(b)  Upon termination of this Agreement  pursuant to Section 6.2, the
licensed rights  granted herein to the Defaulting Licensee shall immediately
cease and be  null  and void, the Defaulting Licensees shall immediately
discontinue any and  all  use, display or advertisement of any kind in any
medium or manner of the  MDS  Marks, or any confusingly similar names or
marks including any brochures,  pamphlets, signs (including, appearing on, in
or around any building or  any  vehicle), business cards, letterhead,
internet sites or web pages and the  Defaulting Licensee shall not adopt any
other mark, name, logo, acronym  or any  other identification of source that
may be considered confusingly similar  with  the MDS Marks or suggest a
relationship, association or affiliation with  Licensor or the MDS Marks.

 

**7.2   ****Destruction of Materials**

 

Notwithstanding Section 7.1 hereof, upon  the expiry or termination of this
Agreement pursuant to either Sections  6.1 or  6.2, all Licensees or the
Defaulting Licensee, as the case may be, will:  (i) use commercially
reasonable efforts to remove any embedded software  codes that contain any
MDS Marks in such Licensee's internal business systems,  to the extent that
such removal may be conducted without disruption, other  than  minor
disruption, to such Licensee's internal business systems; and  (ii) ensure
that any public documents containing a MDS Mark within such  Licensee's
custody or control are destroyed, or where such destruction is 
impracticable, discontinued and shall ensure that such discontinued
documents  remain subject to such Licensee's obligations of confidentiality;
and the Chief  Information Officer of such Licensee shall deliver to Licensor
a certificate  certifying that such Licensee and all Permitted Sub-Licensees
of such Licensee  have complied with this Section. ****

 

**7.3   ****Survival**

 

Notwithstanding the expiration or termination  of this Agreement, all
covenants and acts to be performed and/or observed  by a  Licensee under
this Agreement or which by their nature survive the expiration  or 
termination of this Agreement including this Article 7 and Article 9,  shall
survive any such expiration or termination.

 

**Article 8** ** 
SUB-LICENSING**

 

**8.1   ****Permitted Sub-Licensees**

 

Licensees shall not grant or purport to  grant  any sub-licence of its
rights or obligations under this Agreement, except  that a  Licensee may
sub-license its rights and obligations to any Affiliate, Operator  or BC
Operator within the Territory as long as such Affiliate, Operator  or BC 
Operator is and remains throughout the Transition Period an Affiliate of 
Buyer  or OMERS Administration Corporation, operates any part of the
Diagnostics  Business within the Territory and exercises the sublicensed
rights only  in  connection with such operation as permitted by this
Agreement (a " **Permitted Sub-Licensee** ").

 

**8.2   ****Sub-Licenses**

 

Any sub-license granted under Section  8.1  (each a " **Sub-License** ")
shall be on the following terms:

 

(a)  The sub-license shall not be effective  until a Licensee and the
Permitted  Sub-Licensee have entered into an agreement in writing which is in
all  material  respects the same as this Agreement (save that there will be
no further  right to  sub-license by a Permitted Sub-Licensee) and shall be
executed and delivered  by  the Licensee, the applicable Permitted Sub-
Licensee and Licensor, in the  form  attached hereto as Schedule "B"
attached hereto;

 

(b)  The Licensees shall be fully responsible  and jointly and severally
liable with  each Permitted Sub-Licensee for the acts and omissions of each
Permitted  Sub-Licensee;

 

(c)  The Licensee shall at all times and  solely at its own cost diligently
enforce  the terms and conditions of such Sub-Licenses; and

 

(d)  The permission to sub-licence and  all Sub-Licenses granted pursuant
hereto, will  terminate automatically without any further act or formality
upon the earliest  of (i) expiry of the Transition Period; (ii) termination
of this Agreement;  or  (iii) in the case of any Permitted Sub-Licensee, if
it is no longer an  Affiliate of Buyer or OMERS Administration Corporation.

 

**Article 9** 
 **INDEMNITY**

 

**9.1   ****Indemnity**

 

Licensees shall jointly and severally  indemnify and hold harmless Licensor,
its Affiliates and their respective  directors, shareholders, officers,
employees, agents and other representatives  (each such Person other than
Licensor being a " **Representative** "), from any and all liabilities,
losses, suits,  claims, demands, damages, expenses, costs (including all
legal costs),  fines and  actions of any kind or nature whatsoever to which
they shall or may become  liable for, or suffer by reason of, arising in
connection with or relating  to  any breach, violation or non-performance on
the part of a Licensee or a  Permitted Sub-Licensee of any provision of this
Agreement or applicable  Sub-License. The maximum aggregate liability of
Licensees to Licensor, its  Affiliates and their Representatives pursuant to
this Section 9.1 shall  be one  million dollars ($1,000,000),provided that
this limitation shall not apply  in  the case of any gross negligence or
wilful misconduct by a Licensee, a  Permitted  Sublicensee and/or any of
their respective Affiliates.

 

**Article 10** ** 
REMEDIES**

 

**10.1   ****Remedies**

 

Licensees acknowledge that the goodwill  associated with the MDS Marks is
extremely valuable as it has been used  by  Licensor in connection with its
businesses for over thirty years, Licensor  intends to continue to use the
MDS Marks in its businesses other than the  Diagnostics Business after the
date hereof and monetary damages may not  be a  sufficient remedy for, and
Licensor may suffer irreparable harm as a result  of,  a breach by a
Licensee of this Agreement or by any Permitted Sub-Licensee  of the 
applicable Sub-License. Accordingly, in the event of any breach of this 
Agreement by a Licensee or any Sub-License by any Permitted Sub-Licensee, 
in  addition to any other remedy provided for at law or in equity, Licensor 
shall be  entitled to equitable relief, including an injunction or specific
performance  or  both. The remedies of Licensor under this Agreement are
cumulative and  shall not exclude any other remedies to which Licensor may be
lawfully  entitled.

 

**Article 11** ** 
GENERAL**

 

**11.1   ****Notices**

 

Any notice, demand or other communication  (in  this Section, a " **notice**
") required or permitted to be given or  made hereunder shall be in writing
and shall be sufficiently given or made  if:

 

(a)  delivered in person during normal  business hours of the recipient on a
Business  Day and left with a receptionist or other responsible employee of
the recipient  at the applicable address set forth below; or

 

(b)   sent by any electronic means of sending messages, including facsimile 
transmission (excluding e-mail), which produces a paper record  ("
**Transmission** ") during normal business hours on a Business  Day;

 

in the case of a notice to Licensor,  addressed to it at:

 

MDS Inc. 
100 International  Blvd. 
Toronto, Ontario 
M9W 6J6

 

Attention:  Executive  Vice-President, 
 Corporate Development and General Counsel

 

Fax No.:   (416) 213-4222

 

with a copy to (which shall not  constitute notice):

 

Fasken Martineau DuMoulin LLP 
66  Wellington Street West 
Suite 4200, Toronto Dominion Bank Tower 
Box 20,  Toronto-Dominion Centre 
Toronto, Ontario 
M5K 1N6

 

Attention:  Scott Conover 
Fax No.:   (416) 364-7813

 

and in the case of a notice to a  Licensee, addressed to it at:

 

200 Bay Street 
Royal Bank Plaza,  South Tower 
Suite 2100 
P.O. Box 56 
Toronto, Ontario 
M5J 2J2

 

Attention:  President and Chief Executive  Officer 
Fax No.: (416)  361-6075

 

with a copy to (which shall not  constitute notice):

 

Ogilvy Renault LLP 
200 Bay  Street 
Royal Bank Plaza, South Tower 
Suite 3800 
P.O. Box 84 
Toronto,  Ontario 
M5J 2Z4

 

Attention:  Jacques Demers 
Fax  No.: (416)  216-3930

 

Each notice sent in accordance with this  Section shall be deemed to have
been received:

 

(i)  on the day it was delivered in person  as aforesaid;

 

(ii)  on the same day that it was sent  by Transmission, or on the first
Business Day  thereafter if the day on which it was sent by Transmission was
not a Business  Day or if it was sent after normal business hours on a
Business Day.

 

Either Party may change its address for  notice  by giving notice to the
other Party.

 

**11.2   ****Waiver of Rights**

 

Any waiver of, or consent to depart from,  the  requirements of any
provision of this Agreement shall be effective only  if it is  in writing
and signed by the Party giving it, and only in the specific  instance  and
for the specific purpose for which it has been given. No failure on  the part
of any Party to exercise, and no delay in exercising, any right  under  this
Agreement shall operate as a waiver of such right. No single or  partial
exercise of any such right shall preclude any other or further  exercise  of
such right or the exercise of any other right. No failure on the part  of any
Party to exercise, and no delay in exercising any right under this  Agreement
shall operate as a waiver of such right; nor shall any single  or  partial
exercise of any such right preclude any other or further exercise  of  such
right or the exercise of any other right.

 

**11.3   ****Amendments**

 

This Agreement may only be amended or  otherwise modified by written
agreement executed by Licensor and  Licensees.

 

**11.4   ****Governing Law**

 

This Agreement shall be governed by, and  interpreted and enforced in
accordance with, the laws in force in the Province  of Ontario and the
federal laws of Canada applicable therein. Each Party  irrevocably submits to
the non-exclusive jurisdiction of the courts of  Ontario  and the Federal
Court of Canada with respect to any matter arising hereunder  or  related
hereto.

 

**11.5   ****Entire Agreement**

 

This Agreement and the Purchase Agreements  constitute the entire agreement
between the Parties pertaining to the subject  matter hereof and supersede
all prior agreements, negotiations, discussions  and  understandings,
written or oral, between the Parties. There are no  representations,
warranties, conditions, other agreements or acknowledgements,  whether direct
or collateral, express or implied, that form part of or  affect  this
Agreement, or which induced any Party to enter into this Agreement  or on 
which reliance is placed by any Party, except as specifically set forth  in
this  Agreement and the Purchase Agreements.

 

**11.6   ****Further Assurances**

 

Each Licensee and the Licensor shall do  such  acts and shall execute such
further documents, conveyances, deeds, assignments,  transfers, elections and
the like, and will cause the doing of such acts  and  will cause the
execution, filing and registration of such further documents  as  are within
its power, as the Licensor or Licensees, respectively, may in  writing  at
any time and from time to time reasonably request be done and or executed, 
in  order to give full effect to the provisions of this Agreement.

 

**11.7   ****Counterparts**

 

This Agreement may be executed in  counterparts. Each executed counterpart
shall be deemed to be an original  and all such counterparts taken together
will constitute one Agreement.

 

**11.8   ****Facsimile Execution**

 

To evidence the fact that it has executed  this  Agreement, a Party may send
a copy of its executed counterpart to the other  Parties by Transmission.
That Party shall be deemed to have executed this  Agreement on the date it
sent such Transmission. In such event, such Party  shall forthwith deliver to
the other Parties the counterpart of this Agreement  executed by such Party.

 

**11.9   ****Binding Agreement**

 

Subject to Section 4.1, this Agreement  shall  be binding upon and enure to
the benefit of the Parties and their respective  successors and permitted
assigns.

 

**11.10   ****No Partnership**

 

Nothing contained in this Agreement shall  be  deemed in any way or for any
purpose to constitute any Party a partner  or agent  or legal representative
of any other Party in the conduct of any business  or  otherwise or a member
of a joint venture or joint enterprise with the other,  or  to authorize one
Party to bind the other or to create any fiduciary relationship  between
them.

 

**IN WITNESS WHEREOF** the  Parties have executed this Agreement as of the
day and year first above  written.

 

        

    |  

**MDS INC.**

 

 

    
---|--- 
     

    |  

By:

    |  

    
     

    |  

    |  

Name:

    
     

    |  

    |  

Title:

    
     

 

    |  

 

 

**BOREALIS INFRASTRUCTURE MANAGEMENT  INC.**

 

 

    
     

    |  

By:

    |  

    
     

    |  

    |  

Name:

    
     

    |  

    |  

Title:

    
     

    |  

    |  

    
     

    |  

By:

    |  

    
     

    |  

    |  

Name:

    
     

    |  

    |  

Title:

    
     

    |  

    |  

    
     

 

    |  

 

 

**[DESIGNATED BUYER  AFFILIATES]**

 

 

    
     

    |  

    |  

    
     

    |  

    |  

    
     

    |  

    |  

    
    


 

 

**SCHEDULE  "A"** 
 **MDS  Marks**

 

        

**Trade-mark**

    |  

**Canadian  Registration No.**

    
---|--- 
     

MDS

    |  

TMA  407614

    
     

MDS and  Design

    |  

TMA  426801

    
     

MDS and  Design

    |  

TMA  518767

    
     

Science  Advancing  Health

    |  

TMA  517829

    
    

 


 

**SCHEDULE  "B"** 
 **Form  of  Sub-License**

  * * *

 

 

**SCHEDULE  5.7**

 

 

 

 

 

**_CBS  LICENSE AGREEMENT_**

 

**THIS CBS LICENSE AGREEMENT ** (the " **Agreement** ")  is made and
effective this  day of , 2006 (the " **Effective Date** ").

 

**BETWEEN:**

 

**MDS  INC.** ,

 

 

(hereinafter  referred to as " **MDS** ")

 

-  and -

 

**BOREALIS  INFRASTRUCTURE MANAGEMENT INC.,**

 

(hereinafter  referred to as " **Borealis** ")

 

is as follows:

 

RECITALS:

 

1. Pursuant  to the Asset Purchase Agreement dated  2006 between MDS as vendor and Borealis  as purchaser (the " **Asset Purchase Agreement** ") and the BC  Purchase Agreement (as defined in the Asset Purchase Agreement) MDS has  agreed  to sell and Borealis has agreed to purchase certain of the assets of the  MDS  Diagnostics Division. 

 

2. During  the period of time commencing on the date of the Asset Purchase Agreement  and  continuing until the Closing Date, the Parties have agreed to work together  pursuant to the terms of the Migration Agreement dated  2006 between MDS and  Borealis (the " **Migration Agreement** ") in order to migrate  certain shared aspects of the MDS Diagnostics Division to Borealis as  contemplated therein.

 

3. In  connection with Borealis' operation of the Diagnostics Operations after the  Closing Date, Borealis shall require access to and use of the Licensed  Materials  and MDS has agreed with Borealis that MDS shall license the Licensed Materials  to Borealis on the terms and conditions set out in this Agreement.

 

**NOW THEREFORE** , in  consideration of the foregoing and the respective
covenants set forth herein,  and for other good and valuable consideration
(the receipt and sufficiency  of  which are hereby acknowledged by each
Party), the Parties agree as  follows:

 

**1.0    DEFINITIONS**

 

1.1   **Definitions** : All capitalized  terms used in this Agreement
(including the Recitals hereto) shall have  the  meanings set forth below
(or in the Recitals above).

 

" **CBS** " means MDS' common back  office system solution known internally
by MDS as the "CBS" and used to support  its business operations, including
the MDS Diagnostics Division, prior  to  Closing.

 

" **Claim** " has the meaning set  forth in Section 2.9(a).

 

" **Closing** " has the meaning set  forth in the Asset Purchase Agreement.

 

" **Closing Date** " has the  meaning set forth in the Asset Purchase
Agreement.

 

**" Diagnostics Operations" **has  the meaning set forth in the Migration
Agreement.

 

" **Improvements** " has the  meaning set forth in Section 2.4.

 

" **Licensed Materials** " means  the technology and related materials
described in Schedule A.

 

" **Licensed Rights** " has the  meaning set forth in Section 2.1.

 

**" MDS Diagnostics Division**" has the meaning set  forth in the Asset
Purchase Agreement.

 

" **Migrating Assets** " has the  meaning set forth in the Migration
Agreement.

 

" **notice** " has the meaning set  forth in Section 4.9.

 

" **Party** " means either MDS or  Borealis and " **Parties** " means both of
them.

 

" **Permitted Use** " has the  meaning set forth in Section 2.2.

 

" **Purchased Assets** " means,  collectively, the assets identified as
"Purchased Assets" and "Replacement  Contracts" in the Asset Purchase
Agreement and as "Purchased Assets", "Replacement Contracts" and "Rix Assets"
in the BC Purchase Agreement.

 

" **Transmission** " has the  meaning set forth in Section 4.9.

 

1.2   **Schedules** : The Schedules set out  below are attached to and form
an integral part of this Agreement:

 

Schedule A - Licensed  Materials Description

 

**2.0    LICENSING ****AND  OWNERSHIP**

 

2.1   **Licence** : MDS hereby grants to Borealis  as of the Closing Date a
perpetual (subject to termination pursuant to  Section  3.0), irrevocable,
non-exclusive, royalty free, worldwide and non-transferable  (except as is
permitted under Section 4.6) licence to all of its rights,  inclusive of any
intellectual property rights, in and to the Licensed Materials  for the
Permitted Use (the " **Licensed Rights** ").

 

2.2   **Use of** **Licensed  Materials** :

 

(a)   **Permitted Use** : Pursuant to the Licensed Rights Borealis  may
access, use, copy, reproduce, modify, adapt, change, customize, enhance, 
make derivatives and otherwise use, without limitation or restriction
(subject  to Subsection 2.2(c)), the Licensed Materials as and to the extent
required  by  Borealis to operate and support the conduct of, and the
continued evolution  of,  the Diagnostics Operations. The foregoing rights
as described in this subsection  shall be referred to herein as the "
**Permitted Use** ".

 

(b)   **Third Parties** : For certainty, the Licensed Rights include  the
right of Borealis to: (i) sublicense pursuant to a written agreement  that
is  materially and substantially consistent with the terms and conditions
of  this  Agreement (but otherwise without limitation or restriction), the
access  to and  beneficial use of the Licensed Materials to Borealis'
affiliates (including the  Designated Buyer Affiliates, as defined in the
Asset Purchase Agreement)  and to  such other persons as Borealis determines
is reasonably necessary or required  or  desirable in, and solely for the
purposes of, the conduct, support and  continued  evolution of the
Diagnostics Operations (including, for certainty, the  entity  that operates
and conducts the Diagnostics Operations if different than  Borealis); and
(ii) sublicense pursuant to a written agreement that is  materially and
substantially consistent with the terms and conditions of  this  Agreement,
the access to and use of the Licensed Materials to third party  service
providers solely for the purposes of and to the extent such third  party 
service providers are engaged by a permitted user hereunder to assist in 
the  conduct or support of or the continued evolution of the Diagnostics 
Business.

 

(c)   **Restricted Use and Provision** : For greater certainty, Borealis 
acknowledges and agrees that it shall: (i) access, use, copy, reproduce, 
modify,  adapt, change, customize, enhance and make derivatives of, the
Licensed  Materials, solely for the Permitted Use in accordance with this
Agreement;  and  (ii) not distribute, sell, lease, rent, license, or
otherwise make the  Licensed  Materials available to any person on a for-
profit basis. For certainty,  nothing  in this Agreement shall require MDS
to provide or make available to Borealis  any  employee, contractor, agent
or other representative of MDS or any affiliate  of  MDS. Borealis also
acknowledges and agrees that the license of the Licensed  Materials hereunder
does not obligate MDS to permit Borealis or any authorized  user to access
any computer systems of MDS or any affiliate of MDS.

 

2.3   **Licensed Materials Ownership** : Borealis  acknowledges and agrees
that MDS and its licensors are and shall remain  the sole  and exclusive
owners of all right, title and interest in and to the Licensed  Materials,
including all copyright, trademarks, patents, trade secrets  and all  other
intellectual property or proprietary rights therein.

 

2.4   **Improvements Ownership** : MDS acknowledges and agrees that 
ownership of, and all right, title and interest in and to (including all 
copyright, trademarks, patents, trade secrets and all other intellectual 
property rights therein), any modifications, improvements, adaptations, 
changes,  customizations, enhancements and derivatives to or of the Licensed
Materials  (" **Improvements** ") made by Borealis shall be owned solely
and  exclusively by Borealis.

 

2.5   **Confidential Information** :

 

(a)   The Licensed Materials are the confidential information of MDS.
Borealis  agrees  that it shall take reasonable measures to keep secure and
protect the Licensed  Materials from unauthorized access, disclosure, loss
and theft and to maintain  the confidentiality of all Licensed Materials in
its possession or control,  which measures shall in any event be no less than
the measures it uses  to  maintain the confidentiality of its own
confidential information of similar  importance. Borealis shall not disclose
to any person any of the Licensed  Materials except as expressly permitted in
this Agreement. Borealis may  disclose  the Licensed Materials (or parts
thereof): (i) to the extent required by  compulsion of law, including by
order of a court or other governmental  authority  of competent
jurisdiction, or otherwise as required by applicable law;  (ii) to  its
officers, directors, personnel, professional advisors, third parties  (as
is  permitted under Section 2.2(b) above), provided, however, that prior to 
such  disclosure, Borealis shall inform such persons of the confidential
nature  of the  Licensed Materials and shall be responsible to ensure that
all persons  to whom  it discloses the Licensed Materials comply with the
terms hereof; (iii)  to the  extent, as established by reliable evidence,
that such information is publicly  available when it was received by or
became known to Borealis (including  because  and to the extent it had
previously been disclosed by MDS in the course  of the  conduct of the MDS
Diagnostic Division), or which subsequently entered  the  public domain,
through no fault of or breach of the terms of this Agreement  by  Borealis
(but only after it enters the public domain); (iv) which, as  established by
reliable evidence, is already known to Borealis at the time  of  its
disclosure to Borealis by MDS provided that the receipt of such information 
was not made pursuant to an obligation of confidentiality between MDS and 
Borealis or in contravention of this Agreement or was not made by a person 
in  contravention of an obligation of confidence of any kind that is, or
reasonably  ought to be known, by Borealis.

 

(b)   Borealis agrees that in the event it or any person(s) authorized
hereunder  to  use the Licensed Materials is requested pursuant to, or
required by, applicable  law, regulation or legal process to disclose the
Licensed Materials or  any  portion thereof, it shall notify MDS promptly in
writing so that MDS may  seek a  protective order or other appropriate
remedy. Borealis and such authorized  person(s) shall consent to MDS
obtaining any protective order or other  appropriate remedy that it and/or
its affiliates may seek for the purpose  of  preventing disclosure of any of
the Licensed Materials to the public. In  the event that no such protective
order or other remedy is obtained, Borealis  and such authorized person(s)
shall furnish only that portion of the Licensed  Materials which it is
advised by legal counsel is legally required and  shall  take all
commercially reasonable steps, to the extent permitted by law,  to  remove
from such portion of the Licensed Materials that is required to  be 
disclosed any information that is commercially sensitive to MDS.

 

(c)   Borealis acknowledges that any threatened or actual breach of any of
the  covenants or provisions contained in this Section 2.5 may cause MDS
and/or  its  affiliates to suffer irreparable harm which could not be
adequately compensated  for by damages. In such circumstances, Borealis
agrees that MDS and/or its  affiliates shall be entitled to seek to enforce
the performance of this  Agreement by equitable relief (including injunction
or specific performance)  upon application to a court of competent
jurisdiction. Any such relief or  remedy shall not be exclusive, but shall be
in addition to all other available  legal or equitable remedies. Borealis
agrees that the provisions of this  Section 2.5 are fair and reasonable in
the commercial circumstances of  this  Agreement, and that MDS has relied on
such provisions in entering into  this  Agreement

 

2.6   **Limited Warranty**. MDS warrants to Borealis that it has full  power
and authority to enter into this Agreement, it has all necessary  rights to 
perform its obligations herein and to grant the Licensed Rights and that 
the  execution, delivery and performance of this Agreement are not to any
extent  limited or restricted by, and are not in conflict with, any
obligations,  agreement or instrument to which it is either bound or subject.

 

2.7   **Disclaimer Of Warranties** : OTHER THAN THE LIMITED WARRANTIES 
EXPRESSLY SET OUT IN THIS AGREEMENT, MDS MAKES, AND THERE ARE, NO OTHER 
REPRESENTATIONS, WARRANTIES OR CONDITIONS OF ANY KIND WITH RESPECT TO THE 
LICENSED MATERIALS, WHETHER EXPRESS, IMPLIED, STATUTORY, ARISING OUT OF  A
COURSE  OF DEALING OR USAGE OF TRADE OR OTHERWISE, INCLUDING BUT NOT LIMITED
TO,  ANY  IMPLIED WARRANTIES OR CONDITIONS OF MERCHANTABILITY, FITNESS OR
ADEQUACY  FOR ANY  PARTICULAR PURPOSE.

 

2.8   **No Indirect Damages and Limitation** : NEITHER PARTY SHALL BE 
LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, SPECIAL, PUNITIVE, INCIDENTAL 
OR  CONSEQUENTIAL LOSSES OR DAMAGES ARISING IN ANY MANNER FROM THIS
AGREEMENT  AND  THE PERFORMANCE OR NON-PERFORMANCE OF OBLIGATIONS HEREUNDER,
WHETHER BASED  IN  CONTRACT (INCLUDING FUNDAMENTAL BREACH AND BREACH OF A
FUNDAMENTAL TERM),  TORT  (INCLUDING NEGLIGENCE) OR OTHERWISE, IN LAW OR
EQUITY, EVEN IF IT HAS BEEN  ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. EACH
PARTY'S TOTAL LIABILITY AND  OBLIGATION TO THE OTHER, IN THE AGGREGATE
(INCLUDING CLAIMS MADE UNDER  SECTION  2.9) FOR ANY AND ALL CLAIMS ARISING
OUT OF OR IN ANY CONNECTION WITH THIS  AGREEMENT, WITH RESPECT TO ANY
EXPENSE, DAMAGE, LOSS, INJURY, OR LIABILITY  OF  ANY KIND, REGARDLESS OF THE
FORM OF ACTION OR THEORY OF LIABILITY (INCLUDING  FOR  BREACH OF CONTRACT
(INCLUDING FUNDAMENTAL BREACH AND BREACH OF A FUNDAMENTAL  TERM), TORT
(INCLUDING NEGLIGENCE), BY STATUTE OR OTHERWISE) SHALL NOT  EXCEED  ONE
HUNDRED THOUSAND DOLLARS ($100,000).

 

2.9   **Remedies and Limitation** :

 

(a)  Subject  to Section 2.8, in the event of any claim, suit, action,
threat, allegation  or  proceeding by any third party ("Claim") against
Borealis (and any other  person  authorized hereunder to use the Licensed
Materials) arising out of, or  otherwise  related to the use of the Licensed
Materials (or any part thereof) as and  to the  extent permitted under this
Agreement infringes any patent, trade secret,  confidentiality, copyright or
any other intellectual property rights of  that  person, such Claim shall be
deemed to be a breach by MDS of this Agreement  and  MDS shall indemnify and
hold harmless, and at the option of Borealis, defend  Borealis, its
affiliates and any other person authorized hereunder to use  the  Licensed
Materials and their respective directors, officers and employees  from  any
and all liabilities, damages, losses and expenses (including legal  fees
and  expenses) arising out of such Claim, provided that with respect to
such  Claim:  (i) the indemnity conditions described in Section 2.9(c) below
are complied  with; and (ii) the infringement does not result from any
Improvements made  by  Borealis (or on its behalf by a third party), or the
use or operation of  the  Licensed Materials in combination with any
Improvements, or other software,  products, data, apparatus or equipment.

 

(b)  Subject  to Section 2.8, in the event of any Claim against MDS arising
out of, or  otherwise related to, any allegation that the use of the
Improvements (or  any  part thereof) by Borealis (or any other person
authorized hereunder to  use the  Licensed Materials) infringes any patent,
trade secret, confidentiality,  copyright or any other intellectual property
rights of that person, Borealis  shall indemnify and hold harmless, and at
the option of MDS defend, MDS  and its  affiliates and their respective
directors, officers and employees from  any and  all liabilities, damages,
losses and expenses (including legal fees and  expenses) arising out of such
Claim, provided that with respect to such  Claim  the indemnity
preconditions described in Section 2.9(c) below are complied  with.

 

(c)  To  receive the indemnities contained in this Section 2.9, each Party
seeking  indemnification shall provide: (i) prompt written notice of the
Claim to  the  indemnifying Party; (ii) all reasonable information and
assistance which  the  indemnifying Party may reasonably require to defend
the Claim; and (iii)  the  other party with sole control of the defence of
the Claim, and all negotiations  for its settlement or compromise, provided
that neither Party may settle  any  Claim without the prior written consent
of the other Party which consent  will  not be unreasonably withheld or
delayed; and provided further that the  failure  to give such notice,
information and assistance or to provide such control shall  not relieve the
indemnifying Party of its indemnification obligations pursuant  to this
Section except to the extent that the indemnifying Party was actually 
prejudiced by such failure.

 

**3.0    TERMINATION**

 

3.1   **Termination** : MDS acknowledges and confirms that the use  by
Borealis of the Licensed Materials is required for the ongoing operation 
of  the Diagnostics Operations and therefore, after Closing, this Agreement 
(including the license granted hereunder) may only be terminated as follows: 
(a) upon mutual agreement of the Parties set out in writing; and  (b) by
Borealis at any time on notice to MDS. MDS agrees that the foregoing 
limitation is fair and reasonable in the commercial circumstances of this 
Agreement, the Asset Purchase Agreement and the BC Purchase Agreement and 
agrees  not to assert any right to, and hereby waives to the maximum extent
permitted  by  law, its right to terminate this Agreement inclusive of any
Licensed Rights.  For  certainty, if this Agreement is terminated pursuant
to this Section 3.1  the  Licensed Rights shall terminate.

 

**4.0    GENERAL**

 

4.1   **Governing Law and Jurisdiction** : This  Agreement shall be subject
to and governed by the laws of the province  of  Ontario, and the laws of
Canada applicable therein without regard to the  conflicts of law principles
of such province. The Parties irrevocably attorn  and  submit to the non-
exclusive jurisdiction of the courts of the Province  of  Ontario. The
Parties expressly exclude the application of the United Nations  Convention
on Contracts for the International Sale of Goods.

 

4.2   **Waiver** : No waiver of any provision  of  this Agreement shall be
implied, and no waiver shall be valid unless it  is in  writing and signed
by the Party waiving its rights. No waiver of any  breach of any of the
terms, provisions or conditions of this Agreement  shall be  construed as or
held to be a waiver of any other breach, or a waiver of,  acquiescence in, or
consent to, any further or succeeding breach  hereof.

 

4.3   **Entire Agreement** : This Agreement  constitutes the entire
agreement between the Parties and contains all agreements  between the
Parties with respect to the subject matter hereof. All  Schedules attached
hereto are incorporated herein by reference. This  Agreement supersedes any
and all other agreements, negotiations, discussions  and  understandings,
either oral or written, between the Parties with respect  to the  subject
matter hereof.

 

4.4   **Amendment** : No modification or amendment of this Agreement will 
be binding upon either Party unless in writing, expressly referencing this 
Agreement and duly executed by each Party.

 

4.5   **Severability** : If any provision of  this Agreement shall be
determined by an arbitrator or any court of competent  jurisdiction to be
illegal, invalid or unenforceable, that provision shall  be  severed from
this Agreement to the extent of its illegality, invalidity  or 
unenforceability and the remaining provisions of this Agreement shall
continue  in full force and effect.

 

4.6   **Assignment** : This Agreement shall  be binding upon and shall enure
to the benefit of and be enforceable by  each of  the Parties, their
respective successors and permitted assigns. Neither  Party  may assign this
Agreement without the prior written consent of the other  (not to  be
unreasonably withheld) except as is expressly permitted under this Section. 
MDS may assign this Agreement without the consent of Borealis to an
affiliate.  Borealis may assign this Agreement without the consent of MDS to
an entity  that  operates and conducts any part of the Diagnostics
Operations if different  than  Borealis. Either Party may assign this
Agreement without the consent of  the  other Party to a person that
purchases or acquires all or substantially  all of  that Party's assets or
the business or portion of the business to which the  Licensed Material
relates (which in the case of Borealis is the Diagnostic  Operations). Any
assignment permitted pursuant to this Section 4.6 shall  as a  condition of
assignment require: (a) the assignee or transferee agrees in  writing with
the non-assigning Party to be bound by all the terms and conditions  of this
Agreement; and (b) the assigning Party provides prior notice of the 
assignment to the other Party.

 

4.7   **Counterparts** : This Agreement may be executed in any  number of
counterparts. Each executed counterpart shall be deemed to be an  original.
All executed counterparts taken together shall constitute one  agreement. To
evidence the fact that it has executed this Agreement, a  Party may  send a
copy of its executed counterpart to the other Party by Transmission.  In 
such event, such Party shall forthwith deliver to the other Party the 
counterpart of this Agreement executed by such Party.

 

4.8   **Covenant of Further Assurances** :  MDS agrees that it shall, 
without further consideration, do or cause to be done  all such further acts
and things as may be reasonably necessary or desirable  to  give full effect
to this Agreement.

 

4.9   **Notice** : Any notice, demand or other communication (in this 
Section, a " **notice** ") required or permitted to be given or made 
hereunder shall be in writing and shall be sufficiently given or made if: 
(a) delivered in person during normal business hours of the recipient on a 
business day and left with a receptionist or other responsible employee  of
the  recipient at the applicable address set forth below; or (b) sent by 
facsimile transmission (" **Transmission** ") during normal business  hours
on a business day;

 

in the case of a notice to MDS, addressed  to  it at:

 

MDS Inc.

 

100 International Blvd.

 

Toronto, ON M9W 6J6

 

Attention:  Executive Vice-President, Corporate  Development and General
Counsel

 

Fax No.:    (416) 213-4222

 

 

and in the case of a notice to Borealis, addressed  to  it at:

 

 

200 Bay Street

 

P.O. Box 56

 

Suite 2100

 

Royal Bank Plaza,  South  Tower

 

Toronto, ON M5J  2J2

 

Attention:   Michael J. Rolland,  Senior Vice President

 

Fax No.:    (416) 361-6075

 

 

Each notice sent in accordance  with this  Section shall be deemed to have
been received: (i) on the day it was  delivered in person as aforesaid; (ii)
on the same day that it was sent by  Transmission or on the first (1st)
business day thereafter if the day on  which  it was sent by Transmission
was not a business day or if it was sent after  normal business hours on a
business day. Any Party may change its address  for  notice by giving notice
to the other Party.

 

 

4.10   **Survival** : The obligations and covenants of the  Parties
described in Articles 1, 2 (except Sections 2.1 and 2.2), and 4  and 
Section 3.2 shall survive the termination of this Agreement for any reason 
whatsoever.

 

 

 

 

** IN  WITNESS WHEREOF**, the Parties have executed  this Agreement as of
the Effective Date.

        

**MDS  INC.**

    
--- 
     

By:

    |  

    
     

    |  

Name: 
Title:

    
     

 

**BOREALIS  INFRASTRUCTURE MANAGEMENT INC.**

    
     

By:

    |  

    
     

    |  

Name:  
Title: 

    
    

 


 

 


 

SCHEDULE A 

 _LICENSED MATERIALS DESCRIPTION_

 

 

" **Licensed Materials** " means  all technology, information, materials,
data, components and elements (whether  in written, graphic, electronic,
machine-readable or any other form or medium  whatsoever)forming part of, or
included in, the CBS that are proprietary  to MDS  or an affiliate of MDS
and reasonably necessary and required to replicate  the  CBS and to operate,
support and maintain the CBS and that are used by MDS  in  connection with
the operation of the MDS Diagnostics Division immediately  prior  to the
Closing Date, but that are not included in the Purchased Assets or  the 
Migrating Assets, and including without limitation:

 

(i)  all software code  (in both object code and source code forms and
containing no  passwords or other devices that would prevent, obstruct,
limit, restrict  or  prohibit the use of the software code) including
application programming  interfaces (APIs), graphic user interfaces (GUI's)
and screen designs (including  so-called "look and feel" attributes), and
other interfaces;

 

(ii)  system design attributes,  methods, file layouts, structures, work
flow,  specifications and requirements, order of operations, methodologies,
routines,  designs, data, trade secrets, processes, procedures, systems,
templates,  formulae, algorithms, inventions, drawings, diagrams, studies,
work in progress,  ideas and concepts;

 

(iii)  existing documentation,  including technical and functional
descriptions and  information, any available general flow-charts, field
descriptions, any existing  programmers' commentary and instructions,
programmer specifications, notes  (technical or otherwise), manuals, reports,
reference guides, explanations,  annotations and other documentation; and

 

(iv)  the whole of the  ideas, concepts, know-how and techniques contained
in any of  the foregoing. * * *

 

 

 

 

 

**S** **chedule** **  5.8**

 

**M** **DS  INC.**

 

 

**-  AND -**

 

 

**BOREALIS  INFRASTRUCTURE MANAGEMENT INC.**

 

 

        

**NON-COMPETITION  AND NON-SOLICITATION  AGREEMENT 

**

    
--- 
    

**Dated  this <*> day of <*>, 2006**

 

**Prepared  by:**

 

![](fasken.jpg)

 

Fasken  Martineau DuMoulin LLP

 

Toronto,  Ontario

 

 

 


 

 

**Article 1.........  INTERPRETATION**

 

1.1..........  Definitions

 

1.2.......... Headings,  etc.

 

1.3.......... Plurality  and  Gender

 

1.4.......... Including,  etc.

 

1.5..........  Construction

 

1.6..........  Severability

 

1.7.......... Time  of the  Essence

 

**Article 2.........  NON-COMPETITION AND  NON-SOLICITATION**

 

2.1..........  Recitals

 

2.2..........  Non-Compete

 

2.3.......... Exclusions  from Field

 

2.4..........  Non-Solicitation by MDS and Affiliates

 

2.5.......... MDS  Acknowledgement

 

2.6..........  Non-Solicitation by Buyer and Affiliates

 

2.7.......... Buyer  Acknowledgement

 

2.8.......... Accounting  for  Profits

 

2.9.......... Other  Remedies

 

2.10........ Effective  Time

 

**Article 3.........  EXCEPTIONS**

 

3.1.......... Exceptions  for  MDS and Affiliates

 

3.2.......... Exceptions  for  Buyer Entities

 

**Article 4.........  MISCELLANEOUS**

 

4.1..........  Notices

 

4.2.......... Waiver  of  Rights

 

4.3..........  Amendments

 

4.4.......... Governing  Law

 

4.5.......... Entire  Agreement

 

4.6.......... Successors  and  Assigns

 

4.7..........  Counterparts

 

4.8.......... Facsimile  Execution

 


 

**NON-COMPETITION  AND NON-SOLICITATION  AGREEMENT**

 

 

** This  Non-Competition and  Non-Solicitation Agreement** (" **Agreement**
") is made and  entered into as of <*>, 2006, by and between MDS Inc., a
corporation  incorporated under the laws of Canada (" **MDS** ") and
Borealis  Infrastructure Management Inc., a corporation incorporated under
the laws  of  Canada (" **Buyer** ").

 

 

**RECITALS:**

 

**A.**   MDS and Buyer have entered into the Ontario Purchase Agreement and
the  BC  Purchase Agreement (collectively, the " **Purchase Agreements**
")  pursuant to which, among other things, Buyer is purchasing from MDS and 
the  other Sellers the Purchased Assets on the terms and subject to the
conditions  set forth in the Purchase Agreements.

 

**B.   **MDS will derive economic benefits from the transactions
contemplated  in  the Purchase Agreements.

 

**C.   **So that Buyer may realize the full value associated with its
purchase  of the Purchased Assets pursuant to the Purchase Agreements, MDS
has agreed  that  it will refrain from competing with Buyer, with respect to
the Canadian  Diagnostics Business, all in accordance with the terms of
this  Agreement.

 

**D.   **MDS has voluntarily entered into this Agreement and agrees that 
the  limitations and restrictions set out in this Agreement are reasonable
and  not  oppressive and are intended to protect Buyer's substantial
investment and  legitimate business interests with respect to the Canadian
Diagnostics  Business.

 

**E.**   Buyer has voluntarily entered into this Agreement and agrees that
the  limitations and restrictions set out in this Agreement are reasonable
and  not  oppressive and are intended to protect MDS' substantial investment
and  legitimate business interests with respect to its businesses.

 

**F.   **Buyer has advised MDS that it would not have acquired the
Purchased  Assets and would not have entered into the other transactions and
agreements  contemplated by the Asset Purchase Agreement without a commitment
by MDS  to  execute and deliver this Agreement.

 

**G.**   It is a condition of Closing under the Ontario Purchase Agreement
that  the  Parties enter into this Agreement on the Closing Date.

 

** IN  CONSIDERATION** of the premises, the respective covenants and
agreements  contained herein and of other consideration (the receipt and
sufficiency  of  which are hereby acknowledged by each Party) the Parties
agree as  follows:

 

**Article 1** 
 **INTERPRETATION**

 

**1.1 Definitions**

 

As used in this Agreement,  unless  the context otherwise requires
capitalized terms not expressly defined  in this  Agreement shall have the
meanings ascribed thereto in the Ontario Purchase  Agreement, and the
following terms shall have the following  meanings;

 

(a)   " **Affiliate** " means, with respect to any Person,

 

(i)  any  other Person who  directly or indirectly controls, is controlled
by, or is under direct or  indirect common control with, such Person; or

 

(ii)  any  other Person that  directly or indirectly owns all of the
participating equity of such Person  or  for which all of the participating
equity is directly or indirectly owned  by  such Person; and

 

a  Person shall be deemed to "control" a Person if such Person possesses 
directly or indirectly the power to direct or cause the direction of the 
management and policies of such Person, whether through the ownership of 
voting  securities, by contract or otherwise, and "controlled" shall have a
similar  meaning;

 

(b)   " **Agreement** " has the meaning ascribed thereto in the  recitals;

 

(c)  " **Autolabs  Business** " means the business carried on by MDS and its
Affiliates  relating to the hardware system and related software known as APX
(AutoLab  Process eXpert) that provides specimen management, storage, results
and  instrument interfacing capabilities at testing locations, consisting
of  the  licensing, maintenance and support of such system;

 

(d)  " **BC  Purchase  Agreement** " means the asset purchase agreement
dated <*>, 2006  between MDS, Mether Properties Limited Partnership and
Buyer;

 

(e)   " **Business** **Day** " means a day other than Saturday  or Sunday,
on which Canadian chartered banks are open for the transaction  of  domestic
business in the City of Toronto;

 

(f)  " **Buyer  Entity** " has the meaning ascribed thereto in Section 2.6;

 

(g)  " **Canadian  Diagnostics** **Business** " means the specimen
collection and  diagnostic services businesses carried on in Canada, prior to
the date  hereof,  by MDS, the Operators, BC Operators and the Non-
Controlled Operators (as  defined  in both Purchase Agreements) and after
Closing by Buyer, Buyer Entities  and  their Affiliates, consisting of the
provision of clinical laboratory testing  for  physicians, hospitals, non-
hospital health care institutions, employees  or  insurance companies,
management of hospital laboratories and other support  services for clinical
diagnostics and the AutoLabs Business;

 

(h)  " **Capacity** "  has the meaning ascribed thereto in Section 2.2;

 

(i)   " **Employees** " means, collectively, "Employees" as defined in the 
BC Purchase Agreement and "Employees" as defined in the Ontario Purchase 
Agreement;

 

(j)   " **Field** " means the collection, testing, monitoring and/or 
reporting of test results of bodily, cytological and other specimens from 
a  patient at the request of any other Person, including a patient, health 
care  professional, employer or insurance company;

 

(k)  " **Infringing  Business** " has the meaning ascribed thereto in
Section 3.1(a)(ii)  hereof;

 

(l)  " **MDS  Employee** " has the meaning ascribed thereto in Section 2.6;

 

(m)  " **notice** " has  the  meaning ascribed thereto in Section 4.1
hereof;

 

(n)  " **Ontario  Purchase  Agreement** " means the asset purchase
agreement dated <*>, 2006  between MDS and Buyer;

 

(o)  " **Phase  IV  Trials** " means post-marketing studies to delineate
additional  information including a drug's risks, benefits and optimal use;

 

(p)  " **Purchase  Agreements** " has the meaning ascribed to it in the 
recitals;

 

(q)  " **Purchased  Assets** " means, collectively, the "Purchased Assets"
and "Regional  Assets" as defined in the BC Purchase Agreement (but, for
greater certainty,  excluding any Regional Asset that is an Excluded Asset as
defined in the  BC  Purchase Agreement) and the "Purchased Assets" and
"Regional Assets" as defined  in the Ontario Purchase Agreement (but, for
greater certainty, excluding  any  Regional Asset that is an Excluded Asset
as defined in the Ontario Purchase  Agreement);

 

(r)  " **Regional  Asset** " means "Regional Assets" as defined in each of
the Purchase  Agreements;

 

(s)   " **Territory** " means Canada;

 

(t)  " **Transferred  Employee** " means any Employee or any employee of
MDS, in each case, who  becomes an employee of Buyer, a Buyer Entity or their
Affiliates on Closing  in  accordance with the Purchase Agreements or after
Closing in accordance  with and  as contemplated by the Parties in
connection with a Migration Project (as  defined in the Migration Agreement);
and

 

(u)   " **Transmission** " has the meaning ascribed thereto in Section 
4.1(b) hereof.

 

**1.2   Headings, etc.**

 

The  division of this Agreement into  articles, sections, subsections and
schedules and the insertion of headings  are  for convenience of reference
only and shall not affect the construction  or  interpretation of this
Agreement. The article, section, subsection and  schedule headings in this
Agreement are not intended to be full or precise  descriptions of the text to
which they refer and are not to be considered  part  of this Agreement. All
uses of the words "hereto", "herein", "hereof", "hereby" and "hereunder" and
similar expressions refer to this Agreement and not  to any particular
section or portion of it. References to an Article,  Section, Subsection or
Schedule refer to the applicable article, section,  subsection or schedule of
this Agreement.

 

**1.3   Plurality and Gender**

 

In this Agreement, words  in the  singular include the plural and vice-versa
and words in one gender include  all  genders.

 

**1.4   Including, etc.**

 

Reference in this Agreement  to  the term "including" shall mean "including
without limitation" and shall not be  construed to limit any general
statement which it follows to the specific  or  similar items or matters
immediately following it.

 

**1.5   Construction**

 

This Agreement is the  joint  product of MDS and Buyer, has been subject to
mutual consultation, negotiation  and agreement of the Parties and shall not
be construed for or against  any  Party.

 

**1.6   Severability**

 

If any provision of this  Agreement is determined by a court of competent
jurisdiction to be invalid,  illegal or unenforceable in any respect, such
determination shall not impair  or  affect the validity, legality or
enforceability of the remaining provisions  hereof, and each provision is
hereby declared to be separate, severable  and  distinct.

 

**1.7   Time of the Essence**

 

Time shall be of the essence  of  this Agreement and each provision hereof.

 

**Article 2** 
 **NON-COMPETITION  AND NON-SOLICITATION**

 

**2.1   Recitals**

 

Buyer and MDS represent  and  warrant to each other that the recitals set
forth above are true in substance  and in fact and that the purpose of this
Agreement is to protect the legitimate  business interests of Buyer and of
MDS, as applicable, by providing, _inter  alia_ , for the broadest scope, the
longest duration and the widest territory  permitted by law.

 

**2.2   Non-Compete**

 

MDS agrees that, for a  period of  five (5) years after the Closing neither
MDS nor any of its Affiliates  shall, on  their own behalf or on behalf of,
or together with, any Person, directly  or  indirectly, and whether as an
owner, operator, manager, employer, principal,  agent, joint venturer,
partner, shareholder or other equity holder, investor,  independent
contractor, licensor, licensee, franchisor, franchisee, distributor, 
consultant, supplier, lender, guarantor, financier, promoter, trustee or  in
any  other similar capacity whatsoever (collectively, a " **Capacity** "), 
carry on, be engaged in, or have any financial interest in any business  in
the  Field in the Territory.

 

**2.3   Exclusions from Field**

 

Buyer acknowledges that  the Field  does not include (i) central laboratory
testing (including bioanalytical  testing) and/or clinical diagnostic testing
(including bioanalytical testing)  conducted in each case as part of a
clinical trial undertaken by MDS or  its  Affiliates on behalf of itself
and/or its Affiliates and/or on behalf of  third  parties (including the use
of immune response monitoring services and central  laboratory esoteric
testing (including pharmacogenomic tests)) and all  other  research
activities (beyond clinical trials) that could be related to any  previously
collected biological fluids or specimen (e.g. tissue) such as  extended Phase
IV Trials, newly available validation using diagnostic tests  or 
personalized medicine approaches and all physiological testing (including, 
but  not restricted to, biological samples, genetic analysis, imaging
technologies  and conventional vital indicators) associated with preclinical,
clinical  and  post-market surveillance studies for pharmaceutical and
medical device  products;  (ii) molecular imaging services or collaborations
with Centres of Excellence  in  which a patient may be imaged in whole or
part using a variety of techniques  such as MR, CT, PET, ultrasound and
optical and related point-of-care clinical  diagnostic testing based on
bodily or cytological specimens such as P450  testing, contrast agent
interactions and overall patient responses to  treatments; or (iii) the
development, commercialization and support of  clinical  diagnostic tests
associated with mass spectrometry or cellular analysis  or a  clinical
diagnostics service using mass spectrometry or cellular analysis  tools. 

 

**2.4   Non-Solicitation** **by MDS and  Affiliates**

 

MDS  acknowledges that the Transferred Employees are a key component of
carrying  on  the Canadian Diagnostics Business and therefore agrees to the
covenant  in this  Section 2.4. Accordingly, MDS agrees that, for a period
of three (3) years  after the Closing, neither MDS nor any of its Affiliates
shall, on their  own  behalf or on behalf of, or together with, any Person,
directly or indirectly,  solicit, employ, or offer employment to, any
Transferred  Employee.

 

**2.5   MDS Acknowledgement**

 

MDS: (i) acknowledges  and agrees  that it has carefully considered with the
assistance of its counsel the  nature  and extent of the restrictive
covenants set forth in this Agreement; (ii)  acknowledges and agrees that the
provisions of Sections 2.2 and 2.4 are  reasonable and necessary to protect
and preserve Buyer's interests in and right  to use the Purchased Assets and
the operation of the Canadian Diagnostics  Business (as such business is
carried on as of the date hereof) from and  after  Closing; (iii)
irrevocably waives (and agrees not to raise) as a defence  any  issue of
reasonableness (including the reasonableness of the Territory  or the 
duration and scope of this Agreement) in any proceeding to enforce the 
provisions of Sections 2.2 and 2.4; (iv) acknowledges and agrees that Buyer 
may  suffer irreparable harm if MDS or its Affiliates breach any of their
obligations  set out in Sections 2.2 and 2.4; and (v) acknowledges and agrees
that monetary  damages may not be a sufficient remedy for a breach by MDS or
its Affiliates  of  the provisions of Sections 2.2 and 2.4. Accordingly, in
the event of a  breach or threatened breach by MDS or any of its Affiliates
of any of the  provisions of Sections 2.2 and 2.4, in addition to any remedy
provided  for at  law or in equity, Buyer shall be entitled to seek
equitable relief, including  an  interim injunction, interlocutory
injunction and permanent injunction or  specific performance or both.

 

**2.6   Non-Solicitation by Buyer and Affiliates**

 

Buyer acknowledges that  the  employees of MDS and its Affiliates other than
those who from and after  the date  of this Agreement become employees of
Buyer (in accordance with the Purchase  Agreements or after Closing in
accordance with and as contemplated by the  Parties in connection with a
Migration Project (as defined in the Migration  Agreement)) (" **MDS
Employees** ") are a key component of carrying  on MDS' businesses and
therefore agrees to the covenant in this Section  2.6. Accordingly, Buyer
agrees that, for a period of three (3) years after  the Closing, none of
Buyer, any Designated Buyer Affiliate (as defined  in and  pursuant to the
Purchase Agreements), any BC Operator (as defined in the  Ontario  Purchase
Agreement) excluding Metro GP, Mether LP and Mether GP (as each  is  defined
in the BC Purchase Agreement) or any of their respective Affiliates  (other
than one which is an Affiliate of OMERS Administration Corporation  and  not
a Designated Buyer Affiliate or BC Operator) (each a " **Buyer  Entity** ")
shall, on their own behalf or on behalf of, or together with,  any Person,
directly or indirectly, solicit, employ, or offer employment  to any  MDS
Employee. For avoidance of doubt, this Agreement does not apply in  respect
of OMERS Administration Corporation or any of its Affiliates that  is not  a
Buyer Entity. However, Buyer shall not and shall cause the other Buyer 
Entities not to encourage, assist or facilitate the solicitation or hiring 
of  any MDS Employees by OMERS Administration Corporation or any of its
Affiliates  that is not a Buyer Entity including by disclosing any
information about  any MDS  Employee.

 

**2.7   Buyer Acknowledgement**

 

Buyer acknowledges and  agrees  that: (i) it has carefully considered with
the assistance of its counsel  the  nature and extent of the restrictive
covenant set forth in Section 2.6;  (ii) the provisions of Section 2.6 are
reasonable and necessary to protect  and preserve MDS' interests in and right
to carry on its business from and after  Closing; (iii) MDS may suffer
irreparable harm if Buyer or its Affiliates  breach  any of their
obligations set out in Section 2.6; and (iv) monetary damages  may  not be a
sufficient remedy for a breach by Buyer or its Affiliates of the  provisions
of Section 2.6. Accordingly, in the event of a breach or  threatened breach
by Buyer or any of its Affiliates of any of the provisions  of  Section 2.6,
in addition to any remedy provided for at law or in equity,  MDS  shall be
entitled to seek equitable relief, including an interim injunction, 
interlocutory injunction and permanent injunction or specific performance 
or  both.

 

**2.8   Accounting for Profits**

 

If either Party or its  Affiliates  breaches any of its obligations as set
out in this Agreement the other  Party  shall be entitled to seek an
accounting and repayment of any and all profits,  compensation, royalties,
commissions, remunerations or benefits which the  breaching Party or its
Affiliates, directly or indirectly, shall have realized  or may realize as a
result of, arising out of, or in connection with, any  such  breach.

 

**2.9   Other Remedies**

 

The rights of each Party  hereunder shall be in addition to any and all other
remedies available  to it and  shall not be construed to prevent it from
pursuing, either consecutively  or  concurrently, any and all other legal or
equitable remedies available to  it  including the recovery of monetary
damages.

 

**2.10   Effective Time**

 

Notwithstanding anything  in this  Agreement, the terms and provisions
hereof shall take effect from the date  hereof in relation to activities or
transactions undertaken by the parties  in  the province of Ontario and from
the next day in relation to activities  or  transactions undertaken by the
parties in the rest of Canada.

 

**Article 3** 
 **EXCEPTIONS**

 

**3.1   Exceptions for MDS and Affiliates**

 

(a)  Notwithstanding  anything  herein contained, the covenants set forth
in Sections 2.2 and 2.4 shall  not be  construed so as to:

 

(i)  prohibit  MDS or any  Affiliate of MDS from owning shares or other
securities of any Persons  engaged  in any business in the Field in the
Territory which are listed on a nationally  recognized stock exchange or on
NASDAQ, provided that MDS and its Affiliates,  in  the aggregate, do not
hold more than five percent (5%) of the outstanding  shares  or other
securities of such Persons; or

 

(ii)   restrict, limit or preclude MDS and its Affiliates from (A) carrying
on  (x) its Pharma Services business (including the central laboratory 
operations, the drug development and regulatory services business and the 
bioanalytical operations of its Pharma Services business), its Nordion 
business  and its Sciex business, in each case as such business is currently
carried  on  or, provided such business is not conducted in a manner which
is competitive  with the Canadian Diagnostics Business (as such business is
carried on  as of the  date hereof), as such business may be carried on in
the future, or (y)  any other  businesses that are not within the Field,
including, in the case of both  (x) and  (y), acting as a supplier to any
Person carrying on business in the Field;  (B)  in any Capacity, holding or
acquiring any financial interest in any Person  or  acquiring more than
fifty percent (50%) of the shares or other securities  of a  Person (twenty
percent (20%) in the event that the Person is a public entity)  in  each
case where such Person carries on a business within the Field in the 
Territory (an " **Infringing Business** "), provided that the  Infringing
Business is a minor and incidental part of its business; (C)  soliciting or
hiring any Transferred Employees after they have ceased to  be  employees of
Buyer, a Buyer Entity or their Affiliates; (D) hiring of any  Transferred
Employee who responds to employment advertisements of a general  nature not
targeted to Transferred Employees; (E) hiring of any Transferred  Employee
who initiates discussions regarding such employment with MDS or  an 
Affiliate, without any direct or indirect solicitation or inducement by  MDS
or  any Affiliate; or (F) any solicitation by an independent third party 
employment agency retained by MDS or an Affiliate that independently (and 
with  no direct or indirect guidance or direction from MDS or an Affiliate)
determines  to solicit a Transferred Employee.

 

(b)  Notwithstanding  anything  herein contained, this Agreement shall not
apply to MDS or any Person designated  by MDS to the extent that MDS or any
such Person holds a Non-Assignable  Contract  on or after the date hereof as
contemplated by and in accordance with the  applicable Purchase Agreement nor
shall this Agreement apply to any transferee  of a Non-Assignable Contract or
to the extent that such Non-Assignable  Contract  becomes an Excluded Asset
under the applicable Purchase Agreement.

 

(c)  Notwithstanding  anything  herein contained, this Agreement shall not
apply to MDS or any Person designated  by MDS to the extent that MDS or any
such Person holds a Regional Asset  on or  after the date hereof as
contemplated by and in accordance with the applicable  Purchase Agreement nor
shall this Agreement apply to any transferee of  a  Regional Asset to the
extent that such Regional Asset becomes an Excluded  Asset  under the
applicable Purchase Agreement, provided in all cases MDS: (i) is  only a
passive investor in any such Regional Asset holding no more than  the 
equity or voting interests in such Regional Asset that is currently held  by
MDS  or any of its Affiliates; (ii) uses its commercially reasonable efforts
to  obtain the consent or approval of other holders of equity or voting
interests  in  the Regional Asset to the sale of such Regional Assets to the
Buyer or  a  Designated Buyer Affiliate or, if such efforts are not
successful, seeks  to sell  its interests in any such Regional Assets in an
orderly manner; provided  that  nothing herein shall require MDS to sell a
Regional Asset at a price that  is  less than fair value.

 

**3.2   Exceptions for Buyer Entities**

 

Notwithstanding anything  herein  contained, the covenants set forth in
Section 2.6 shall not be construed  so as  to restrict, limit or preclude
Buyer or any other Buyer Entity from  (i) soliciting or hiring any MDS
Employee after they have ceased to be  employees of MDS or its Affiliates;
(ii) hiring of any MDS Employee who  responds  to employment advertisements
of a general nature not targeted to MDS Employees;  (iii) hiring of any MDS
Employee who initiates discussions regarding such  employment with a Buyer
Entity, without any direct or indirect solicitation  or  inducement by any
Buyer Entity; (iv) any solicitation by an independent  third  party
employment agency retained by a Buyer Entity that independently (and  with 
no direct or indirect guidance or direction from a Buyer Entity) determines 
to  solicit an MDS Employee; or (v) the hiring of any Employee or MDS
Employee  in  accordance with the terms of a Purchase Agreement or in
accordance with  and as  contemplated by the Parties in connection with a
Migration Project (as  defined  in the Migration Agreement).

 

**Article 4** 
 **MISCELLANEOUS**

 

**4.1   Notices**

 

Any notice, demand or  other  communication (in this Section, a " **notice**
") required or  permitted to be given or made hereunder shall be in writing
and shall be  sufficiently given or made if:

 

(a)  delivered  in person during  normal business hours of the recipient on
a Business Day and left with  a  receptionist or other responsible employee
of the recipient at the applicable  address set forth below; or

 

(b)   sent by any electronic means of sending messages, including facsimile 
transmission (excluding e-mail), which produces a paper record  ("
**Transmission** ") during normal business hours on a Business  Day;

 

in the case of a  notice to  MDS, addressed to it at:

 

MDS Inc. 
100  International Blvd. 
Toronto, Ontario 
M9W 6J6

 

Attention:  Executive  Vice-President,  
 Corporate Development and General Counsel 
Fax No.:   (416) 213-4222

 

with  a copy to (which shall not constitute notice):

 

Fasken Martineau  DuMoulin  LLP 
66 Wellington Street West 
Suite 4200, Toronto Dominion Bank  Tower 
Box 20, Toronto-Dominion Centre 
Toronto, Ontario 
M5K  1N6

 

Attention:   Scott  Conover 
Fax No.:   (416) 364-7813

 

and in the case of  a notice  to Buyer, addressed to it at:

 

200 Bay Street 
P.O. Box  56 
Suite 2100 
Royal Bank Plaza, South Tower 
Toronto, Ontario 
M5J  2J2

 

Attention:  President and Chief  Executive  Officer 
Fax No.: (416)  361-6075

 

with a copy to (which  shall  not constitute notice):

 

200 Bay Street 
P.O. Box  84 
Suite 3800 
Royal Bank Plaza, South Tower 
Toronto, Ontario 
M5J  2Z4

 

Attention: Jacques  Demers 
Fax No.:  (416) 216-3930

 

Each notice sent in accordance  with this Section shall be deemed to have
been received:

 

(i)  on  the day it was  delivered in person as aforesaid;

 

(ii)  on  the same day that it  was sent by Transmission, or on the first
Business Day thereafter if the  day on  which it was sent by Transmission
was not a Business Day or if it was sent  after  normal business hours on a
Business Day.

 

Either Party may change  its  address for notice by giving notice to the
other Party.

 

**4.2   Waiver of Rights**

 

Any waiver of, or consent  to  depart from, the requirements of any
provision of this Agreement shall  be  effective only if it is in writing
and signed by the Party giving it, and  only  in the specific instance and
for the specific purpose for which it has  been  given. No failure on the
part of any Party to exercise, and no delay in  exercising, any right under
this Agreement shall operate as a waiver of  such  right. No single or
partial exercise of any such right shall preclude any  other or further
exercise of such right or the exercise of any other  right. No failure on the
part of either party to exercise, and no delay in  exercising any right under
this Agreement shall operate as a waiver of  such  right; nor shall any
single or partial exercise of any such right preclude  any  other or further
exercise of such right or the exercise of any other  right.

 

**4.3   Amendments**

 

This Agreement may only  be  amended or otherwise modified by written
agreement executed by Buyer and  MDS.

 

**4.4   Governing Law**

 

This Agreement shall be  governed  by, and interpreted and enforced in
accordance with, the laws in force  in the  Province of Ontario and the
federal laws of Canada applicable therein.  Each Party irrevocably submits to
the non-exclusive jurisdiction of the  courts  of Ontario with respect to
any matter arising hereunder or related  hereto.

 

**4.5   Entire Agreement**

 

This Agreement and the  Purchase  Agreements constitute the entire agreement
between the Parties pertaining  to the  subject matter hereof and supersede
all prior agreements, negotiations,  discussions and understandings, written
or oral, between the Parties.  There are no representations, warranties,
conditions, other agreements  or  acknowledgements, whether direct or
collateral, express or implied, that  form  part of or affect this
Agreement, or which induced either Party to enter  into  this Agreement or
on which reliance is placed by either Party, except as  specifically set
forth in this Agreement and the Purchase  Agreements.

 

**4.6   Successors and Assigns**

 

This Agreement shall be  binding  upon and enure to the benefit of the
Parties and their respective successors  and  permitted assigns. This
Agreement shall not be assignable by MDS or Buyer,  other than in the same
manner assignment is permitted under Section 10.4  of the  Ontario Purchase
Agreement (and for such purposes, the term "Affiliate" shall  include an
Affiliate of OMERS Administration Corporation).

 

**4.7   Counterparts**

 

This Agreement may be  executed in  any number of counterparts. Each
executed counterpart shall be deemed to  be an original. All executed
counterparts taken together shall constitute  one agreement.

 

**4.8   Facsimile Execution**

 

To evidence the fact that  it has  executed this Agreement, a Party may send
a copy of its executed counterpart  to  the other Party by Transmission.
That Party shall be deemed to have  executed this Agreement on the date it
sent such Transmission. In such  event, such Party shall forthwith deliver to
the other Party the counterpart  of  this Agreement executed by such Party.

 

**IN WITNESS  WHEREOF** the parties executed this Agreement as of the day and
year  first above written.

 

        

    |  

**MDS INC.**

 

 

    
---|--- 
     

    |  

By:

    |  

    
     

    |  

    |  

Name:

    
     

    |  

    |  

Title:

    
     

 

    |  

 

 

**BOREALIS INFRASTRUCTURE MANAGEMENT  INC.**

 

 

    
     

    |  

By:

    |  

    
     

    |  

    |  

Name:

    
     

    |  

    |  

Title:

    
     

 

    |  

    
     

    |  

By:

    |  

    
     

    |  

    |  

Name:

    
     

    |  

    |  

Title:

    
    

  * * *

 

 

**SCHEDULE  5.9**

 

 

 

**SUPPORT  SERVICES AGREEMENT 
TERM SHEET**

 

 

 

**A.  Remaining AutoLabs Contracts**

 

**Purpose**

 

To the extent that any of the contracts  listed  on Schedule "A" hereto (the
**" AutoLabs Contracts"**) have not been  validly assigned to the Buyer or an
applicable Designated Buyer Affiliate  (a " **Buyer Entity** ") on the
Closing Date (such non-assigned AutoLabs  Contracts, the **" Remaining
AutoLabs Contracts"**), notwithstanding  Section 2.3 of the Agreement, then
under the terms of the Support  Services  Agreement, a Buyer Entity will
assume responsibility for the performance  of all  services, covenants and
obligations under such contracts.

 

**Performance of  Obligations**

 

Pursuant to the Support Services  Agreement,  from and after the Closing
Date, MDS or the MDS entity party to the  applicable  contract (the " **MDS
Contracting Party** ") will hold the Remaining  AutoLabs Contracts in trust
for the applicable Buyer Entity, and  the Buyer  Entity will be required to
assume and perform all of the covenants  and  obligations of the MDS
Contracting Parties under the Remaining AutoLabs  Contracts under such trust
arrangement until the earliest of: (i)  such contract  being validly
assigned to a Buyer Entity; (ii) such contract being  validly  assigned to a
service provider (e.g. [REDACTED]), provided that the  MDS  Contracting
Party is released from any obligations or liabilities  in respect of  future
performance under the contract; (iii) the expiration or termination  of 
such contract, or (iv) the extension, amendment or renewal of such  contract
to  remove the MDS Contracting Party as a party to the contract. The 
performance by the Buyer Entity will be in accordance with the terms  of
the  applicable Remaining AutoLabs Contract. For certainty, the MDS
Contracting  Party shall not, without the written consent of Buyer, have the
right  to  terminate or refuse to extend or renew a Remaining AutoLabs
Contract  if such  termination, non-extension or non-renewal could, pursuant
to the  terms of the  applicable AutoLabs Contract, result in the right of
the applicable  third party  to obtain the source code for the software
licensed to such person  pursuant to  the applicable AutoLabs Contract.

 

The applicable Buyer Entity will  grant the  applicable MDS Contracting
Party a limited, non-exclusive and non-transferable  license to the AutoLabs
Assets to extent required to effect the license  of the  AutoLabs Assets to
the applicable third party. Each applicable MDS  Contracting  Party shall
indemnify Buyer and the applicable Buyer Entity from  any breach of  such
license.

 

Each applicable MDS Contracting  Party shall  take or provide such
reasonable action, assistance and/or information  so as to  provide the
applicable Buyer Entity with the benefits of and to allow  the  applicable
Buyer Entity to comply with the obligations under the  Remaining  AutoLabs
Contracts, and each applicable MDS Contracting Party shall  pay over to 
Buyer all money received by such MDS Contracting Party in respect  of
services  performed by a Buyer Entity under each Remaining AutoLabs
Contract  within a ten  (10) business days **)** following receipt of such
money.

 

Buyer shall be responsible for any  failure to  perform the services,
covenants and obligations under the Remaining  AutoLabs  Contracts, except
to the extent caused by MDS.

 

**B.  U.S. Transition Services  Contracts**

 

**" U.S. Transition Services  Contracts" **means the U.S. Support Services
Contracts relating to the  provision of  transition services in connection
with the sale of the diagnostics  business in  the U.S. to (i) [REDACTED],
as are more particularly set out and  described in  Schedule "B" hereto.

 

Pursuant to the Support Services  Agreement,  from and after the Closing
Date, the applicable Buyer Entity will  use  commercially reasonable efforts
to provide the applicable MDS Contracting  Party  with services, on a sub-
contract basis, as may be required to enable  such MDS  Contracting Party to
fulfill its obligations under the U.S. Transition  Services  Contracts (the
**" Transition Support Services"**). Buyer and MDS  acknowledge that the
performance of any such sub-contracting arrangement  shall  be on terms and
conditions that provide for the ownership and licensing  of work  product,
the protection of confidential information and privacy related  obligations
in a manner consistent with the applicable U.S. Transition  Services 
Contracts.

 

The Transition Support Services  shall be  provided on a cost-recovery
basis, with customary provisions for  verification of  such costs by MDS.
Each applicable MDS Contracting Party shall pay  to Buyer the  costs
incurred by applicable Buyer Entity in respect of services  performed by 
such Buyer Entity within a ten (10) business days) following receipt  of
the  applicable Buyer Entity invoice.

 

The liability of the Buyer Entity  in  connection with its performance of
the Transition Support Services  will be  subject to a customary limitation
of liability. The Buyer Entity  will only be  liable for direct damages (and
not any indirect damages of any kind  or nature  whatsoever).

 

 


 

 

**SCHEDULE  "A"**

 

**AutoLabs  Contracts**

 

[REDACTED]

 


 

**SCHEDULE  "B"**

 

**U.S.  Transition Services Contracts**

 

 

[REDACTED]

 

  * * *

 

 

 

**SCHEDULE   5.12**

 

**C** **ONFIDENTIALITY  AGREEMENT**

 

This  Confidentiality Agreement (the " **Agreement** ") entered into and 
made effective **[** l **]** , 2006 is between:

 

**MDS  INC**. 
(" **MDS** ")

 

\- and  -

 

**MDS  LABORATORY SERVICES LIMITED PARTNERSHIP 
** (" **MDS ONT  LP** ")

 

\- and  -

 

**LABORATOIRES  MDS QU BEC LTE. 
**(" **MDS  Quebec** ")

 

\- and  -

 

**METRO  MCNAIR CLINICAL LABORATORIES LTD. 
("Metro GP")**

 

\- and  -

 

**METHER  PROPERTIES LIMITED PARTNERSHIP 
("Mether LP")**

 

\- and  -

 

**METHER  MANAGEMENT LTD. 
("Mether GP")**

 

\- and  -

 

**BOREALIS  INFRASTRUCTURE MANAGEMENT INC.** 
(" **Buyer** ")

 

**[ _NTD : Designated Buyer  Affiliates to be added as parties to this
agreement and all defined  as  Buyer Entities _ _._ ]**

 

 

**WHEREAS** MDS and Buyer have entered  into an asset purchase agreement with
respect to the Ontario Diagnostics  Business dated **[** l **]** , 2006 (as
such agreement  may be amended from time to time, the " **Ontario Purchase 
Agreement** "), as well as an asset purchase agreement with respect to  the 
BC Diagnostics Business dated **[** l **]** , 2006 (as  such agreement may be
amended from time to time, the " **BC Purchase  Agreement** " and, together
with the Ontario Purchase Agreement, the " **Purchase Agreements** ")
pursuant to which, among other things,  MDS has agreed to sell and, subject
to receipt of all necessary consents,  to  cause various Affiliates of MDS
to sell, and Mether LP has agreed to  sell, to  the Buyer Entities, and the
Buyer Entities have agreed to purchase,  certain  assets relating to the MDS
Diagnostics Division;

 

 

**AND WHEREAS** pursuant to the Purchase  Agreements, MDS and Buyer agreed
that, prior to the Closing Time, MDS,  MDS ONT  LP, MDS Quebec, Metro GP,
Mether LP and Mether GP (collectively, the  " **MDS Entities** ") and the
Buyer Entities would enter into a  confidentiality agreement for the purpose
of ensuring the confidentiality  post-Closing of all Information in the
possession or control of the  other;

 

 

**AND WHEREAS** Buyer and MDS are also  parties to a migration agreement
dated **[** l **]** ,  2006 (the " **Migration Agreement** "), pursuant to
which, during the  period of time commencing on the date of the Ontario
Purchase Agreement  and  continuing until the Closing Date unless extended
as necessary to complete  the  projects contemplated therein, the Parties
have agreed to cooperate  and work  together to transition certain aspects
of the MDS Diagnostics Division  to the  Buyer Entities;

 

 

**AND WHEREAS** pursuant to the Migration  Agreement, Buyer and MDS agreed,
in respect of the mutual exchange  of  confidential information required in
connection with the Migration  Agreement, to  enter into a confidentiality
agreement for the purpose of ensuring  the  confidentiality from and after
the date of this Agreement of all information  exchanged between such parties
pursuant to the Migration Agreement;

 

 

**AND WHEREAS** the MDS Entitieshave  voluntarily entered into this Agreement
and agree that the limitations  and  restrictions set out in this Agreement
are reasonable and not oppressive  and are  intended to protect the Buyer
Entities' substantial investment and legitimate  business interests under the
Purchase Agreements;

 

 

**AND WHEREAS** the Buyer Entities  voluntarily entered into this Agreement
and agree that the limitations  and  restrictions set out in this Agreement
are reasonable and not oppressive  and are  intended to protect the MDS
Entities' substantial investment and legitimate  business interests in their
respective on-going business operations  that do not  comprise the MDS
Diagnostics Division;

 

 

**AND WHEREAS** the Parties acknowledge  that the Information of the other is
highly sensitive;

 

 

**NOW THEREFORE** in considerationof the  premises and the respective
agreements in this Agreement, and of other  consideration (the receipt and
sufficiency of which are acknowledged  by each  Party hereto), the Parties
hereto agree as follows:

 

1.   **Definitions**

 

As  used in this Agreement, unless the context otherwise requires,
capitalized  terms  not expressly defined in this Agreement shall have the
meanings ascribed  thereto  in the Ontario Purchase Agreement, and the
following terms shall have  the  following meanings:

 

(a)   " **Affiliate** " means, with respect to any Person,

 

(i)   any other Person who directly or indirectly controls, is controlled 
by, or is  under direct or indirect common control with, such Person; or

 

(ii)   any other Person that directly or indirectly owns all of the
participating  equity of such Person or for which all of the participating
equity  is directly  or indirectly owned by such Person; and

 

  a Person shall be deemed to "control" a Person if such Person possesses
directly  or indirectly the power to direct or cause the direction of the
management  and  policies of such Person, whether through the ownership of
voting securities,  by  contract or otherwise, and "controlled" shall have a
similar meaning;

 

(a)   " **Agreement** " has the meaning set forth in the preamble  hereof;

 

(b)   " **BC Diagnostics Business** " means the specimen collection and 
diagnostic services businesses carried on, prior to the date hereof,  by MDS,
in  British Columbia, and the BC Operators consisting of the provision  of
clinical  laboratory testing for physicians, hospitals, non-hospital health
care  institutions, employers or insurance companies, management of
hospital  laboratories and other support services for clinical diagnostics;

 

(c)   " **BC Purchase Agreement** " has the meaning set forth in the 
recitals to this Agreement;

 

(d)   " **Business Day** " means any day, other than a Saturday or Sunday, 
on which Canadian chartered banks are open for the transaction of business 
in  the City of Toronto;

 

(e)   " **Buyer Confidential Information** " means all information, 
knowledge and data (regardless of form) concerning or related to: (i) the 
MDS Diagnostics Division, the Purchased Assets, the BC Purchased Assets, 
the  Replacement Contracts and the Migrating Assets; (ii) the business and 
affairs of Buyer (other than pertaining to the MDS Diagnostics Division, 
the  Purchased Assets, the BC Purchased Assets, the Replacement Contracts 
and the  Migrating Assets) disclosed by Buyer to the MDS Entities prior to
or  after the  date of this Agreement; (iii) the migration of the MDS
Diagnostics Division  (inclusive of Buyer's proposed or actual changes and
plans related thereto) in  connection with the performance of the Migration
Agreement; and (iv)  the  business and affairs of the MDS Diagnostics
Division as carried on  by the Buyer  Entities after the Closing Date;
including without limitation, in each  of the  foregoing cases, trade
secrets, processes, practices, ideas, concepts,  know-how,  formulas,
assays, recipes, and all other information, knowledge and  data of an 
intellectual, proprietary, technical, scientific, commercial, financial  or 
industrial nature provided that Buyer Confidential Information does  not
include  any information, knowledge or data concerning any Regional Asset
that  is an  Excluded Asset under the applicable Purchase Agreement;

 

(f)   " **Buyer Entities** " has the meaning set forth in the recitals to 
this Agreement;

 

(g)   " **Governmental Authority** " means any domestic or foreign 
government whether federal, provincial, state or municipal and any 
governmental  agency, governmental authority, governmental tribunal or
governmental  commission  of any kind whatever;

 

(h)   " **Information** " means either Buyer Confidential Information or 
MDS Confidential Information, as the case may be;

 

(i)   " **MDS Confidential Information** " means all information, knowledge 
and data (regardless of form) concerning or related to the business  and
affairs  of the MDS Entities, or the business and affairs of an Affiliate
of  MDS (but in  each case excluding information, knowledge and data
(regardless of  form)  relating Primarily (as such term is defined and
interpreted under the  Purchase  Agreements) to the MDS Diagnostics
Division), including without limitation,  trade secrets, processes,
practices, ideas, concepts, know-how, formulas,  assays, recipes, and all
other information, knowledge and data of an  intellectual, proprietary,
technical, scientific, commercial, financial  or  industrial nature
disclosed (i) by or on behalf of the MDS Entities  or any  Affiliate of MDS
to Buyer or employees of the MDS Entities that are  employed by  Buyer after
Closing prior to or after the date of this Agreement, including,  without
limitation, in connection with the performance of the Migration  Agreement,
or (ii) that is or has been disclosed by, or is within the  knowledge  or
possession of, employees of the MDS Entities that are employed by  Buyer
after  Closing;

 

(j)   " **MDS Diagnostics Division** " means the Ontario Diagnostics 
Business and BC Diagnostics Business carried on by MDS up to the Closing 
Date,  the Operators and the BC Operators and including the businesses
carried  on by  Toronto Labs, Windsor Labs, Trainor Laboratories Limited
Partnership,  Dynacare  Kasper Medical Laboratories Partnership, Excelleris
Technologies Inc.  and  Excelleris Technologies LP;

 

(k)   " **MDS Entities** " has the meaning set forth in the recitals to 
this Agreement;

 

(l)   " **notice** " has the meaning set forth in Section 14 hereof;

 

(m)   " **Ontario Diagnostics Business** " means the specimen collection 
and diagnostic services businesses carried on, prior to the date hereof,  by
MDS  and the Operators in Ontario and Quebec consisting of the provision  of
clinical  laboratory testing for physicians, hospitals, non-hospital health
care  institutions, employers or insurance companies, management of
hospital  laboratories and other support services for clinical diagnostics
and  the  AutoLabs Business;

 

(n)   " **Ontario Purchase Agreement** " has the meaning set forth in the 
recitals to this Agreement;

 

(o)   " **Parties** " means the MDS Entities and the Buyer Entities, 
collectively, and " **Party** " means any one of them;

 

(p)   " **Person** " shall be broadly interpreted and includes an 
individual, body corporate, partnership, joint venture, trust, association, 
unincorporated organization, the Crown, any Governmental Authority  or any
other  entity recognized by law;

 

(q)   " **Purchase Agreements** " has the meaning set forth in the recitals 
to this Agreement;

 

(r)   " **Representatives** " means the directors, officers, employees, 
agents, solicitors, accountants, consultants, financial or legal advisors 
and  all other representatives of the Party being referred to; and

 

(s)   " **Transmission** " has the meaning set forth in Subsection 14(b) 
hereof.

 

2.   Subject to the provisions of this Agreement, neither the MDS Entities  nor the  Buyer Entities shall, at any time, use or disclose to any Person, directly  or  indirectly, the Information of the other except as otherwise provided  herein.  The MDS Entities and Buyer Entities acknowledge that (i) the Information  of the  other is vital, sensitive, confidential and proprietary to, in the  case of  Buyer, the specimen collection and diagnostic services business carried  on by  the Buyer after the date of this Agreement and, in the case of the  MDS Entities,  MDS' businesses and the businesses of its Affiliates, other than the MDS  Diagnostics Division, and (ii) use by, or unauthorized disclosure of,  the  others' Information would be materially prejudicial and detrimental to the  interests and business of the Buyer Entities or the MDS Entities, as  the case  may be.

 

3.  Neither  the MDS Entities nor the Buyer Entities shall disclose the Information  of the  other to any Person other than to those of its Representatives who  have a need  to know and who have agreed to maintain such Information in the strictest  confidence. The MDS Entities, on the one hand, and the Buyer Entities,  on the  other hand, shall protect, to the same extent and in the same manner  as it  protects its own confidential information (provided that such standard  is not  less than commercially reasonable efforts), all Information of the  other that it  retains in its respective possession or under its respective control  from all  harm, loss, theft, reproduction and unauthorized access and shall ensure  that  such Information is not disclosed, published, released, transferred  or otherwise  made available in any form to, for the use or benefit of, any Person  except as  provided in this Agreement, without the prior written approval of Buyer  or MDS,  as applicable. The MDS Entities shall be jointly and severally liable  for  breaches hereunder and shall be responsible for any breach of this  Agreement by  their Representatives (or any other Person to whom the MDS Entities  disclose  Buyer Confidential Information), whether or not such Representatives  (or other  Persons) have agreed to maintain such confidentiality, other than for  any  breaches hereunder caused by an employee of an MDS Entity provided  that the MDS  Entities have taken all commercially reasonable steps to protect the  Buyer  Confidential Information to the same extent and in the same manner  as it  protects its own confidential information and further provided it takes  all  reasonable steps to prevent any further breaches of this Agreement  by such  employee which may include, without limitation, appropriate disciplinary  measures for the employee who caused the breach of this Agreement. The  Buyer Entities shall be jointly and severally liable for breaches hereunder  and  shall be responsible for any breach of this Agreement by their Representatives  (or any other Person to whom the Buyer Entities disclose Buyer Confidential  Information), whether or not such Representatives (or other Persons)  have agreed  to maintain such confidentiality, other than for any breaches hereunder  caused  by an employee of a Buyer Entity provided that the Buyer Entities have  taken all  commercially reasonable steps to protect the MDS Confidential Information  to the  same extent and in the same manner as it protects its own confidential  information and further provided it takes all reasonable steps to prevent  any  further breaches of this Agreement by such employee which may include,  without  limitation, appropriate disciplinary measures for the employee who  caused the  breach of this Agreement.

 

4.  The  non-disclosure obligations in this Agreement shall not restrict disclosure  of  Information by a Party where: 

 

(a)   the disclosure is required by law (including, in the case of MDS, any 
published  policies of applicable securities regulators and applicable stock
exchange  rules);

 

(b)   the disclosure is required to defend any claim or other proceeding 
as  contemplated in Section 7.2 (Litigation) of the Purchase Agreements, 
the filing  of Tax Returns or dealing with any matters contemplated in
Section  7.5 (Tax  Matters) of the Purchase Agreements;

 

(c)   in the case of the MDS Entities, the disclosure is required by the 
MDS  Entities relating to the MDS Diagnostics Division (as defined in the 
Ontario Purchase Agreement) to the extent required to address financial 
reporting requirements; or

 

(d)   such information has been, or at any time is, made available to the 
public  through no fault of the applicable Parties or their Representatives;

 

provided  in each case, that the applicable disclosing Party has provided
the  other Party  with at least three (3) Business Days notice prior to such
disclosure,  other  than in the case of paragraph (d) or if disclosure is
required pursuant  to  applicable securities laws, published policies of
applicable securities  regulators or any applicable stock exchange rules.

 

5.   Each Party acknowledges and agrees that the obligations of confidentiality  and  trust in this Agreement are in addition to and not in substitution  for any  duties or obligations of secrecy, confidence or trust arising from  or implied by  any statute or rule of law.

 

6.  Each  Party  acknowledges that any threatened or actual breach of any of the covenants  or  provisions contained herein would cause the other Party and/or any  of the other  Party's Affiliates to suffer irreparable harm which could not be adequately  compensated for by damages. In such circumstances, subject to Section 3,  each Party agrees that the other Party and/or its Affiliates shall,  in addition  to any other remedy or relief, be entitled to seek to enforce the performance  of  this Agreement by equitable relief (including injunction or specific  performance) upon application to a court of competent jurisdiction  without proof  of actual damage to such Party or its Affiliates and notwithstanding  that  damages may be readily quantifiable, and each Party agrees not to contest,  object to, or otherwise delay, obstruct or oppose (including by pleading  sufficiency of damages as a defence) an application for equitable relief  by any  other Party in the circumstances of such threatened or actual breach,  on notice  or _ex parte_ , and hereby waive any and all immunities from injunctive or  other equitable relief to which they may be entitled. Any such relief or  remedy shall not be exclusive, but shall be in addition to all other  available  legal or equitable remedies. Each Party agrees that the provisions of this  Section 6 are fair and reasonable in the commercial circumstances of  this  Agreement, and that it has relied on such provisions in entering into  this  Agreement, the Migration Agreement and each of the Purchase  Agreements.

 

7.   In the event of litigation relating to this Agreement, if a court of  competent  jurisdiction determines that a Party or any of itsRepresentatives have  breached  this Agreement, the breaching Party shall be liable and pay to the  other Party  the reasonable legal fees incurred by the other Party in connection  with such  litigation, including without limitation any appeals therefrom.

 

8.   Each Party agrees that in the event it or any of its Representatives  are  requested pursuant to, or required by, applicable law, regulation or  legal  process (other than under applicable securities laws, published policies  of  applicable securities regulators or any applicable stock exchange rules)  to  disclose any Information of the other Party, it shall notify the other  Party  promptly in writing so that the other Party may seek a protective order  or other  appropriate remedy. The notifying Party shall consent to the other  obtaining any protective order or other appropriate remedy that it  and/or its  Affiliates may seek for the purpose of preventing disclosure of any  of the  Information to the public. In the event that no such protective order or  other remedy is obtained, such Party shall furnish only that portion  of the  other Party's Information which it is advised by legal counsel is legally  required and shall take all commercially reasonable steps, to the extent  permitted by law, to remove from such Information that is required  to be  disclosed any information that is commercially sensitive to the other. 

 

9.   Each Party agrees that all of the terms, conditions and restrictions  in this  Agreement are reasonable in the circumstances and are intended to protect,  in  the case of Buyer, Buyer's substantial investment and legitimate business  interests in carrying on the specimen collection and diagnostic services  business carried on by the Buyer after the date of this Agreement,  and, in the  case of MDS, MDS' businesses and the businesses of its Affiliates, other than  the MDS Diagnostics Division. Nevertheless, if any such restrictions shall  be held invalid, the remaining restrictions shall not be so affected.  In  addition, if any amendment to any restriction would be necessary in  order to  ensure its validity, such restriction shall apply with such amendment  or  modification as may be necessary to make it valid and effective.

 

10.   Nothing contained in this Agreement shall be construed, by implication,  estoppel  or otherwise, as a grant of a licence to use any of the Information  of the other  Party.

 

11.   A Party's obligation of confidentiality under this Agreement survives  indefinitely. 

 

12.   This Agreement sets out the entire agreement between the Parties pertaining  to  the subject matter hereof and supersedes all prior agreements, understandings,  negotiations and discussions, whether oral or written.

 

13.   No waiver of or consent to depart from the requirements of any provision  of this  Agreement shall be binding on a Party and/or its Affiliates unless  it is in  writing and is signed by such Party. Such waiver or consent shall be  effective only in the specific instance and for the specific purpose  for which  it has been given. No failure on the part of a Party to exercise, and no  delay in exercising, any right under this Agreement shall operate as  a waiver of  such right. No single or partial exercise of any such right shall preclude  any other or further exercise of such right or the exercise of any  other  right.

 

14.  Any  notice, demand or  other communication (a " **notice** ") required or permitted to be  given or made hereunder shall be in writing and shall be sufficiently  given or  made if:

 

(a)   delivered in Person during normal business hours on a Business Day 
and left with  a receptionist or other responsible employee at the applicable
address  set forth  below; or

 

(b)  sent  by any  electronic means of sending messages, including
facsimile transmission  (excluding e-mail), which produces a paper record 
(" **Transmission** ") during normal business hours on a Business  Day.

 

In the case of a notice to **Buyer  Entity** :

 

200 Bay Street, 
P.O. Box 56, Suite  2100 
Toronto, Ontario 
M5J 2J2

 

Attention: President and Chief  Executive Officer 
Facsimile Number: (416) 361-6075

 

and in the  case of a  notice to **MDS** :

 

75 International Boulevard 
Toronto,  Ontario 
M9W 6J6

 

Attention: **[** l] 
Facsimile  Number: **[ l** **]**

 

and  in the case of a notice to **MDS LP ONT** :

 

**[ l** **] 

**

 

Attention:  **[ l** **] **

 

Facsimile  Number: **[ l** **]**

 

and in the  case of a  notice to **MDS Quebec** :

 

**[ l** **]**

 

Attention: **[ l** **]  
** Facsimile Number: **[ l** **]**

 

and in the  case of a  notice to **Metro GP** :

 

**[ l** **]**

 

Attention: **[ l** **]  
** Facsimile Number: **[ l** **]**

 

and in the  case of a  notice to **Mether LP** :

 

**[ l** **]**

 

Attention: **[ l** **]  
** Facsimile Number: **[ l** **]**

 

and in the  case of a  notice to **Mether GP** :

 

**[ l** **]**

 

Attention: **[ l** **]  
** Facsimile Number: **[ l** **]**

 

Each notice  sent in  accordance with this Section shall be deemed to have
been received:

 

(a)   if delivered in Person, on the day of delivery;

 

(b)   on the same day that it was sent by Transmission, or on the first
Business  Day  thereafter if the day on which it was sent by Transmission
was not  a Business  Day or if it was sent after normal business hours on a
Business Day.

 

 Any Party may change its address for  notice by giving notice to the
other  Parties.

 

15.   Each Party represents and warrants to the other that the execution  and delivery  of this Agreement has been duly authorized by all necessary corporate  action on  their respective parts and that the Person signing this Agreement on  behalf of  it is duly authorized to do so.

 

16.   This Agreement is personal to the Parties and may not be assigned without  the  prior written consent of the other Parties.

 

17.   Any amendments to this Agreement must be made in writing and signed  by all of  the Parties.

 

18.  This  Agreement shall  be governed by and construed in accordance with the laws of the Province  of  Ontario and the Parties hereby attorn and submit to the non-exclusive  jurisdiction of the courts of the Province of Ontario with respect  to any  dispute arising under this Agreement.

 

19.   This Agreement shall enure to the benefit of and be binding upon the  Parties and  their respective successors and permitted assigns.

 

20.   The parties have agreed that this Agreement be drawn up in the English  language. Les parties aux presentes ont convenu que le present contrat  soit redige en anglais. 

 

**IN WITNESS WHEREOF** , the  Parties hereto have executed this Agreement as
of the date first written  above.

 

 

        

    |  

**MDS INC.**

 

    
---|--- 
     

    |  

By:

    |  

    
     

    |  

    |  

Name:

    
     

    |  

    |  

Title:

    
     

    |  

    |  

I have the authority to bind the  Corporation

    
    

        

    |  

    |  

**MDS  LABORATORY SERVICES LIMITED PARTNERSHIP**

    
---|---|--- 
     

    |  

    |  

By:

    |  

    
     

    |  

    |  

    |  

Name: 

    
     

    |  

    |  

    |  

Title: 

    
     

    |  

    |  

    |  

    |  

I  have the authority to bind the Partnership

    
    

        

    |  

    |  

**LABORATOIRES  MDS QU BEC LT**

    
---|---|--- 
     

    |  

    |  

By:

    |  

    
     

    |  

    |  

    |  

Name: 

    
     

    |  

    |  

    |  

Title: 

    
     

    |  

    |  

    |  

    |  

I  have the authority to bind the Corporation

    
    

 

        

    |  

**BOREALIS INFRASTRUCTURE MANAGEMENT  INC.**

 

    
---|--- 
     

    |  

By:

    |  

    
     

    |  

    |  

Name:

    
     

    |  

    |  

Title:

    
     

    |  

    
     

    |  

By:

    |  

    
     

    |  

    |  

Name:

    
     

    |  

    |  

Title:

    
     

    |  

    |  

We have the authority to bind the  Corporation

    
    

        

    |  

    |  

**METRO  MCNAIR CLINICAL LABORATORIES LTD.**

    
---|---|--- 
     

    |  

    |  

By:

    |  

    
     

    |  

    |  

    |  

Name: 

    
     

    |  

    |  

    |  

Title: 

    
     

    |  

    |  

    |  

    |  

I  have the authority to bind the Corporation

    
    

        

    |  

    |  

**METHER  PROPERTIES LIMITED PARTNERSHIP**

    
---|---|--- 
     

    |  

    |  

By:

    |  

    
     

    |  

    |  

    |  

Name: 

    
     

    |  

    |  

    |  

Title: 

    
     

    |  

    |  

    |  

    |  

I  have the authority to bind the Corporation

    
    

        

    |  

    |  

**METHER  MANAGEMENT LTD.**

    
---|---|--- 
     

    |  

    |  

By:

    |  

    
     

    |  

    |  

    |  

Name: 

    
     

    |  

    |  

    |  

Title: 

    
     

    |  

    |  

    |  

    |  

I  have the authority to bind the Corporation

    
     

    |  

    |  

**[designated  buyer affiliates]**

    
     

    |  

    |  

    |  

    
     

    |  

    |  

    |  

    
     

    |  

    |  

    |  

    
     

    |  

    |  

    |  

    |  
 * * *

 

 

**SCHEDULE  6.1.5(B)**

 

Closing  Conditions in Favour of Buyer

 

 

[REDACTED]

 

 

 


 

**SCHEDULE  6.2.4(B)**

 

 

Closing  Conditions in Favour of MDS

 

 

[REDACTED]

 

  * * *

 

 

 

**Schedule  9.3 
Rules of Procedure for  Arbitration**

 

The following rules and procedures  shall apply  with respect to any matter
to be arbitrated by the Parties under  the terms of  the Agreement.

 

1.   INITIATION OF ARBITRATION PROCEEDINGS

 

(a)   If any Party to this Agreement wishes to have any dispute under
Sections  3.4,  3.5 and 3.6 and Schedule 3.1 arbitrated in accordance with
the provisions  of  this Agreement, it shall give notice to the other Party
hereto specifying  particulars of the matter or matters in dispute and
proposing the  name of the  person it wishes to be the single arbitrator.
Within 15 days after receipt  of such notice, the other Party to this
Agreement shall give notice  to the first  Party advising whether such Party
accepts the arbitrator proposed  by the first  Party. If such notice is not
given within such 15 day period, the other  Party shall be deemed to have
accepted the arbitrator proposed by  the first  Party. If the Parties do not
agree upon a single arbitrator within such  15  day period, either party may
request that the ADR Institute of Canada,  Inc.  select a single arbitrator
(the " **Arbitrator** ").

 

(b)   The individual selected as Arbitrator shall be qualified by education 
and  experience to decide the matter in dispute. The Arbitrator shall be at 
arm's length from both Parties and shall not be a member of the audit  or
legal  firm or firms who advise either Party, nor shall the Arbitrator be 
an individual  who is, or is a member of a firm, otherwise regularly retained
by  either of the  Parties.

 

2.   SUBMISSION OF WRITTEN STATEMENTS

 

(a)   Within 30 days of the appointment of the Arbitrator, the Party
initiating  the  arbitration (the " **Claimant** ") shall send the other
Party (the " **Respondent** ") a Statement of Claim setting  out in
sufficient  detail the facts and any contentions of law on which it relies,
and  the relief  that it claims.

 

(b)   Within 30 days of the receipt of the Statement of Claim, the
Respondent  shall  send the Claimant a Statement of Defence stating in
sufficient detail  which of  the facts and contentions of law in the
Statement of Claim it admits  or denies,  on what grounds, and on what other
facts and contentions of law it  relies.

 

(c)   Within 15 days of receipt of the Statement of Defence, the Claimant 
may send the  Respondent a Statement of Reply.

 

(d)   All Statements of Claim, Defence and Reply shall be accompanied by 
copies (or,  if they are especially voluminous, lists) of all essential
documents  on which  the Party concerned relies and which have not
previously been submitted  by any  Party.

 

(e)   After submission of all the Statements, the Arbitrator will give 
directions for  the further conduct of the arbitration.

 

3.   MEETINGS AND HEARINGS

 

(a)   The arbitration shall take place in the City of Toronto, Ontario  or
in such  other place as the Claimant and the Respondent shall agree upon in 
writing  within 5 days after the Statements of Claim, Defence and Reply
have  been  delivered. The arbitration shall be conducted in English unless
otherwise  agreed by such Parties and the Arbitrator. Subject to any
adjournments  which the Arbitrator allows, the final hearing will be
continued  on successive  working days until it is concluded.

 

(b)   All meetings and hearings will be in private unless the Parties
otherwise  agree.

 

(c)   Any Party may be represented at any meetings or hearings by legal 
counsel.

 

(d)   Each Party may examine, cross-examine and re-examine all witnesses  at
the  arbitration.

 

4.   THE DECISION

 

(a)   The Arbitrator will make a decision in writing and, unless the
Parties  otherwise  agree, will set out reasons for the decision in the
decision.

 

(b)   The Arbitrator will send the decision to the Parties as soon as
practicable  after the conclusion of the final hearing, but in any event no
later  than 45  days thereafter, unless that time period is extended for a
fixed  period by the  Arbitrator on written notice to each Party because of
illness or  other cause  beyond the Arbitrator's control.

 

(c)   The provisions of this Agreement and this Schedule requiring the 
determination  of certain disputes of arbitration shall not operate to
prevent recourse  to the  court by any Party as permitted by the Arbitration
Act, 1991 (Ontario)  with  respect to injunctions, receiving orders and
orders regarding the  detention,  preservation and inspection of property,
or whenever enforcement  of an award by  the sole arbitrator reasonably
requires access to any remedy which  an arbitrator  has no power to award or
enforce.

 

(d)   The decision of the Arbitrator shall be conclusive, final and binding 
on the  Parties and no appeal shall lie therefrom.

 

5.   JURISDICTION AND POWERS OF THE ARBITRATOR

 

(a)   By submitting to arbitration under these Rules, the Parties shall  be
taken to  have conferred on the Arbitrator the following jurisdiction and
powers,  to be  exercised at the Arbitrator's discretion subject only to
these Rules and the  relevant law with the object of ensuring the just,
expeditious, economical  and  final determination of the dispute referred to
arbitration.

 

(b)   Without limiting the jurisdiction of the Arbitrator at law, the
Parties  agree  that the Arbitrator shall have jurisdiction to:

 

(i)   determine any question of law arising in the arbitration including 
claims in  tort, contract or relating to the validity of the Agreement or
any  Closing  Document;

 

(ii)   determine any question as to the Arbitrator's jurisdiction;

 

(iii)   determine any question of good faith, dishonesty or fraud arising 
in the  dispute;

 

(iv)   order any Party to furnish further details of that Party's case, in
fact or in  law;

 

(v)   proceed in the arbitration notwithstanding the failure or refusal  of
any Party  to comply with these Rules or with the Arbitrator's orders or
directions, or to  attend any meeting or hearing, but only after giving that
Party written  notice  that the Arbitrator intends to do so;

 

(vi)   receive and take into account such written or oral evidence tendered 
by the  Parties as the Arbitrator determines is relevant, whether or not 
strictly  admissible in law;

 

(vii)   make one or more interim awards;

 

(viii)   hold meetings and hearings, and make a decision (including a final 
decision) in  Ontario or elsewhere with the concurrence of the Parties
thereto;

 

(ix)   order the Parties to produce to the Arbitrator, and to each other 
for  inspection, and to supply copies of, any documents or classes of 
documents in  their possession or power which the Arbitrator determines to be
relevant;

 

(x)   order the preservation, storage, sale or other disposal of any
property  or thing  under the control of any of the Parties;

 

(xi)   make interim orders to secure all or part of any amount in dispute 
in the  arbitration; and

 

(xii)   make an award of interest in respect of any amount determined to  be
owing and  make an award as to costs of the arbitration.

 


 

 

 

 

 

 

 

 

       '

